EGFL6 specific monoclonal antibodies and methods of their use
EGFL6-specific monoclonal antibodies address the need for targeted therapies by inhibiting cancer cell proliferation and angiogenesis, offering effective treatment options for cancers with high EGFL6 expression.
Patent Information
- Application Number
- JP2024140677
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2016-02-05
- Filing Date
- 2024-08-22
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There is a need for effective reagents and therapies targeting EGFL6-positive cancers, as high expression of EGFL6 is associated with certain cancer types such as ovarian and lung cancers, with limited expression in healthy adult tissues.
Development of EGFL6-specific monoclonal antibodies that bind to EGFL6, reducing EGFL6 signaling and inhibiting cancer cell proliferation, including antibodies with specific CDR sequences and potential humanization or deimmunization, and conjugation with agents like auristatin for targeted therapy.
The EGFL6-specific monoclonal antibodies effectively inhibit cancer cell proliferation and angiogenesis, providing a targeted therapeutic approach for cancers like breast, lung, and ovarian cancer, with potential for systemic and localized administration.
Smart Images

Figure 2024164139000001_ABST
Abstract
Description
[Technical field]
[0001] This application claims the benefit of U.S. Provisional Patent Application No. 62 / 291,987, filed February 5, 2016, which is incorporated by reference in its entirety.
[0002] 2. Background of the Invention 1. Field of the invention The present invention relates generally to the field of cancer biology, and more specifically to monoclonal antibodies targeting EGFL6 for the treatment and detection of cancer. [Background technology]
[0003] 2. Description of Related Technology Human epidermal growth factor (EGF)-like domain 6 (EGFL6) was first discovered in tumor and fetal tissues and is a member of the EGF repeat superfamily. EGFL6 was identified as a secreted protein with four and a half EGF-like repeat domains, two N-linked glycosylation sites, one integrin association motif (RGD), a tyrosine phosphorylation site, and a MAM domain (Yeung et al., 1999). Studies have shown that high expression of EGFL6 is associated with tumor tissues in certain cancer types, such as ovarian and lung cancer, with limited expression seen in healthy adult tissues (Buckanovich et al., 2007, Chim et al., 2011, and Oberauer et al., 2010). However, there remains a need for reagents and therapies for the treatment of EGFL6-positive cancers. Summary of the Invention
[0004] Described herein is an EGFL6 monoclonal antibody that binds to EGFL6. In a further aspect, the provided EGFL6 binding antibody can be used to reduce EGFL6 signaling and inhibit cancer cell proliferation. Thus, in a first embodiment, an isolated or recombinant monoclonal antibody that specifically binds to EGFL6 is provided. In a particular aspect, an antibody that competes with the binding of EGFL6 to E1-33, E1-34, E1-80, E1-89, E2-93, E1-38, E1-52, E2-36, E1-95, E2-116, E2-135, or E1-142 monoclonal antibody is provided. In certain aspects, the antibody can comprise all or a portion of the heavy chain variable region and / or light chain variable region of the E1-33, E1-34, E1-80, E1-89, E2-93, E1-38, E1-52, E2-36, E1-95, E2-116, E2-135, or E1-142 monoclonal antibody. In further aspects, the antibody can comprise amino acid sequences corresponding to the first, second, and / or third complementarity determining regions (CDRs) from the light chain and / or heavy chain of the E1-33, E1-34, E1-80, E1-89, E2-93, E1-38, E1-52, E2-36, E1-95, E2-116, E2-135, or E1-142 monoclonal antibody of this embodiment.
[0005] In certain aspects, the isolated antibodies comprise CDR sequences that are at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the CDR regions of the E1-33, E1-34, E1-80, E1-89, E2-93, E1-38, E1-52, E2-36, E1-95, E2-116, E2-135, or E1-142 heavy and light chain amino acid sequences. In further embodiments, the antibody comprises CDR regions identical to the E1-33, E1-34, E1-80, E1-89, E2-93, E1-38, E1-52, E2-36, E1-95, E2-116, E2-135, or E1-142 CDR regions, except for one or two amino acid substitutions, deletions, or insertions in one or more of the CDRs. For example, the antibody comprises an antibody in which the CDR sequences are VVVVVVVVVVV compared to the CDRs of the E1-33, E1-34, E1-80, E1-89, E2-93, E1-38, E1-52, E2-36, E1-95, E2-116, E2-135, or E1-142 monoclonal antibody. H CDR1, V H CDR2, V H CDR3, V L CDR1, V L CDR2 and / or V L Thus, in some particular aspects, an antibody of the embodiment may comprise a CDR that comprises one or two amino acid substitutions in CDR3. Thus, in some particular aspects, an antibody of the embodiment may comprise (a) a CDR that comprises one or two amino acid substitutions in CDR3 of E1-33 (SEQ ID NO: 4), E1-34 (SEQ ID NO: 10), E1-80 (SEQ ID NO: 16), E1-89 (SEQ ID NO: 22), E2-93 (SEQ ID NO: 28), E1-38 (SEQ ID NO: 34), E1-52 (SEQ ID NO: 40), E2-36 (SEQ ID NO: 46), E1-95 (SEQ ID NO: 52), E2-116 (SEQ ID NO: 58), E2-135 (SEQ ID NO: 64), or E1-142 (SEQ ID NO: 70). H a first V that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to CDR1; H(b) a V of E1-33 (SEQ ID NO:5), E1-34 (SEQ ID NO:11), E1-80 (SEQ ID NO:17), E1-89 (SEQ ID NO:23), E2-93 (SEQ ID NO:29), E1-38 (SEQ ID NO:35), E1-52 (SEQ ID NO:41), E2-36 (SEQ ID NO:47), E1-95 (SEQ ID NO:53), E2-116 (SEQ ID NO:59), E2-135 (SEQ ID NO:65), or E1-142 (SEQ ID NO:71). H a second V that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to CDR2; H (c) a CDR and a V of E1-33 (SEQ ID NO:6), E1-34 (SEQ ID NO:12), E1-80 (SEQ ID NO:18), E1-89 (SEQ ID NO:24), E2-93 (SEQ ID NO:30), E1-38 (SEQ ID NO:36), E1-52 (SEQ ID NO:42), E2-36 (SEQ ID NO:48), E1-95 (SEQ ID NO:54), E2-116 (SEQ ID NO:60), E2-135 (SEQ ID NO:66), or E1-142 (SEQ ID NO:72). H a third V that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to CDR3; H (d) a CDR and a V of E1-33 (SEQ ID NO:76), E1-34 (SEQ ID NO:82), E1-80 (SEQ ID NO:88), E1-89 (SEQ ID NO:93), E2-93 (SEQ ID NO:99), E1-38 (SEQ ID NO:104), E1-52 (SEQ ID NO:108), E2-36 (SEQ ID NO:113), E1-95 (SEQ ID NO:117), E2-116 (SEQ ID NO:121), E2-135 (SEQ ID NO:126), or E1-142 (SEQ ID NO:131). L a first V that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to CDR1; L(e) a V of E1-33 (SEQ ID NO:77), E1-34 (SEQ ID NO:83), E1-80 (SEQ ID NO:77), E1-89 (SEQ ID NO:94), E2-93 (SEQ ID NO:100), E1-38 (SEQ ID NO:100), E1-52 (SEQ ID NO:77), E2-36 (SEQ ID NO:83), E1-95 (SEQ ID NO:83), E2-116 (SEQ ID NO:100), E2-135 (SEQ ID NO:127), or E1-142 (SEQ ID NO:100). L a second V that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to CDR2; L (f) a V of E1-33 (SEQ ID NO:78), E1-34 (SEQ ID NO:84), E1-80 (SEQ ID NO:89), E1-89 (SEQ ID NO:95), E2-93 (SEQ ID NO:101), E1-38 (SEQ ID NO:105), E1-52 (SEQ ID NO:109), E2-36 (SEQ ID NO:114), E1-95 (SEQ ID NO:118), E2-116 (SEQ ID NO:122), E2-135 (SEQ ID NO:128), or E1-142 (SEQ ID NO:132). L a third V that is at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to CDR3; L In certain embodiments, such antibodies are humanized or deimmunized antibodies that comprise the aforementioned CDRs on a human IgG (e.g., IgG1, IgG2, IgG4, or genetically modified IgG) backbone.
[0006] In a further aspect, the isolated antibody comprises a first V sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the corresponding CDR sequences of monoclonal antibody E1-33, represented by SEQ ID NOs: 4, 5, 6, 76, 77, and 78, respectively. H , the second V H , the third V H , 1st V L , the second V L , and the third V LCDR sequences. In one embodiment, the isolated antibody comprises CDR sequences which are identical to the CDR sequences of monoclonal antibody E1-33.
[0007] In another embodiment, the isolated antibody comprises the V H Humanized V domain or E1-33mAB H V that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the domain H Domain and V of E1-33 L Domain (SEQ ID NO: 158) or humanized V of E1-33mAB L V that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the domain L For example, the antibody may comprise the V domain of humanized E1-33mAB. H Domain with at least 95% identity to V H Domain and V of humanized E1-33mAB L Domain with at least 95% identity to V L Thus, in some embodiments, the antibody can comprise the V domain of humanized E1-33mAB. H Same V as domain H Domain and V of humanized E1-33mAB L Same V as domain L In a specific example, the isolated antibody comprises a V domain identical to that of monoclonal antibody E1-33. H and V L It may include a domain.
[0008] In a further aspect, the isolated antibody comprises a first V sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the corresponding CDR sequences of monoclonal antibody E1-34, represented by SEQ ID NOs: 10, 11, 12, 82, 83, and 84, respectively. H , the second V H , the third V H, the first V L , the second V L , and the third V L CDR sequences. In one embodiment, the isolated antibody comprises CDR sequences which are identical to the CDR sequences of monoclonal antibody E1-34.
[0009] In another embodiment, the isolated antibody comprises the V H Humanized V domain or E1-34mAB H V that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the domain H domain and V of E1-34 (SEQ ID NO: 160) L Humanized V domain or E1-34mAB L V that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the domain L For example, the antibody may comprise the V domain of humanized E1-34mAB. H Domain with at least 95% identity to V H domain and V of humanized E1-34mAB L Domain with at least 95% identity to V L Thus, in some embodiments, the antibody can comprise the V domain of humanized E1-34 mAB. H Same V as domain H domain and V of humanized E1-34mAB L Same V as domain L In a specific example, the isolated antibody comprises a V domain identical to that of monoclonal antibody E1-34. H and V L It may include a domain.
[0010] In a further aspect, the isolated antibody comprises a first V sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the corresponding CDR sequences of monoclonal antibody E1-80, represented by SEQ ID NOs: 16, 17, 18, 88, 77, and 89, respectively. H , the second V H , the third V H , 1st V L , the second V L , and the third V L CDR sequences. In one embodiment, the isolated antibody comprises CDR sequences which are identical to the CDR sequences of monoclonal antibody E1-80.
[0011] In another embodiment, the isolated antibody comprises the V H Humanized V domain or E1-80mAB H V that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the domain H domain and V of E1-80 (SEQ ID NO: 162) L Humanized V domain or E1-80mAB L V that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the domain L For example, the antibody may comprise the V domain of humanized E1-80mAB. H Domain with at least 95% identity to V H Domain and V of humanized E1-80mAB L Domain with at least 95% identity to V L Thus, in some embodiments, the antibody can comprise the V domain of humanized E1-80mAB. H V identical to the domain H Domain and V of humanized E1-80mAB L Same V as domain L In a specific example, the isolated antibody comprises a V domain identical to that of monoclonal antibody E1-80. H and V LIt may include a domain.
[0012] In a further aspect, the isolated antibody comprises a first V sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the corresponding CDR sequences of monoclonal antibody E1-89, represented by SEQ ID NOs: 22, 23, 24, 93, 94, and 95, respectively. H , the second V H , the third V H , the first V L , the second V L , and the third V L CDR sequences. In one embodiment, the isolated antibody comprises CDR sequences which are identical to the CDR sequences of monoclonal antibody E1-89.
[0013] In another embodiment, the isolated antibody comprises the V H Humanized V domain or E1-89mAB H V that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the domain H domain and V of E1-89 (SEQ ID NO: 164) L Humanized V domain or E1-89mAB L V that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the domain L For example, the antibody may comprise the V domain of humanized E1-89mAB. H Domain with at least 95% identity to V H Domain and V of humanized E1-89mAB L Domain with at least 95% identity to V L Thus, in some embodiments, the antibody can comprise the V domain of humanized E1-89mAB. H Same V as domain H Domain and V of humanized E1-89mAB L Same V as domain LIn a specific example, the isolated antibody comprises a V domain identical to that of monoclonal antibody E1-89. H and V L It may include a domain.
[0014] In a further aspect, the isolated antibody comprises a first V sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the corresponding CDR sequences of monoclonal antibody E2-93, represented by SEQ ID NOs: 28, 29, 30, 99, 100, and 101, respectively. H , the second V H , the third V H , 1st V L , the second V L , and the third V L CDR sequences. In one embodiment, the isolated antibody comprises CDR sequences that are identical to the CDR sequences of monoclonal antibody E2-93.
[0015] In another embodiment, the isolated antibody comprises the V H Domain or humanized V of E2-93mAB H V that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the domain H domain and V of E2-93 (SEQ ID NO: 166) L Domain or humanized V of E2-93mAB L V that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the domain L For example, the antibody may comprise the V domain of humanized E2-93mAB. H Domain with at least 95% identity to V H Domain and V of humanized E2-93mAB L Domain with at least 95% identity to V L Thus, in some embodiments, the antibody can comprise the V domain of humanized E2-93mAB. H Same V as domain HDomain and V of humanized E2-93mAB L Same V as domain L In a specific example, the isolated antibody comprises a V domain identical to that of monoclonal antibody E2-93. H and V L It may include a domain.
[0016] In a further aspect, the isolated antibody comprises a first V sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the corresponding CDR sequences of monoclonal antibody E1-38, represented by SEQ ID NOs: 34, 35, 36, 104, 100, and 105, respectively. H , the second V H , the third V H , 1st V L , the second V L , and the third V L CDR sequences. In one embodiment, the isolated antibody comprises CDR sequences which are identical to the CDR sequences of monoclonal antibody E1-38.
[0017] In another embodiment, the isolated antibody comprises the V H Domain or humanized V of E1-38mAB H V that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the domain H domain and V of E1-38 (SEQ ID NO: 168) L Domain or humanized V of E1-38mAB L V that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the domain L For example, the antibody may comprise the V domain of humanized E1-38mAB. H Domain with at least 95% identity to V H Domain and V of humanized E1-38mAB L Domain with at least 95% identity to V LThus, in some embodiments, the antibody can comprise the V domain of humanized E1-38 mAB. H Same V as domain H Domain and V of humanized E1-38mAB L Same V as domain L In a specific example, the isolated antibody comprises a V domain identical to that of monoclonal antibody E1-38. H and V L It may include a domain.
[0018] In a further aspect, the isolated antibody comprises a first V sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the corresponding CDR sequences of monoclonal antibody E1-52, represented by SEQ ID NOs: 40, 41, 42, 108, 77, and 109, respectively. H , the second V H , the third V H , the first V L , the second V L , and the third V L CDR sequences. In one embodiment, the isolated antibody comprises CDR sequences which are identical to the CDR sequences of monoclonal antibody E1-52.
[0019] In another embodiment, the isolated antibody comprises the V H Humanized V domain of E1-52mAB H V that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the domain H domain and V of E1-52 (SEQ ID NO: 170) L Humanized V domain of E1-52mAB L V that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the domain L For example, the antibody may comprise the V domain of humanized E1-52 mAB. H Domain with at least 95% identity to V HDomain and V of humanized E1-52mAB L Domain with at least 95% identity to V L Thus, in some embodiments, the antibody can comprise the V domain of humanized E1-52 mAB. H Same V as domain H Domain and V of humanized E1-52mAB L Same V as domain L In a specific example, the isolated antibody comprises a V domain identical to that of monoclonal antibody E1-52. H and V L It may include a domain.
[0020] In a further aspect, the isolated antibody comprises a first V sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the corresponding CDR sequences of monoclonal antibody E2-36, represented by SEQ ID NOs: 46, 47, 48, 113, 83, and 114, respectively. H , the second V H , the third V H , the first V L , the second V L , and the third V L CDR sequences. In one embodiment, the isolated antibody comprises CDR sequences that are identical to the CDR sequences of monoclonal antibody E2-36.
[0021] In another embodiment, the isolated antibody comprises the V H Domain or humanized V of E2-36mAB H V that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the domain H domain and V of E2-36 (SEQ ID NO: 172) L Domain or humanized V of E2-36mAB L V that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the domain LFor example, the antibody may comprise the V domain of humanized E2-36mAB. H Domain with at least 95% identity to V H Domain and V of humanized E2-36mAB L Domain with at least 95% identity to V L Thus, in some embodiments, the antibody can comprise the V domain of humanized E2-36mAB. H Same V as domain H Domain and V of humanized E2-36mAB L Same V as domain L In a specific example, the isolated antibody comprises a V domain identical to that of monoclonal antibody E2-36. H and V L It may include a domain.
[0022] In a further aspect, the isolated antibody comprises a first V sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the corresponding CDR sequences of monoclonal antibody E1-95, represented by SEQ ID NOs: 52, 53, 54, 117, 83, and 119, respectively. H , the second V H , the third V H , 1st V L , the second V L , and the third V L CDR sequences. In one embodiment, the isolated antibody comprises CDR sequences which are identical to the CDR sequences of monoclonal antibody E1-95.
[0023] In another embodiment, the isolated antibody comprises the V H Humanized V domain of E1-95mAB H V that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the domain H domain and V of E1-95 (SEQ ID NO: 174) L Humanized V domain of E1-95mAB LV that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the domain L For example, the antibody may comprise the V domain of humanized E1-95mAB. H Domain with at least 95% identity to V H Domain and V of humanized E1-95mAB L Domain with at least 95% identity to V L Thus, in some embodiments, the antibody can comprise the V domain of humanized E1-95mAB. H Same V as domain H Domain and V of humanized E1-95mAB L Same V as domain L In a specific example, the isolated antibody comprises a V domain identical to that of monoclonal antibody E1-95. H and V L It may include a domain.
[0024] In a further aspect, the isolated antibody comprises a first V sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the corresponding CDR sequences of monoclonal antibody E2-116, represented by SEQ ID NOs: 58, 59, 60, 121, 100, and 122, respectively. H , the second V H , the third V H , the first V L , the second V L , and the third V L CDR sequences. In one embodiment, the isolated antibody comprises CDR sequences which are identical to the CDR sequences of monoclonal antibody E2-116.
[0025] In another embodiment, the isolated antibody comprises the V H Domain or humanized V of E2-116mAB H V that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the domain Hdomain and V of E2-116 (SEQ ID NO: 176) L Domain or humanized V of E2-116mAB L V that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the domain L For example, the antibody may comprise the V domain of humanized E2-116mAB. H Domain with at least 95% identity to V H Domain and V of humanized E2-116mAB L Domain with at least 95% identity to V L Thus, in some embodiments, the antibody can comprise the V domain of humanized E2-116mAB. H Same V as domain H Domain and V of humanized E2-116mAB L Same V as domain L In a specific example, the isolated antibody comprises a V domain identical to that of monoclonal antibody E2-116. H and V L It may include a domain.
[0026] In a further aspect, the isolated antibody comprises a first V sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the corresponding CDR sequences of monoclonal antibody E2-135, represented by SEQ ID NOs: 64, 65, 66, 126, 127, and 128, respectively. H , the second V H , the third V H , the first V L , the second V L , and the third V L CDR sequences. In one embodiment, the isolated antibody comprises CDR sequences that are identical to the CDR sequences of monoclonal antibody E2-135.
[0027] In another embodiment, the isolated antibody comprises the V H Domain or humanized V of E2-135mAB HV that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the domain H domain and V of E2-135 (SEQ ID NO: 178) L Domain or humanized V of E2-135mAB L V that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the domain L For example, the antibody may comprise the V domain of humanized E2-135mAB. H Domain with at least 95% identity to V H Domain and V of humanized E2-135mAB L Domain with at least 95% identity to V L Thus, in some embodiments, the antibody can comprise the V domain of humanized E2-135mAB. H Same V as domain H Domain and V of humanized E2-135mAB L Same V as domain L In a specific example, the isolated antibody comprises a V domain identical to that of monoclonal antibody E2-135. H and V L It may include a domain.
[0028] In a further aspect, the isolated antibody comprises a first V sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the corresponding CDR sequences of monoclonal antibody E1-142, represented by SEQ ID NOs: 70, 71, 72, 131, 100, and 132, respectively. H , the second V H , the third V H , 1st V L , the second V L , and the third V L CDR sequences. In one embodiment, the isolated antibody comprises CDR sequences which are identical to the CDR sequences of monoclonal antibody E1-142.
[0029] In another embodiment, the isolated antibody comprises the V H Domain or humanized V of E1-142mAB H V that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the domain H domain and V of E1-142 (SEQ ID NO: 180) L Domain or humanized V of E1-142mAB L V that is at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the domain L For example, the antibody may comprise the V domain of humanized E1-142mAB. H Domain with at least 95% identity to V H Domain and V of humanized E1-142mAB L Domain with at least 95% identity to V L Thus, in some embodiments, the antibody can comprise the V domain of humanized E1-142 mAB. H Same V as domain H Domain and V of humanized E1-142mAB L Same V as domain L In a specific example, the isolated antibody comprises a V domain identical to that of monoclonal antibody E1-142. H and V L It may include a domain.
[0030] In some aspects, the antibody of the embodiment may be an IgG (e.g., IgG1, IgG2, IgG3, or IgG4), IgM, IgA, genetically modified IgG isotype, or an antigen-binding fragment thereof. The antibody may be a Fab', F(ab')2, F(ab')3, monovalent scFv, bivalent scFv, bispecific, or single domain antibody. The antibody may be a human, humanized, or deimmunized antibody. In further aspects, the isolated antibody is an E1-33, E1-34, E1-80, E1-89, E2-93, E1-38, E1-52, E2-36, E1-95, E2-116, E2-135, or E1-142 antibody.
[0031] In some embodiments, the antibody may be conjugated to an imaging agent, a chemotherapeutic agent, a toxin, or a radionuclide. In specific embodiments, the antibody may be conjugated to an auristatin, or in particular monomethylauristatin E (MMAE).
[0032] In one embodiment, the V H CDR1 to 3 of domain E1-34 (SEQ ID NOs: 10, 11, and 12) H CDR1 to 3 of domain E1-80 (SEQ ID NOs: 16, 17, and 18) H CDR1 to 3 of domain E1-89 (SEQ ID NOs: 22, 23, and 24) H CDR1 to 3 of domain E2-93 (SEQ ID NOs: 28, 29, and 30) H CDR1 to 3 of domain E1-38 (SEQ ID NOs: 34, 35, and 36) H CDR1 to 3 of domain E1-52 (SEQ ID NOs: 40, 41, and 42) H CDR1 to 3 of domain E2-36 (SEQ ID NOs: 46, 47, and 48) H CDR1 to 3 of domain E1-95 (SEQ ID NOs: 52, 53, and 54) H CDR1 to 3 of domain E2-116 (SEQ ID NOs: 58, 59, and 60) H CDR1 to 3 of domain E2-135 (SEQ ID NOs: 64, 65, and 66) H CDR1 to 3 of domain, or V of E1-142 (SEQ ID NOs: 70, 71, and 72) H Antibody V containing CDR1-3 of domain H In another embodiment, a recombinant polypeptide is provided comprising the V domain of E1-33 (SEQ ID NOs: 76, 77, and 78). L CDR1 to 3 of domain E1-34 (SEQ ID NOs: 82, 83, and 84) L CDR1-3 of domain E1-80 (SEQ ID NOs: 88, 77, and 89) L CDR1-3 of domain E1-89 (SEQ ID NOs: 93, 94, and 95) LCDR1 to 3 of domain E2-93 (SEQ ID NOs: 99, 100, and 101) L CDR1 to 3 of domain E1-38 (SEQ ID NOs: 104, 100, and 105) L CDR1 to 3 of domain E1-52 (SEQ ID NOs: 108, 77, and 109) L CDR1 to 3 of domain E2-36 (SEQ ID NOs: 113, 83, and 114) L CDR1-3 of domain E1-95 (SEQ ID NOs: 117, 83, and 118) L CDR1 to 3 of domain E2-116 (SEQ ID NOs: 121, 100, and 122) L CDR1 to 3 of domain E2-135 (SEQ ID NOs: 126, 127, and 128) L CDR1 to 3 of domain, or V of E1-142 (SEQ ID NOs: 131, 100, and 132) L Antibody V containing CDR1-3 of domain L A recombinant polypeptide comprising the domain is provided.
[0033] In some embodiments, the antibody or antibody V disclosed herein H Or V L An isolated polynucleotide molecule is provided that comprises a nucleic acid sequence that encodes a polypeptide that includes the domain.
[0034] In further embodiments, a host cell is provided that produces the monoclonal antibody or recombinant polypeptide of the embodiments. In some aspects, the host cell is a mammalian cell, a yeast cell, a bacterial cell, a ciliate cell, or an insect cell. In certain aspects, the host cell is a hybridoma cell.
[0035] In yet a further embodiment, the V of an antibody disclosed herein in a cell L or V H Methods for producing an antibody of the invention are provided, comprising expressing one or more polynucleotide molecules encoding the chains and purifying the antibody from a cell.
[0036] In additional embodiments, there are pharmaceutical compositions comprising an antibody or antibody fragment as described herein. Such compositions further comprise a pharma- ceutically acceptable carrier and may or may not contain additional active ingredients.
[0037] In an embodiment of the present invention, a method of treating a subject having cancer is provided, comprising administering an effective amount of an antibody disclosed herein. In a particular aspect, the antibody is a monoclonal antibody of the embodiments herein, such as an E1-33, E1-34, E1-80, E1-89, E2-93, E1-38, E1-52, E2-36, E1-95, E2-116, E2-135, or E1-142 antibody or a recombinant polypeptide comprising an antibody fragment derived therefrom.
[0038] In certain aspects, the cancer may be breast cancer, lung cancer, head and neck cancer, prostate cancer, esophageal cancer, tracheal cancer, brain cancer, liver cancer, bladder cancer, stomach cancer, pancreatic cancer, ovarian cancer, uterine cancer, cervical cancer, testicular cancer, colon cancer, rectal cancer, or skin cancer. In specific aspects, the cancer is an epithelial cancer. In other aspects, the cancer may be colorectal adenocarcinoma, lung adenocarcinoma, lung squamous cell carcinoma, breast cancer, hepatocellular carcinoma, ovarian cancer, clear cell renal cell carcinoma, lung cancer, or kidney cancer.
[0039] In one embodiment, the antibody can be administered systemically.In additional embodiments, the antibody can be administered intravenously, intradermally, intratumorally, intramuscularly, intraperitoneally, subcutaneously, or locally.The method can further comprise administering to the subject at least a second anti-cancer therapy.Examples of the second anti-cancer therapy include, but are not limited to, surgery, chemotherapy, radiation therapy, cryotherapy, hormone therapy, immunotherapy, or cytokine therapy.
[0040] In further embodiments, the methods may further comprise administering to the subject a composition of the invention one or more times, such as, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20 or more times.
[0041] In another embodiment, a method for detecting cancer in a subject is provided, comprising testing for the presence of high EGFL6 in a sample from the subject compared to a control, wherein the testing comprises contacting the sample with the antibody disclosed herein.For example, the method can be an in vitro or in vivo method.
[0042] Certain embodiments are directed to an antibody or recombinant polypeptide composition comprising an isolated and / or recombinant antibody or polypeptide that specifically binds to EGFL6. In certain aspects, the antibody or polypeptide has a sequence that is at least or at most 80, 85, 90, 95, 96, 97, 98, 99, or 100% identical (or to any extent derivable therein) to all or a portion of any of the monoclonal antibodies provided herein. In yet further aspects, the isolated and / or recombinant antibody or polypeptide has at least or at most 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100% identical (or to any extent derivable therein 4, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more contiguous amino acids.
[0043] In yet further aspects, an antibody or polypeptide of the embodiments comprises one or more amino acid segments of any of the amino acid sequences disclosed herein. For example, the antibody or polypeptide may be about, at least, or at most 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25-25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 85, 90, 95, 96, 97, 98, 99, or 100% identical to any of the amino acid sequences disclosed herein, including all values and ranges therebetween. , 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 1 08, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 199, 198, 199, 199, 199, 198, 199, 199, 199, 199, 1 The amino acid segment may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acid segments comprising 1, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, or 200 amino acids in length. In certain embodiments, the amino acid segment is selected from one of the amino acid sequences of the EGFL6 binding antibodies provided herein.
[0044] In still further aspects, antibodies or polypeptides of the embodiments comprise an amino acid segment of any of the amino acid sequences disclosed herein, the segment being located at amino acid positions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25-25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 109, 109, 108, 110, 111, 112, 113, 3, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 7, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158 , 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, or 200, and in the same provided sequence, amino acid positions 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25-25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64,65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 1 38, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 17 0, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, or 200. In certain embodiments, the amino segment, or a portion thereof, is selected from one of the amino acid sequences of the EGFL6 binding antibodies provided herein.
[0045] In still further aspects, antibodies or polypeptides of the embodiments comprise amino acid segments that are at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical (or to any extent derivable therein) to the V, VJ, VDJ, D, DJ, J or CDR domains of an EGFL6 binding antibody (as provided in Tables 1 and 2). For example, a polypeptide may comprise one, two or three amino acid segments that are at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical (or to any extent derivable therein) to CDR1, 2 and / or 3 of an EGFL6 binding antibody as provided in Tables 1 and 2.
[0046] An embodiment discussed in the context of a method and / or composition of the invention may be used with respect to any other method or composition described herein, and thus an embodiment with respect to one method or composition may also be applied to other methods and compositions of the invention.
[0047] As used herein, "a" or "an" may mean one or more. When used in the claims, when used with the word "comprising," the words "a" or "a n" may mean one or more.
[0048] Use of the term "or" in the claims means "and / or" unless there is a clear indication that only alternatives are referred to or the alternatives are not mutually exclusive, however, the present disclosure supports the definition that refers only to alternatives and "and / or." As used herein, "another" may mean at least a second or more.
[0049] Throughout this specification, the term "about" is used to indicate that a value includes the inherent variation of error for the device, the method used to determine the value, or the variation that exists among study subjects.
[0050] [The present invention 1001] An isolated monoclonal antibody, the antibody specifically binding to EGFL6, (I) (a) The first V H the CDRs are identical to SEQ ID NO:4; (b) The second V H the CDRs are identical to SEQ ID NO:5; (c) The third V H the CDRs are identical to SEQ ID NO:6; (d) The first V L the CDRs are identical to SEQ ID NO: 76; (e) The second V L the CDRs are identical to SEQ ID NO: 77; (f) The third V L the CDRs are identical to SEQ ID NO: 78; (II) (a) The first V H the CDRs are identical to SEQ ID NO: 10; (b) The second V H the CDRs are identical to SEQ ID NO: 11; (c) The third V H the CDRs are identical to SEQ ID NO: 12; (d) The first V L the CDRs are identical to SEQ ID NO: 82; (e) The second V L the CDRs are identical to SEQ ID NO: 83; (f) The third V L the CDRs are identical to SEQ ID NO: 84; (III) (a) The first V H the CDRs are identical to SEQ ID NO: 16; (b) The second V H the CDRs are identical to SEQ ID NO: 17; (c) The third V H the CDRs are identical to SEQ ID NO: 18; (d) The first V L the CDRs are identical to SEQ ID NO: 88; (e) The second V L the CDRs are identical to SEQ ID NO: 77; (f) The third V L the CDRs are identical to SEQ ID NO:89; (IV) (a) The first V H the CDRs are identical to SEQ ID NO: 22; (b) The second V H the CDRs are identical to SEQ ID NO: 23; (c) The third V H the CDRs are identical to SEQ ID NO: 24; (d) The first V L the CDRs are identical to SEQ ID NO: 93; (e) The second V L the CDRs are identical to SEQ ID NO: 94; (f) The third V L the CDRs are identical to SEQ ID NO: 95; (V) (a) The first V H the CDRs are identical to SEQ ID NO: 28; (b) The second V H the CDRs are identical to SEQ ID NO:29; (c) The third V H the CDRs are identical to SEQ ID NO: 30; (d) The first V L the CDRs are identical to SEQ ID NO: 99; (e) The second V L the CDRs are identical to SEQ ID NO: 100; (f) The third V L the CDRs are identical to SEQ ID NO: 101; (VI) (a) The first V H the CDRs are identical to SEQ ID NO: 34; (b) The second V H the CDRs are identical to SEQ ID NO: 35; (c) The third V H the CDRs are identical to SEQ ID NO: 36; (d) The first V L the CDRs are identical to SEQ ID NO: 104; (e) The second V L the CDRs are identical to SEQ ID NO: 100; (f) The third V L the CDRs are identical to SEQ ID NO: 105; (VII) (a) The first V H the CDRs are identical to SEQ ID NO: 40; (b) The second V H the CDRs are identical to SEQ ID NO: 41; (c) The third V H the CDRs are identical to SEQ ID NO: 42; (d) The first V L the CDRs are identical to SEQ ID NO: 108; (e) The second V L the CDRs are identical to SEQ ID NO: 77; (f) The third V L the CDRs are identical to SEQ ID NO: 109; (VIII) (a) The first V H the CDRs are identical to SEQ ID NO: 46; (b) The second V H the CDRs are identical to SEQ ID NO: 47; (c) The third V H the CDRs are identical to SEQ ID NO: 48; (d) The first V L the CDRs are identical to SEQ ID NO: 113; (e) The second V L the CDRs are identical to SEQ ID NO: 83; (f) The third V L the CDRs are identical to SEQ ID NO: 114; (IX) (a) The first V H the CDRs are identical to SEQ ID NO: 52; (b) The second V H the CDRs are identical to SEQ ID NO: 53; (c) The third V H the CDRs are identical to SEQ ID NO:54; (d) The first V L the CDRs are identical to SEQ ID NO: 117; (e) The second V L the CDRs are identical to SEQ ID NO: 83; (f) The third V L the CDRs are identical to SEQ ID NO: 119; (X) (a) The first V H the CDRs are identical to SEQ ID NO:58; (b) The second V H the CDRs are identical to SEQ ID NO:59; (c) The third V H the CDRs are identical to SEQ ID NO: 60; (d) The first V L the CDRs are identical to SEQ ID NO: 121; (e) The second V Lthe CDRs are identical to SEQ ID NO: 100; (f) The third V L the CDRs are identical to SEQ ID NO: 122; (XI) (a) The first V H the CDRs are identical to SEQ ID NO: 64; (b) The second V H the CDRs are identical to SEQ ID NO: 65; (c) The third V H the CDRs are identical to SEQ ID NO: 66; (d) The first V L the CDRs are identical to SEQ ID NO: 126; (e) The second V L the CDRs are identical to SEQ ID NO: 127; (f) The third V L the CDRs are identical to SEQ ID NO: 128, or (XII) (a) The first V H the CDRs are identical to SEQ ID NO: 70; (b) The second V H the CDRs are identical to SEQ ID NO: 71; (c) The third V H the CDRs are identical to SEQ ID NO: 72; (d) The first V L the CDRs are identical to SEQ ID NO: 131; (e) The second V L the CDRs are identical to SEQ ID NO: 100; (f) The third V L The CDRs are identical to SEQ ID NO: 132 1. An isolated antibody comprising: [The present invention 1002] (a) The first V H the CDRs are identical to SEQ ID NO:4; (b) The second V H the CDRs are identical to SEQ ID NO:5; (c) The third V H the CDRs are identical to SEQ ID NO:6; (d) The first V Lthe CDRs are identical to SEQ ID NO: 76; (e) The second V L the CDRs are identical to SEQ ID NO: 77; (f) The third V L The CDRs are identical to SEQ ID NO:78 1001. An isolated antibody of the present invention comprising: [The present invention 1003] (a) The first V H the CDRs are identical to SEQ ID NO: 10; (b) The second V H the CDRs are identical to SEQ ID NO: 11; (c) The third V H the CDRs are identical to SEQ ID NO: 12; (d) The first V L the CDRs are identical to SEQ ID NO: 82; (e) The second V L the CDRs are identical to SEQ ID NO: 83; (f) The third V L The CDRs are identical to SEQ ID NO:84 1001. An isolated antibody of the present invention comprising: [The present invention 1004] (a) The first V H the CDRs are identical to SEQ ID NO: 16; (b) The second V H the CDRs are identical to SEQ ID NO: 17; (c) The third V H the CDRs are identical to SEQ ID NO: 18; (d) The first V L the CDRs are identical to SEQ ID NO: 88; (e) The second V L the CDRs are identical to SEQ ID NO: 77; (f) The third V L The CDRs are identical to SEQ ID NO:89 1001. An isolated antibody of the present invention comprising: [The present invention 1005] (a) The first V H the CDRs are identical to SEQ ID NO: 22; (b) The second V Hthe CDRs are identical to SEQ ID NO: 23; (c) The third V H the CDRs are identical to SEQ ID NO: 24; (d) The first V L the CDRs are identical to SEQ ID NO: 93; (e) The second V L the CDRs are identical to SEQ ID NO: 94; (f) The third V L The CDRs are identical to SEQ ID NO:95 1001. An isolated antibody of the present invention comprising: [The present invention 1006] (a) The first V H the CDRs are identical to SEQ ID NO: 28; (b) The second V H the CDRs are identical to SEQ ID NO:29; (c) The third V H the CDRs are identical to SEQ ID NO: 30; (d) The first V L the CDRs are identical to SEQ ID NO: 99; (e) The second V L the CDRs are identical to SEQ ID NO: 100; (f) The third V L The CDRs are identical to SEQ ID NO: 101 1001. An isolated antibody of the present invention comprising: [The present invention 1007] (a) The first V H the CDRs are identical to SEQ ID NO: 34; (b) The second V H the CDRs are identical to SEQ ID NO: 35; (c) The third V H the CDRs are identical to SEQ ID NO: 36; (d) The first V L the CDRs are identical to SEQ ID NO: 104; (e) The second V L the CDRs are identical to SEQ ID NO: 100; (f) The third V L The CDRs are identical to SEQ ID NO: 105 1001. An isolated antibody of the present invention comprising: [The present invention 1008] (a) The first V H the CDRs are identical to SEQ ID NO: 40; (b) The second V H the CDRs are identical to SEQ ID NO: 41; (c) The third V H the CDRs are identical to SEQ ID NO: 42; (d) The first V L the CDRs are identical to SEQ ID NO: 108; (e) The second V L the CDRs are identical to SEQ ID NO: 77; (f) The third V L The CDRs are identical to SEQ ID NO: 109 1001. An isolated antibody of the present invention comprising: [The present invention 1009] (a) The first V H the CDRs are identical to SEQ ID NO: 46; (b) The second V H the CDRs are identical to SEQ ID NO: 47; (c) The third V H the CDRs are identical to SEQ ID NO: 48; (d) The first V L the CDRs are identical to SEQ ID NO: 113; (e) The second V L the CDRs are identical to SEQ ID NO: 83; (f) The third V L The CDRs are identical to SEQ ID NO: 114 1001. An isolated antibody of the present invention comprising: [The present invention 1010] (a) The first V H the CDRs are identical to SEQ ID NO: 52; (b) The second V H the CDRs are identical to SEQ ID NO: 53; (c) The third V H the CDRs are identical to SEQ ID NO:54; (d) The first V L the CDRs are identical to SEQ ID NO: 117; (e) The second VL the CDRs are identical to SEQ ID NO: 83; (f) The third V L The CDRs are identical to SEQ ID NO: 119 1001. An isolated antibody of the present invention comprising: [The present invention 1011] (a) The first V H the CDRs are identical to SEQ ID NO:58; (b) The second V H the CDRs are identical to SEQ ID NO:59; (c) The third V H the CDRs are identical to SEQ ID NO: 60; (d) The first V L the CDRs are identical to SEQ ID NO: 121; (e) The second V L the CDRs are identical to SEQ ID NO: 100; (f) The third V L The CDRs are identical to SEQ ID NO: 122 1001. An isolated antibody of the present invention comprising: [The present invention 1012] (a) The first V H the CDRs are identical to SEQ ID NO: 64; (b) The second V H the CDRs are identical to SEQ ID NO: 65; (c) The third V H the CDRs are identical to SEQ ID NO: 66; (d) The first V L the CDRs are identical to SEQ ID NO: 126; (e) The second V L the CDRs are identical to SEQ ID NO: 127; (f) The third V L The CDRs are identical to SEQ ID NO: 128 1001. An isolated antibody of the present invention comprising: [The present invention 1013] (a) The first V H the CDRs are identical to SEQ ID NO: 70; (b) The second V H the CDRs are identical to SEQ ID NO: 71; (c) The third V H the CDRs are identical to SEQ ID NO: 72; (d) The first V L the CDRs are identical to SEQ ID NO: 131; (e) The second V L the CDRs are identical to SEQ ID NO: 100; (f) The third V L The CDRs are identical to SEQ ID NO: 132 1001. An isolated antibody of the present invention comprising: [The present invention 1014] (i) V of E1-33 (SEQ ID NO: 157) H Domain or humanized V of E1-33mAB H Domains that are at least about 80% identical to V H domain, and V of E1-33 (SEQ ID NO: 158) L Domain or humanized V of E1-33mAB L Domains that are at least about 80% identical to V L domain, (ii) V of E1-34 (SEQ ID NO: 159) H Domain or humanized V of E1-34mAB H Domains that are at least about 80% identical to V H domain, and V of E1-34 (SEQ ID NO: 160) L Domain or humanized V of E1-34mA L Domains that are at least about 80% identical to V L domain, (iii) V of E1-80 (SEQ ID NO: 161) H Domain or humanized V of E1-80mAB H Domains that are at least about 80% identical to V H domain, and V of E1-80 (SEQ ID NO: 162) L Domain or humanized V of E1-80mAB L Domains that are at least about 80% identical to V L domain, (iv) V of E1-89 (SEQ ID NO: 163) H Domain or humanized V of E1-89mAB H Domains that are at least about 80% identical to VH domain, and V of E1-89 (SEQ ID NO: 164) L Domain or humanized V of E1-80mAB L Domains that are at least about 80% identical to V L domain, (v) V of E2-93 (SEQ ID NO: 165) H Domain or humanized V of E2-93mAB H Domains that are at least about 80% identical to V H domain, and V of E2-93 (SEQ ID NO: 166) L Domain or humanized V of E2-93mAB L Domains that are at least about 80% identical to V L domain, (vi) V of E1-38 (SEQ ID NO: 167) H Domain or humanized V of E1-38mAB H Domains that are at least about 80% identical to V H Domain, and V of E1-38 (SEQ ID NO: 168) L Domain or humanized V of E1-38mAB L Domains that are at least about 80% identical to V L domain, (vii) V of E1-52 (SEQ ID NO: 169) H Domain or humanized V of E1-52mAB H Domains that are at least about 80% identical to V H domain, and V of E1-52 (SEQ ID NO: 170) L Domain or humanized V of E1-52mAB L Domains that are at least about 80% identical to V L domain, (viii) V of E2-36 (SEQ ID NO: 171) H Domain or humanized V of E2-36mAB H Domains that are at least about 80% identical to V H domain, and V of E2-36 (SEQ ID NO: 172) L Domain or humanized V of E2-36mAB L Domains that are at least about 80% identical to V L domain, (ix) V of E1-95 (SEQ ID NO: 173) H Domain or humanized V of E1-95mAB H Domains that are at least about 80% identical to V H domain, and V of E1-95 (SEQ ID NO: 174) L Domain or humanized V of E1-95mAB L Domains that are at least about 80% identical to V L domain, (x) V of E2-116 (SEQ ID NO: 175) H Domain or humanized V of E2-116mAB H Domains that are at least about 80% identical to V H domain, and V of E2-116 (SEQ ID NO: 176) L Domain or humanized V of E2-116mAB L Domains that are at least about 80% identical to V L domain, (xi) V of E2-135 (SEQ ID NO: 177) H Domain or humanized V of E2-135mAB H Domains that are at least about 80% identical to V H domain, and V of E2-135 (SEQ ID NO: 178) L Domain or humanized V of E2-135mAB L Domains that are at least about 80% identical to V L Domain, or (xii) V of E1-142 (SEQ ID NO: 179) H Domain or humanized V of E1-142mAB H Domains that are at least about 80% identical to V H domain, and V of E1-142 (SEQ ID NO: 180) L Domain or humanized V of E1-142mAB L Domains that are at least about 80% identical to V L domain The antibody of the present invention, [The present invention 1015] V of E1-33 (SEQ ID NO: 157) H Same V as domain Hdomain and V of E1-33 (SEQ ID NO: 158) L Same V as domain L The antibody of the present invention, comprising: [The present invention 1016] V of E1-34 (SEQ ID NO: 159) H Same V as domain H domain and V of E1-34 (SEQ ID NO: 160) L Same V as domain L The antibody of the present invention, comprising: [The present invention 1017] V of E1-80 (SEQ ID NO: 161) H Same V as domain H domain and V of E1-80 (SEQ ID NO: 162) L Same V as domain L The antibody of the present invention, comprising: [The present invention 1018] V of E1-89 (SEQ ID NO: 163) H Same V as domain H domain and V of E1-89 (SEQ ID NO: 164) L Same V as domain L The antibody of the present invention, comprising: [The present invention 1019] V of E2-93 (SEQ ID NO: 165) H Same V as domain H domain and V of E2-93 (SEQ ID NO: 166) L Same V as domain L The antibody of the present invention, comprising: [The present invention 1020] V of E1-38 (SEQ ID NO: 167) H Same V as domain H domain and V of E1-38 (SEQ ID NO: 168) L Same V as domain L The antibody of the present invention, comprising: [The present invention 1021] V of E1-52 (SEQ ID NO: 169) H Same V as domain Hdomain and V of E1-52 (SEQ ID NO: 170) L Same V as domain L The antibody of the present invention, comprising: [The present invention 1022] V of E2-36 (SEQ ID NO: 171) H Same V as domain H domain and V of E2-36 (SEQ ID NO: 172) L Same V as domain L The antibody of the present invention, comprising: [The present invention 1023] V of E1-95 (SEQ ID NO: 173) H Same V as domain H domain and V of E1-95 (SEQ ID NO: 174) L Same V as domain L The antibody of the present invention, comprising: [The present invention 1024] V of E2-116 (SEQ ID NO: 175) H Same V as domain H domain and V of E2-116 (SEQ ID NO: 176) L Same V as domain L The antibody of the present invention, comprising: [The present invention 1025] V of E2-135 (SEQ ID NO: 177) H Same V as domain H domain and V of E2-135 (SEQ ID NO: 178) L Same V as domain L The antibody of the present invention, comprising: [The present invention 1026] V of E1-142 (SEQ ID NO: 179) H Same V as domain H domain and V of E1-142 (SEQ ID NO: 180) L Same V as domain L The antibody of the present invention, comprising: [The present invention 1027] The antibody of the present invention which is an E1-33, E1-34, E1-80, E1-89, E2-93, E1-38, E1-52, E2-36, E1-95, E2-116, E2-135, or E1-142 antibody. [The present invention 1028] The antibody of any one of the antibodies 1001 to 1027 of the present invention, which is a recombinant antibody. [The present invention 1029] The antibody of the present invention which is an IgG, IgM, IgA, or an antigen-binding fragment thereof. [The present invention 1030] The antibody of any one of claims 1001 to 1027, which is a Fab', F(ab')2, F(ab')3, monovalent scFv, divalent scFv, or single domain antibody. [The present invention 1031] The antibody of any one of claims 1001 to 1013, which is a human antibody, a humanized antibody, or a deimmunized antibody. [The present invention 1032] The antibody of any of claims 1001 to 1027, conjugated to an imaging agent, a chemotherapeutic agent, a toxin, or a radionuclide. [The present invention 1033] The antibody of the present invention, conjugated to a toxin. [The present invention 1034] The antibody of the present invention, wherein the toxin is an auristatin. [The present invention 1035] The antibody of the present invention, wherein the toxin is monomethylauristatin E (MMAE). [The present invention 1036] A composition comprising any one of the antibodies of the present invention 1001 to 1027 in a pharma- ceutically acceptable carrier. [The present invention 1037] An isolated polynucleotide molecule comprising a nucleic acid sequence encoding any one of the antibodies of the present invention 1001 to 1027. [The present invention 1038] V of E1-33 (SEQ ID NOs: 4, 5, and 6) H CDR1-3 of the domain, V of E1-34 (SEQ ID NOs: 10, 11, and 12) HCDR1-3 of the domain, V of E1-80 (SEQ ID NOs: 16, 17, and 18) H CDR1-3 of the domain, V of E1-89 (SEQ ID NOs: 22, 23, and 24) H CDR1-3 of the domain, V of E2-93 (SEQ ID NOs: 28, 29, and 30) H CDR1-3 of the domain, V of E1-38 (SEQ ID NOs: 34, 35, and 36) H CDR1-3 of the domain, V of E1-52 (SEQ ID NOs: 40, 41, and 42) H CDR1-3 of the domain, V of E2-36 (SEQ ID NOs: 46, 47, and 48) H CDR1-3 of the domain, V of E1-95 (SEQ ID NOs: 52, 53, and 54) H CDR1-3 of the domain, V of E2-116 (SEQ ID NOs: 58, 59, and 60) H CDR1-3 of the domain, V of E2-135 (SEQ ID NOs: 64, 65, and 66) H CDRs 1-3 of a domain, or V of E1-142 (SEQ ID NOs: 70, 71, and 72) H CDR1-3 of the domain Antibody V containing H A recombinant polypeptide comprising a domain. [The present invention 1039] V of E1-33 (SEQ ID NOs: 76, 77, and 78) L CDR1-3 of the domain, V of E1-34 (SEQ ID NOs: 82, 83, and 84) L CDR1-3 of the domain, V of E1-80 (SEQ ID NOs: 88, 77, and 89) L CDR1-3 of the domain, V of E1-89 (SEQ ID NOs: 93, 94, and 95) L CDR1-3 of the domain, V of E2-93 (SEQ ID NOs: 99, 100, and 101) LCDR1-3 of the domain, V of E1-38 (SEQ ID NOs: 104, 100, and 105) L CDR1-3 of the domain, V of E1-52 (SEQ ID NOs: 108, 77, and 109) L CDR1-3 of the domain, V of E2-36 (SEQ ID NOs: 113, 83, and 114) L CDR1-3 of the domain, V of E1-95 (SEQ ID NOs: 117, 83, and 118) L CDR1-3 of the domain, V of E2-116 (SEQ ID NOs: 121, 100, and 122) L CDR1-3 of the domain, V of E2-135 (SEQ ID NOs: 126, 127, and 128) L CDRs 1-3 of a domain, or E1-142 (SEQ ID NOs: 131, 100, and 132) V L CDR1-3 of the domain Antibody V containing L A recombinant polypeptide comprising a domain. [The present invention 1040] An isolated polynucleotide molecule comprising a nucleic acid sequence encoding a 1038 or 1039 polypeptide of the present invention. [The present invention 1041] A host cell comprising one or more polynucleotide molecules encoding the antibody of any of the inventions 1001 to 1027 or the recombinant polypeptide of the inventions 1038 or 1039. [The present invention 1042] The host cell of the invention 1041, which is a mammalian cell, a yeast cell, a bacterial cell, a ciliate cell, or an insect cell. [The present invention 1043] (a) In a cell, V of any one of antibodies 1001 to 1027 of the present invention L and V H expressing one or more polynucleotide molecules encoding the chains; (b) purifying the antibody from the cells; A method for producing an antibody, comprising: [The present invention 1044] A method for treating a subject having cancer, comprising the step of administering to the subject an effective amount of any one of the antibodies of the present invention, 1001 to 1027. [The present invention 1045] The method of claim 1044, wherein said cancer is breast cancer, lung cancer, head and neck cancer, prostate cancer, esophageal cancer, tracheal cancer, skin cancer, brain cancer, liver cancer, bladder cancer, stomach cancer, pancreatic cancer, ovarian cancer, uterine cancer, cervical cancer, testicular cancer, colon cancer, rectal cancer, or skin cancer. [The present invention 1046] The method of claim 1044, wherein the cancer is an epithelial cancer. [The present invention 1047] The method of claim 1044, wherein said cancer is colorectal adenocarcinoma, lung adenocarcinoma, lung squamous cell carcinoma, breast cancer, hepatocellular carcinoma, ovarian cancer, clear cell renal cell carcinoma, lung cancer, or kidney cancer. [The present invention 1048] The method of claim 1044, wherein said antibody is in a pharma- ceutically acceptable composition. [The present invention 1049] The method of claim 1044, wherein the antibody is administered systemically. [The present invention 1050] The method of claim 1044, wherein said antibody is administered intravenously, intradermally, intratumorally, intramuscularly, intraperitoneally, subcutaneously, or topically. [The present invention 1051] The method of claim 1044, further comprising administering to said subject at least a second anti-cancer therapy. [The present invention 1052] The method of claim 1051, wherein said second anticancer therapy is surgical therapy, chemotherapy, radiation therapy, cryotherapy, hormonal therapy, immunotherapy, or cytokine therapy. [The present invention 1053] 1. A method for detecting cancer in a subject, comprising testing for the presence of elevated EGFL6 in a sample from the subject as compared to a control, The method, wherein the step of testing comprises contacting the sample with an antibody of any of the inventions 1014-1027 or 1032. [The present invention 1054] The method of the present invention 1053 further defined as an in vitro method. [The present invention 1055] (a) V of E1-33 (SEQ ID NO: 4), E1-34 (SEQ ID NO: 10), E1-80 (SEQ ID NO: 16), E1-89 (SEQ ID NO: 22), E2-93 (SEQ ID NO: 28), E1-38 (SEQ ID NO: 34), E1-52 (SEQ ID NO: 40), E2-36 (SEQ ID NO: 46), E1-95 (SEQ ID NO: 52), E2-116 (SEQ ID NO: 58), E2-135 (SEQ ID NO: 64), or E1-142 (SEQ ID NO: 70) H A first V that is at least 80% identical to CDR1 H CDRs, (b) V of E1-33 (SEQ ID NO:5), E1-34 (SEQ ID NO:11), E1-80 (SEQ ID NO:17), E1-89 (SEQ ID NO:23), E2-93 (SEQ ID NO:29), E1-38 (SEQ ID NO:35), E1-52 (SEQ ID NO:41), E2-36 (SEQ ID NO:47), E1-95 (SEQ ID NO:53), E2-116 (SEQ ID NO:59), E2-135 (SEQ ID NO:65), or E1-142 (SEQ ID NO:71). H A second V that is at least 80% identical to CDR2 H CDRs, (c) V of E1-33 (SEQ ID NO: 6), E1-34 (SEQ ID NO: 12), E1-80 (SEQ ID NO: 18), E1-89 (SEQ ID NO: 24), E2-93 (SEQ ID NO: 30), E1-38 (SEQ ID NO: 36), E1-52 (SEQ ID NO: 42), E2-36 (SEQ ID NO: 48), E1-95 (SEQ ID NO: 54), E2-116 (SEQ ID NO: 60), E2-135 (SEQ ID NO: 66), or E1-142 (SEQ ID NO: 72). H A third V that is at least 80% identical to CDR3 H CDRs, (d) V of E1-33 (SEQ ID NO:76), E1-34 (SEQ ID NO:82), E1-80 (SEQ ID NO:88), E1-89 (SEQ ID NO:93), E2-93 (SEQ ID NO:99), E1-38 (SEQ ID NO:104), E1-52 (SEQ ID NO:108), E2-36 (SEQ ID NO:113), E1-95 (SEQ ID NO:117), E2-116 (SEQ ID NO:121), E2-135 (SEQ ID NO:126), or E1-142 (SEQ ID NO:131). L A first V that is at least 80% identical to CDR1 L CDRs, (e) V of E1-33 (SEQ ID NO: 77), E1-34 (SEQ ID NO: 83), E1-80 (SEQ ID NO: 77), E1-89 (SEQ ID NO: 94), E2-93 (SEQ ID NO: 100), E1-38 (SEQ ID NO: 100), E1-52 (SEQ ID NO: 77), E2-36 (SEQ ID NO: 83), E1-95 (SEQ ID NO: 83), E2-116 (SEQ ID NO: 100), E2-135 (SEQ ID NO: 127), or E1-142 (SEQ ID NO: 100). L A second V that is at least 80% identical to CDR2 L CDRs, (f) V of E1-33 (SEQ ID NO:78), E1-34 (SEQ ID NO:84), E1-80 (SEQ ID NO:89), E1-89 (SEQ ID NO:95), E2-93 (SEQ ID NO:101), E1-38 (SEQ ID NO:105), E1-52 (SEQ ID NO:109), E2-36 (SEQ ID NO:114), E1-95 (SEQ ID NO:118), E2-116 (SEQ ID NO:122), E2-135 (SEQ ID NO:128), or E1-142 (SEQ ID NO:132). L A third V that is at least 80% identical to CDR3 L CDR and 1. An isolated antibody comprising: Other objects, features, and advantages of the present invention will become apparent from the following detailed description, but it should be understood that the detailed description and specific examples, while indicating preferred embodiments of the present invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the present invention will become apparent to those skilled in the art from this detailed description. [Brief description of the drawings]
[0051] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein. The patent or application file contains at least one color drawing. Copies of this patent or patent application publication including color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
[0052] [Figure 1]Schematic diagram showing the principle of action of ADC (antibody-drug conjugate). After binding to its target antigen, the MAb-antigen complex is internalized into endosomes, which then fuse with lysosomes, where the MAb is degraded and the drug is released. [Diagram 2] Detection of high-binding EGFL6 antibodies by ELISA. Human (left bar) or mouse (right bar) EGFL6 protein (Sino Biologicals) was coated onto 96-well high-binding plates overnight at 4°C in PBS. B cell culture supernatant (5 μl medium and 95 μl PBS) was added to the EGFL6 antigen coated on the plate for binding. Bound antibodies were detected using a secondary antibody against rabbit IgG conjugated with HRP and TMB substrate. The experiment was repeated twice for confirmation. [Diagram 3] Determination of the binding affinity of EGFL6 antibody in ELISA. A range of antibody concentrations was analyzed in ELISA, and a four-parameter fitting was used to calculate the binding affinity of the antibody. The experiment had three replicates, and the error bars indicate the standard deviation. [Figure 4A] EGFL6 is upregulated in tumor-associated endothelial cells, but not in normal ovarian and wound healing tissues. A) Summary of endothelial cell isolation. [Figure 4B] EGFL6 is upregulated in tumor-associated endothelial cells, but not in normal ovaries and wound healing tissue. B) Gene microarrays of endothelial cells from normal ovaries, wound healing tissue, and ovarian tumor-associated endothelial cells. [Figure 4C] EGFL6 is upregulated in tumor-associated endothelial cells, but not in normal ovarian and wound healing tissues. C) EGFL6, CD31, and VEGF expression in ovarian patients. [Figure 4D] EGFL6 is upregulated in tumor-associated endothelial cells, but not in normal ovarian and wound healing tissues. D) Validation of gene microarray data using Q-RT PCR. Scale bar = 100 μm. [Figure 5A]EGFL6 gene silencing did not impair wound healing and reduced tumor burden in the A2780ip2 ovarian orthotopic mouse model. A) Expression of EGFL6 in siControl and SiEGFL6-treated dermal endothelial cells. [Figure 5B] EGFL6 gene silencing did not impair wound healing and reduced tumor burden in the A2780ip2 ovarian orthotopic mouse model. B) Effect of EGFL6 silencing on wound healing in vitro. [Figure 5C] EGFL6 gene silencing did not impair wound healing and reduced tumor burden in the A2780ip2 ovarian orthotopic mouse model. C) Bar graph represents wound healing area. [Figure 5D] EGFL6 gene silencing did not impair wound healing and reduced tumor burden in the A2780ip2 ovarian orthotopic mouse model. D) Effect of EGFL6 silencing on wound healing. [Figure 5E] EGFL6 gene silencing did not impair wound healing and reduced tumor burden in the A2780ip2 ovarian orthotopic mouse model. E) Wound volume. [Figure 5F] EGFL6 gene silencing did not impair wound healing and reduced tumor burden in the A2780ip2 ovarian orthotopic mouse model. F) Representative images of tumor burden. [Figure 5G] EGFL6 gene silencing did not impair wound healing and reduced tumor burden in the A2780ip2 ovarian orthotopic mouse model. G) Tumor weight. [Figure 5H] EGFL6 gene silencing did not impair wound healing and reduced tumor burden in the A2780ip2 ovarian orthotopic mouse model. H) Tumor nodules. [Figure 6A] TWIST1 induces EGFL6 expression in hypoxia. A) EGFL6 promoter reporter analysis under normoxic and hypoxic conditions. [Figure 6B] TWIST1 induces EGFL6 expression in hypoxia. B) EGFL6 promoter reporter analysis under normoxic and hypoxic conditions. [Figure 6C] TWIST1 induces EGFL6 expression in hypoxia. C) TWIST1 increases EGFL6 expression under hypoxic conditions. [Figure 6D] TWIST1 induces EGFL6 expression in hypoxia. D) TWIST1 binds to the promoter region of EGFL6. [Figure 6E] TWIST1 induces EGFL6 expression in hypoxia. E) Ectopic expression of TWIST1 increases EGFL6 expression in RF24 cells. [Figure 6F] TWIST1 induces EGFL6 expression in hypoxia. F) Ectopic expression of TWIST1 increases EGFL6 expression in RF24 cells. [Figure 6G] TWIST1 induces EGFL6 expression in hypoxia. G) ChIP analysis of TWIST1 binding to the EGFL6 promoter region in hypoxia compared to normoxia. EGFL6 and ChIP assays of TWIST1 binding to the EGFL6 promoter in human ovarian endothelial cells (RF24). Crosslinked chromatin from RF24 cells treated with TWIST1 and immunoprecipitated with EGFL6 or IgG control antibodies. Input and immunoprecipitated DNA were subjected to PCR using primers corresponding to base pairs upstream of the EGFL6 transcription start site. PCR products were examined on ethidium bromide stained agarose gels. [Figure 6H] TWIST1 induces EGFL6 expression in hypoxia. H) EGFL6 gene silencing using siRNA results in increased cell death in hypoxic conditions. [Figure 6I] TWIST1 induces EGFL6 expression in hypoxia. I) Hindlimb ischemia. After arterial ligation, the femoral artery was isolated and mice were separated into three groups (n=5): normal, ischemia-24 hours, and ischemia-96 hours. Blood flow was monitored before and after femoral artery ligation using continuous laser Doppler. At each time point, tissues were harvested, frozen, and immunofluorescence was performed. [Figure 6J]TWIST1 induces EGFL6 expression in hypoxia. J) EGFL6 expression was increased in endothelial cells in ischemic (hypoxic) conditions compared to normal conditions. [Figure 6K] TWIST1 induces EGFL6 expression in hypoxia. K) EGFL6 expression was increased in endothelial cells in ischemic (hypoxic) conditions compared to normal conditions. [Figure 7A] Treatment of endothelial cells with EGFL6 activates PI3 kinase / AKT signaling. A) RPPA analysis in control and EGFL6-treated RF24 cells. [Figure 7B] Treatment of endothelial cells with EGFL6 activates PI3 kinase / AKT signaling. B) Western blotting of EGFL6-mediated activation of PI3 kinase / AKT signaling. [Figure 7C] Treatment of endothelial cells with EGFL6 activates PI3 kinase / AKT signaling. C) Western blotting of EGFL6-mediated IGF-R, EGFR, and Tie2 receptor activation. [Figure 7D] Treatment of endothelial cells with EGFL6 activates PI3 kinase / AKT signaling. D) Tie2 antibody pulled down integrin proteins. [Figure 7E] Treatment of endothelial cells with EGFL6 activates PI3 kinase / AKT signaling. E) Tie2 and AKT signaling pathways in cytosolic and membrane fraction proteins. [Figure 7F] Treatment of endothelial cells with EGFL6 activates PI3 kinase / AKT signaling. F) Tie2 and AKT signaling pathways in siITGB1 and siTie2 treated RF24 cells. [Figure 7G] Treatment of endothelial cells with EGFL6 activates PI3 kinase / AKT signaling. G) Silencing of integrins and Tie2 using specific siRNA reduces EGFL6-mediated tube formation in endothelial cells. [Figure 7H]Treatment of endothelial cells with EGFL6 activates PI3 kinase / AKT signaling. H) Silencing of integrins and Tie2 using specific siRNA reduces migration in endothelial cells. [Figure 7I] Treatment of endothelial cells with EGFL6 activates PI3 kinase / AKT signaling. I) RGD blocking peptide reduces integrin-mediated signaling pathway J) migration K) and tube formation in endothelial cells. [Figure 7J] Treatment of endothelial cells with EGFL6 activates PI3 kinase / AKT signaling. I) RGD blocking peptide reduces integrin-mediated signaling pathway J) migration K) and tube formation in endothelial cells. [Figure 7K] Treatment of endothelial cells with EGFL6 activates PI3 kinase / AKT signaling. I) RGD blocking peptide reduces integrin-mediated signaling pathway J) migration K) and tube formation in endothelial cells. [Figure 8-1] EGFL6 functional blocking antibodies reduce angiogenesis and tumor growth. A) Line graph represents antibody binding affinity. B) Effect of EGFL6 blocking antibodies on Tie2 / AKT activation in RF24 cells. Control, mAb93, and mAb135 working concentrations are 10ug / ml. C) Effect of EGFL6 blocking antibodies on wound healing assay in dermal endothelial cells. D) Effect of EGFL6 blocking antibodies on tube formation and E) migration in RF24 cells. F) Effect of EGFL6 blocking antibodies on tumor weight, tumor nodules in SKOV3ip1 tumor-bearing mice. G) Ki67 and CD31 expression indicated cell proliferation and tube density. Seven days after tumor cell injection, mice were randomly divided into three groups (10 mice / group) and received therapy: (1) control Ab (5mg / kg), (2) EGFL6Ab93 (5mg / kg), and (3) EGFL6Ab135 (5mg / kg). Antibodies were administered weekly. Tumors were harvested as described in the Examples herein. Wounds were created and tumors were harvested as described in the Examples herein. Error bars indicate SEM. *P<0.05 vs. control Ab. [Figure 8-2]Inhibition of tube formation in endothelial cells (RF24 cells) by EGFL6 antibody. In comparison with a control antibody, the antibody was added (at a concentration of 5 μg / ml) to the cell culture (RF24). The number of tubes was counted after 48 hours of treatment in a 96-well assay plate. Figure 8H shows a representative of each group, and the bar graph shows the average number of tubes in each treatment group. Error bars indicate standard error, n=3. [Figure 9-1] Generation of Tie2-cre, EGFL6f / f knockout mice. A) Generation of Tie2cre, EGFL6 knockout mice. B) CD31 expression in isolated endothelial cells in littermates and EGFL6 knockout mice. C) EGFL6 expression in isolated endothelial cells. [Figure 9-2] EGFL6 gene silencing reduces tumor burden and angiogenesis in the SKOV3ip1 ovarian orthotopic mouse model. D) Expression of EGFL6 in various ovarian cancer cells. E,F) Effect of endothelial cell (mEGFL6 siRNA) or tumor (hEGFL6 siRNA) targeted EGFL6 siRNA on tumor weight and tumor nodules in the SKOV3ip1 orthotopic mouse model of ovarian cancer. Seven days after tumor cell injection, mice were randomly divided into four groups (10 mice / group) and received therapy: (1) control siRNA, (2) mEGFL6 siRNA, (3) hEGFL6 siRNA, (4) mEGFL6 siRNA+hEGFL6 siRNA. Mice were sacrificed when any animal in the control or treatment group became moribund (3-4 weeks after therapy) and tumor weight (E) and number of tumor nodules (F) were recorded. Error bars indicate SEM. G) Effect of targeted EGFL6 siRNA on proliferation and microvessel density. Harvested tumors were stained for Ki67 proliferation and CD31. Scale bar = 50 μm. Bars in the graph correspond consecutively to labeled columns in the image on the left. Error bars indicate SEM. [Figure 10]EGFL6 regulates tumor angiogenesis. A) Human normal ovary, ovarian tumor, and wound healing tissues were dissociated, isolated endothelial cells and samples were processed for microarrays. B) VEGF expression in human normal ovary, wound, and ovarian tumor samples. C), D), E) Control siRNA and EGFL6 siRNA treated RF24 cells and characteristic tube formation and migration. Representative images of human ovarian cancer vasculature with low or high immunohistochemical staining for EGFL6. Scale bar = 200 μm. Error bars indicate SEM. *p<0.05 vs. control siRNA. [Figure 11] Animals were treated with either control siRNA-CH or mEGFL6 siRNA-CH with or without wounding. Harvested tumors were stained for Ki67 (proliferation) and CD31 (microvessels). Error bars indicate SEM. [Figure 12] Treatment of endothelial cells with EGFL6 activates PI3K / AKT signaling. A) Heat map representation of RPPA analysis showing protein expression changes in control and EGFL6-treated RF24 endothelial cells. B) Heat map representation of RPPA analysis showing protein expression changes in control and EGFL6-treated RMG2 cells. C), D) EGFL6-mediated migration and tube formation was reduced by PI3K inhibition in endothelial cells (lower panel). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0053] Description of exemplary embodiments EGFL6 is a member of the EGF repeat superfamily involved in wound healing. However, high EGFL6 has also been found in various cancer cell types, such as ovarian cancer and lung cancer. Research herein shows that inhibition of EGFL6 activity is effective in inhibiting cancer cell proliferation and angiogenesis in tumor tissue. Also, the EGFL6 binding antibody provided herein has been found to be effective in inhibiting EGFL6 activity and cancer cell proliferation. Thus, the antibody of the embodiment provides a new and effective method for treating cancer and inhibiting angiogenesis.
[0054] I. Antibodies of the Invention In certain embodiments, an antibody or fragment thereof is considered that binds to at least a portion of the EGFL6 protein and inhibits EGFL6 signal transduction and cancer cell proliferation. As used herein, the term "antibody" is intended to broadly refer to any immunological binding agent, such as IgG, IgM, IgA, IgD, IgE, and genetically modified IgG, as well as polypeptides that contain an antibody CDR domain that retains antigen-binding activity. The antibody may be selected from the group consisting of a chimeric antibody, an affinity-matured antibody, a polyclonal antibody, a monoclonal antibody, a humanized antibody, a human antibody, or an antigen-binding antibody fragment or a natural or synthetic ligand. Preferably, the anti-EGFL6 antibody is a monoclonal antibody or a humanized antibody.
[0055] Thus, by known means and as described herein, polyclonal or monoclonal antibodies, antibody fragments, and binding domains and CDRs (including engineered forms of any of the foregoing) can be produced which are specific for the EGFL6 protein, one or more of its epitopes, or any of the foregoing complexes, whether such antigens or epitopes are isolated from natural sources or are synthetic derivatives or variants of the natural compounds.
[0056] Examples of antibody fragments suitable for this embodiment include, without limitation, (i) V L , V H , C L , and C H1 (ii) a Fab fragment consisting of the V domain; H and C H1 (iii) an “Fd” fragment consisting of the V domain of a single antibody; L and V H (iv) an "Fv" fragment consisting of the V H (v) an isolated CDR region; (vi) an F(ab')2 fragment, a bivalent fragment comprising two binding Fab fragments; (vii) a V H Domain and V LThese include single chain Fv molecules ("scFv"), in which the domains are linked by a peptide linker that allows the two domains to associate to form a binding domain; (viii) bispecific single chain Fv dimers (see U.S. Pat. No. 5,091,513); and (ix) diabodies, multivalent or multispecific fragments constructed by genetic fusion (U.S. Patent Application Publication No. 2005 / 0214860). Fv, scFv, or diabody molecules are comprised of a V H and V L It may be stabilized by the incorporation of disulfide bridges linking the domains. Minibodies may also be generated that contain an scFv linked to a CH3 domain (Hu et al., 1996).
[0057] In embodiments, antibody-like binding peptidomimetics are also contemplated. Liu et al. (2003) describe "antibody-like binding peptidomimetics" (ABiPs), peptides that act as tapered antibodies and have the particular advantages of longer serum half-lives and less cumbersome synthesis methods.
[0058] An animal can be inoculated with an antigen, such as EGFL6 extracellular domain (ECD) protein, to produce antibodies specific to the EGFL6 protein. Often, the antigen is bound or conjugated to another molecule that enhances the immune response. As used herein, a conjugate is any peptide, polypeptide, protein, or non-proteinaceous substance bound to an antigen that is used to induce an immune response in an animal. The antibodies produced in an animal in response to antigen inoculation include a variety of non-identical molecules (polyclonal antibodies) made from a variety of individual antibody-producing B lymphocytes. Polyclonal antibodies are a mixed population of antibody species, each of which may recognize a different epitope on the same antigen. Given the correct conditions for polyclonal antibody production in an animal, most of the antibodies in the animal's serum will recognize a collective epitope on the antigenic compound with which the animal was immunized. This specificity is further improved by affinity purification, which selects only those antibodies that recognize the antigen or epitope of interest.
[0059] Monoclonal antibodies are a single species of antibody, and each antibody molecule recognizes the same epitope, since all antibody-producing cells are derived from a single B-lymphocyte cell line. Methods for producing monoclonal antibodies (MAbs) generally begin the same as those for preparing polyclonal antibodies. In some embodiments, rodents such as mice and rats are used to produce monoclonal antibodies. In some embodiments, rabbit, sheep, or frog cells are used to produce monoclonal antibodies. The use of rats is well known and may offer certain advantages. Mice (e.g., BALB / c mice) are routinely used and generally result in a high percentage of stable fusions.
[0060] Hybridoma technology involves the fusion of a single B lymphocyte from a mouse previously immunized with the EGFL6 antigen with an immortal myeloma cell (usually a mouse myeloma). This technology provides a method to grow a single antibody-producing cell for an indefinite output so that limitless quantities of structurally identical antibodies with the same antigen or epitope specificity (monoclonal antibodies) can be produced.
[0061] Plasma B cells (CD45+CD5-CD19+) can be isolated from freshly prepared rabbit peripheral blood mononuclear cells of immunized rabbits and further selected from EGFL6-binding cells. After enrichment of antibody-producing B cells, total RNA can be isolated and cDNA can be synthesized. DNA sequences of antibody variable regions from both heavy and light chains can be amplified, constructed into phage display Fab expression vectors, and transformed into E. coli. EGFL6-specific binding Fabs can be selected through multiple rounds of enrichment panning and sequenced. Selected EGFL6-binding hits can be expressed as full-length IgG in rabbit and rabbit / human chimeric forms using a mammalian expression vector system in human embryonic kidney (HEK293) cells (Invitrogen) and purified using protein G resin in a fast protein liquid chromatography (FPLC) separation unit.
[0062] In one embodiment, the antibody is a chimeric antibody, e.g., an antibody that comprises antigen-binding sequences from a non-human donor grafted onto heterologous non-human, human, or humanized sequences (e.g., framework and / or constant domain sequences). Methods have been developed to replace the light and heavy constant domains of a monoclonal antibody with the analogous domains of human origin, leaving the variable regions of the foreign antibody intact. Alternatively, "fully human" monoclonal antibodies are produced in mice transgenic for human immunoglobulin genes. Methods have also been developed to convert the variable domains of monoclonal antibodies into a more human form by recombinantly constructing antibody variable domains with both rodent, e.g., mouse, and human amino acid sequences. In "humanized" monoclonal antibodies, only the hypervariable CDRs are derived from a mouse monoclonal antibody, while the framework and constant regions are derived from human amino acid sequences (see U.S. Patent Nos. 5,091,513 and 6,881,557). It is believed that replacing amino acid sequences in an antibody characteristic of a rodent with amino acid sequences found at the corresponding positions in a human antibody will reduce the likelihood of adverse immune reactions during therapeutic use. Hybridomas or other cells which produce antibodies may also be subject to genetic mutations or other alterations which may or may not change the binding specificity of the antibodies produced by the hybridoma.
[0063] Methods for producing polyclonal antibodies in various animal species, as well as for producing various types of monoclonal antibodies, including humanized, chimeric, and fully human, are well known in the art and highly predictable, see, for example, the following U.S. patents and patent applications: U.S. Patent Application Nos. 2004 / 0126828 and 2002 / 0172677, and U.S. Patents 3,817,837, 3,850,752, 3,939,350, 3,996,345, 4,196,265, 4,275,149, 4,277,437, 4,366,241, 4,469,797, 4,472,509, 4,606,855, 4,703,003, 4,742,159, 4,767,720, 4,816,567, 4,867,973, 4,938,948, 4,946,778, 5,021,236, 5,164,296, 5,196,066, 5,223,409, 5, 403,484, 5,420,253, 5,565,332, 5,571,698, 5,627,052, 5,656,434, 5,770,376, 5,789,208, 5,821,337, 5,844,091, 5,858,657, 5,861,155, 5,871,907, 5,969,108, 6,05 Nos. 4,297, 6,165,464, 6,365,157, 6,406,867, 6,709,659, 6,709,873, 6,753,407, 6,814,965, 6,849,259, 6,861,572, 6,875,434, and 6,891,024 provide enabling descriptions for such methods. This specification and all patents, patent application publications, and other publications cited therein are hereby incorporated by reference.
[0064] Antibodies can be produced from any animal source, including birds and mammals. Preferably, the antibodies are ovine, murine (e.g., mouse and rat), rabbit, goat, guinea pig, camel, horse, or chicken. In addition, newer technologies allow for the development and screening of human antibodies from human combinatorial antibody libraries. For example, bacteriophage antibody expression technology allows specific antibodies to be produced in the absence of animal immunization, as described in U.S. Patent No. 6,946,546, which is incorporated herein by reference. These techniques are further described in Marks (1992), Stemmer (1994), Gram et al. (1992), Barbas et al. (1994), and Schier et al. (1996).
[0065] It is fully expected that antibodies against EGFL6 will have the ability to neutralize or counter the effects of EGFL6, regardless of the animal species, monoclonal cell line, or other source of the antibody. Certain animal species may be less favorable for producing therapeutic antibodies, since they may be more likely to cause allergic responses by activating the complement system through the "Fc" portion of the antibody. However, whole antibodies can be enzymatically digested into "Fc" (complement binding) fragments and into antibody fragments with binding domains or CDRs. Removal of the Fc portion reduces the likelihood that the antigen-antibody fragments will induce undesirable immunological responses, and thus antibodies without Fc may be preferred for prophylactic or therapeutic treatments. As described above, antibodies can also be constructed to be chimeric or partially or fully human to reduce or eliminate adverse immunological consequences resulting from administering to animals antibodies produced in or with sequences from other species.
[0066] Substitution variants typically contain the exchange of one amino acid for another at one or more sites within the protein, and can be designed to modulate one or more properties of the polypeptide, with or without loss of other functions or properties. Substitutions can be conservative, that is, one amino acid is replaced with one of similar shape and charge. Conservative substitutions are well known in the art and include, for example, changing alanine to serine, arginine to lysine, asparagine to glutamine or histidine, aspartate to glutamate, cysteine to serine, glutamine to asparagine, glutamate to aspartate, glycine to proline, histidine to asparagine or glutamine, isoleucine to leucine or valine, leucine to valine or isoleucine, lysine to arginine, methionine to leucine or isoleucine, phenylalanine to tyrosine, leucine, or methionine, serine to threonine, threonine to serine, tryptophan to tyrosine, tyrosine to tryptophan or phenylalanine, and valine to isoleucine or leucine. Alternatively, the substitution may be non-conservative such that the function or activity of the polypeptide is affected. Non-conservative changes typically involve replacing residues with chemically dissimilar ones, such as a polar or charged amino acid with a non-polar or uncharged amino acid, and vice versa.
[0067] The proteins may be recombinant or synthesized in vitro. Alternatively, non-recombinant or recombinant proteins may be isolated from bacteria. It is also contemplated that bacteria containing such variants may be implemented in the compositions and methods. As a result, the proteins do not need to be isolated.
[0068] It is contemplated that there will be from about 0.001 mg to about 10 mg of total polypeptide, peptide, and / or protein per ml in the composition. Thus, the concentration of protein in the composition can be about, at least about, or at most about 0.001, 0.010, 0.050, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0 mg / ml or more (or any range derivable therein). Of these, about, at least about, or at most about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% can be antibodies that bind to EGFL6.
[0069] An antibody, or preferably an immunological portion of an antibody, may be chemically conjugated to, or represented as, a fusion protein with another protein, and for purposes of this specification and the appended claims, all such fusion proteins are included within the definition of an antibody or immunological portion of an antibody.
[0070] The embodiments provide antibodies and antibody-like molecules against EGFL6, polypeptides, and peptides conjugated with at least one agent to form an antibody conjugate or payload. To increase the effectiveness of an antibody molecule as a diagnostic or therapeutic agent, it is conventional to bind or covalently bind or complex at least one desired molecule or moiety. Such a molecule or moiety may be, but is not limited to, at least one effector or reporter molecule. Effector molecules include molecules with a desired activity, e.g., cytotoxic activity. Non-limiting examples of effector molecules attached to an antibody include toxins, therapeutic enzymes, antibiotics, radiolabeled nucleotides, and the like. In contrast, a reporter molecule is defined as any moiety that can be detected using an assay. Non-limiting examples of reporter molecules conjugated to an antibody include enzymes, radiolabels, haptens, fluorescent labels, phosphorescent molecules, chemiluminescent molecules, chromophores, luminescent molecules, photoaffinity molecules, colored particles or ligands, such as biotin.
[0071] Several methods for attachment or conjugation of antibodies to their conjugate moieties are known in the art. Some attachment methods include, for example, the use of metal chelate complexes using organic chelators such as diethylenetriaminepentaacetic anhydride (DTPA), ethylenetriaminetetraacetic acid, N-chloro-p-toluenesulfonamide, and / or tetrachloro-3-6?-diphenylglycouril-3 attached to the antibody. Monoclonal antibodies can also be reacted with enzymes in the presence of coupling agents such as glutaraldehyde or periodate. Conjugates with fluorescein markers are prepared in the presence of these coupling agents or by reaction with isothiocyanates.
[0072] II. Treatment of Disease Certain aspects of this embodiment can be used to prevent or treat diseases or disorders related to EGFL6 signal transduction. EGFL6 signal transduction can be reduced by any suitable drug to prevent cancer cell proliferation.Preferably, such substance will be anti-EGFL6 antibody.
[0073] "Treatment" and "treating" refer to the administration or application of a therapeutic agent to a subject, or the performance of a procedure or modality on a subject for the purpose of obtaining a therapeutic benefit for a disease or health-related condition. For example, treatment can include the administration of a pharmacologic effective amount of an antibody that inhibits EGFL6 signaling.
[0074] "Subject" and "patient" refer to either humans or non-humans, such as primates, mammals, and vertebrates. In certain embodiments, the subject is a human.
[0075] The term "therapeutic benefit" or "therapeutic effect" as used throughout this application refers to anything that promotes or improves the health of a subject with respect to the medical treatment of the condition. This includes, but is not limited to, reducing the frequency or severity of signs or symptoms of a disease. For example, treating cancer can include, for example, reducing the size of a tumor, reducing the invasiveness of a tumor, reducing the growth rate of a cancer, or preventing metastasis. Treating cancer can also refer to the prolongation of the survival of a subject with cancer.
[0076] A. Pharmaceutical Preparations When a clinical application of a therapeutic composition containing an inhibitory antibody is made, it will generally be beneficial to prepare a pharmaceutical or therapeutic composition appropriate for the intended application. In certain embodiments, a pharmaceutical composition may contain, for example, at least about 0.1% of an active compound. In other embodiments, the active compound may comprise from about 2% to about 75% of the weight of the unit, or, for example, from about 25% to about 60%, and any range derivable therein.
[0077] The therapeutic compositions of the present embodiments are advantageously administered in the form of injectable compositions, either as liquid solutions or suspensions; solid forms suitable for dissolution in, or suspension in, liquid prior to injection may also be prepared. These preparations may also be emulsified.
[0078] The phrases "pharmaceutical or pharmacologically acceptable" refer to molecular entities and compositions that do not produce adverse, allergic, or other untoward reactions when administered to an animal, such as a human, as appropriate. The preparation of pharmaceutical compositions containing an antibody or additional active ingredient will be known to those of skill in the art in light of the present disclosure. It will also be understood that for animal (e.g., human) administration, preparations should meet sterility, pyrogenicity, general safety, and purity standards as required by the FDA Office of Biological Standards.
[0079] As used herein, "pharmaceutically acceptable carriers" include any and all aqueous solvents (e.g., parenteral vehicles such as water, alcoholic / aqueous solutions, saline solutions, sodium chloride, Ringer's dextrose, etc.), non-aqueous solvents (e.g., propylene glycol, polyethylene glycol, vegetable oils, and injectable organic esters such as ethyl oleate), dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial or antifungal agents, antioxidants, chelating agents, and inert gases), isotonicity agents, absorption delaying agents, salts, drugs, drug stabilizers, gels, binders, excipients, disintegrants, lubricants, sweeteners, flavoring agents, dyes, fluid and nutritional supplements, and the like, and combinations thereof, as would be known to one skilled in the art. The pH and exact concentration of the various components in the pharmaceutical composition are adjusted according to well-known parameters.
[0080] The term "unit dose" or "dosage" refers to a physically discrete unit suitable for use in a subject, each unit containing a predetermined amount of a therapeutic composition calculated to produce the desired response discussed above in connection with its administration, i.e., the appropriate route and treatment regimen. The amount administered according to both the number of treatments and the unit dose depends on the desired effect. The actual dosage of the composition of the present embodiment administered to a patient or subject can be determined by physical and physiological factors such as the subject's weight, age, health, and sex, the type of disease being treated, the degree of disease penetration, previous or concomitant therapeutic interventions, the patient's idiopathic disease, the route of administration, and the efficacy, stability, and toxicity of the particular therapeutic agent. For example, the dosage can also include from about 1 μg / kg / body weight to about 1000 mg / kg / body weight per administration (such ranges including intervening doses) or more, and any range derivable therein. Non-limiting examples of ranges derivable from the numbers recited herein include ranges from about 5 μg / kg / body weight to about 100 mg / kg / body weight, from about 5 μg / kg / body weight to about 500 mg / kg / body weight, etc. The physician responsible for administration will, in any event, determine the concentration of active ingredient(s) in the composition and dose appropriate for the individual subject.
[0081] The active compounds can be formulated for parenteral administration, for example, for injection via intravenous, intramuscular, subcutaneous, or even intraperitoneal routes. Typically, such compositions can be prepared as either liquid solutions or suspensions, solid forms suitable for use in preparing solutions or suspensions by adding liquid prior to injection can also be prepared, and the preparations can also be emulsified.
[0082] Pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions, formulations containing sesame oil, peanut oil, or aqueous propylene glycol, and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and fluid to the extent that it can be easily syruppable. It should also be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
[0083] Proteinaceous compositions may be formulated in neutral or salt form. Pharmaceutically acceptable salts include acid addition salts (formed with the free amino groups of the protein) which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or organic acids such as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine, and the like.
[0084] The pharmaceutical compositions may contain a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, etc.), suitable mixtures thereof, and vegetable oils. Proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. Prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the composition of agents which delay absorption, for example, aluminum monostearate and gelatin.
[0085] B. Combination Treatment In certain embodiments, the compositions and methods of the present embodiment comprise an antibody or antibody fragment against EGFL6, which inhibits its activity in cancer cell proliferation, in combination with a second or additional therapy. Such therapy can be applied in the treatment of any disease related to EGFL6-mediated cell proliferation. For example, the disease can be cancer.
[0086] The methods and compositions, including combination therapy, improve the therapeutic or prophylactic effect and / or increase the therapeutic effect of another anti-cancer or anti-hyperproliferative therapy. The therapeutic and prophylactic methods and compositions can be provided in a combined amount effective to achieve a desired effect, such as killing of cancer cells and / or inhibiting cell hyperproliferation. The process can include contacting the cells with both the antibody or antibody fragment and the second therapy. The tissue, tumor, or cells can be contacted with one or more compositions or pharmacological formulations including one or more of the agents (i.e., antibody or antibody fragment or anti-cancer agent), or the tissue, tumor, and / or cells can be contacted with two or more different compositions or formulations, such that one composition provides 1) an antibody or antibody fragment, 2) an anti-cancer agent, or 3) both an antibody or antibody fragment and an anti-cancer agent. It is also contemplated that such combination therapy can be used with chemotherapy, radiation therapy, surgery, or immunotherapy.
[0087] The terms "contacted" and "exposed," when applied to a cell, are used herein to describe the process by which a therapeutic composition and a chemotherapeutic or radiotherapeutic agent are delivered to or placed directly adjacent to a target cell. To achieve cell killing, for example, both agents are delivered to the cell in a combined amount effective to kill the cell or prevent it from dividing.
[0088] The inhibitory antibody may be administered prior to, during, after, or in various combinations with respect to the anti-cancer therapy. Administration may be spaced apart, ranging from simultaneously to minutes, days, or weeks. In embodiments in which the antibody or antibody fragment is provided to the patient separately from the anti-cancer drug, one will generally ensure that there is no time lapse between each delivery, so that the two compounds can still exert their beneficially combined effect on the patient. In such instances, it is contemplated that the antibody therapy and the anti-cancer therapy may be provided to the patient within about 12-24 or 72 hours of each other, and more specifically, within about 6-12 hours of each other. In some circumstances, it may be desirable to significantly extend the treatment period, with days (2, 3, 4, 5, 6, or 7) to weeks (1, 2, 3, 4, 5, 6, 7, or 8) elapsing between each administration.
[0089] In certain embodiments, the course of treatment will last from 1 to 90 days or more (such ranges include intervening days). It is contemplated that one agent may be administered on any of days 1 to 90 (such ranges include intervening days) or any combination thereof, and another agent may be administered on any of days 1 to 90 (such ranges include intervening days) or any combination thereof. Within a single day (24 hours), the patient may receive one or more doses of the agent. It is also contemplated that after the course of treatment, there will be a period during which no anti-cancer treatment is administered. This period may last from 1 to 7 days, and / or 1 to 5 weeks, and / or 1 to 12 months or more (such ranges include intervening days), depending on the condition of the patient, such as their prognosis, strength, health, etc. It is anticipated that the treatment cycle will be repeated as necessary.
[0090] Various combinations may be used. For the example below, the antibody therapy is "A" and the anti-cancer therapy is "B". TIFF2024164139000002.tif17128
[0091] Administration of any of the compounds or therapies of the present embodiments to a patient will follow general protocols for administration of such compounds, taking into account the toxicity, if any, of the agents. Thus, in some embodiments, there is a step of monitoring for toxicity due to the combination therapy.
[0092] i.Chemotherapy A wide variety of chemotherapeutic agents may be used in accordance with this embodiment. The term "chemotherapy" refers to the use of drugs to treat cancer. "Chemotherapeutic agent" is used to refer to a compound or composition administered in the treatment of cancer. These agents or drugs are classified according to their mode of activity within the cell, for example, whether and at what stage they affect the cell cycle. Alternatively, agents may be characterized based on their ability to directly crosslink DNA, intercalate into DNA, or induce chromosomal and mitotic abnormalities by affecting nucleic acid synthesis.
[0093] Examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclosphosphamide; alkylsulfonates such as busulfan, improsulfan, and piposulfan; aziridines such as benzodopa, carboxyone, meturedopa, and uredopa; ethylenimines and methylamelanamines, including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, and trimethylolomelanamine; acetogenins (especially bullatacin and bullatacinone); camptothecins (including the synthetic analog topotecan); bryostatin, kallistatin, CC-1065 (including its synthetic analogs adozelesin, carzelesin, and bizelesin), cryptophycins (particularly cryptophycin 1 and cryptophycin 8), dolastatin, duocarmycins (including synthetic analogs KW-2189 and CB1-TM1), eleutherobin, pancratistatin, sarcodictin, spongistatin, chlorambucil, chlornaphazine, chlorophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine hydrochloride oxide, melphalan, novembitin, fumarate, furantoin ... Nitrogen mustards, such as phenesterin, prednimustine, trophosphamide, and uracil mustard; nitrosureas, such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustine; antibiotics, such as enediyne antibiotics (e.g., calicheamicin, particularly calicheamicin gamma 1 and calicheamicin omega 1); dynemicins, including dynemicin A; bisphosphonates, such as clodronate; esperamicins; and neocarzinostatin chromophore and related chromoproteins. Quality enediyne antibiotic chromophores, aclacinomycin, actinomycin, autarubicin, azaserine, bleomycin, cactinomycin, carabicin, carminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin, and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin,Mitomycin, such as mitomycin C, mycophenolic acid, nogalarnisin, olivomycin, peplomycin, potfilomycin, puromycin, queramycin, rodolubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, and zorubicin; antimetabolites, such as methotrexate and 5-fluorouracil (5-FU); formic acid analogs, such as denopterin, pteropterin, and trimetrexate; purines, such as fludarabine, 6-mercaptopurine, thiamiprine, and thioguanine; pyrimidine analogues, such as ancitabine, azacitidine, 6-azauridine, carmoful, cytarabine, dideoxyuridine, doxifluridine, enocitabine, and floxuridine; androgens, such as calsterone, dromostanolone propionate, epitostanol, mepitiostane, and testolactone; antiadrenals, such as mitotane and trilostane; folic acid supplements, such as floric acid; aceglatone, aldophosphamide glycosides, aminolevulinic acid, eniluracil, amsacrine, bestravcil, bisantre maytansinoids such as sirolimus, edatraxate, defofamine, demecolcine, diaziquone, elformitin, elliptinium acetate, epothilone, etoglucide, gallium nitrate, hydroxyurea, lentinan, lonidain, maytansine and ansamitocin, mitoguazone, mitoxantrone, mopidamol, nitraelin, pentostatin, phenamet, pirarubicin, losoxantrone, podophyllinic acid, 2-ethylhydrazide, procarbazine, PSK polysaccharide complex, razoxane, rhizoxin, schizophyllan, spirogermani. urethanes, vindesine, dacarbazine, mannomustine, mitobronitol, mitraktol, pipobroman, gacitosine, arabinoside ("Ara-C"), cyclophosphamide, taxoids such as paclitaxel and docetaxel gemcitabine, 6-thioguanine, mercaptopurine, platinum coordination complexes such as cisplatin, oxaliplatin, and carboplatin,Vinblastine, platinum, etoposide (VP-16), ifosfamide, mitoxantrone, vincristine, vinorelbine, novantrone, teniposide, edatraxate, daunomycin, aminopterin, xeloda, ibandronate, irinotecan (e.g., CPT-11), topoisomerase inhibitors RFS2000, difluoromethylornithine (DMFO), retinoids such as retinoic acid, capecitabine, carboplatin, procarbazine, plicomycin, gemcitabine, novelbine, farnesyl-protein transferase inhibitors, transplatinum, as well as pharma- ceutical acceptable salts, acids, or derivatives of any of the above.
[0094] ii.Radiation therapy Other agents that cause DNA damage and are widely used include what are commonly known as gamma radiation, X-rays, and / or specific delivery of radioisotopes to tumor cells. Other forms of DNA damaging agents are also considered, such as microwaves, proton beam irradiation (U.S. Patents 5,760,395 and 4,870,287), and UV irradiation. All of these agents most likely affect a wide range of DNA damage, DNA precursors, DNA replication and repair, and chromosome assembly and maintenance. Dose ranges for X-rays range from daily doses of 50-200 roentgens over prolonged periods (3-4 weeks) to single doses of 2000-6000 roentgens. Dose ranges for radioisotopes vary widely and depend on the half-life of the isotope, the strength and type of radiation emitted, and uptake by neoplastic cells.
[0095] iii. Immunotherapy Those skilled in the art will appreciate that additional immunotherapies may be used in combination with or with the methods of the embodiments. In the context of cancer therapy, immunotherapeutics generally rely on the use of immune effector cells and molecules to target and destroy cancer cells. Rituximab (RITUXAN®) is such an example. The immune effector may be, for example, an antibody specific for some marker on the surface of the tumor cell. The antibody alone may act as an effector of therapy or may recruit other cells to actually affect cell killing. The antibody may also be conjugated with a drug or toxin (chemotherapeutic agent, radionuclide, ricin A chain, cholera toxin, pertussis toxin, etc.) and act as a targeting agent. Alternatively, the effector may be a lymphocyte bearing a surface molecule that interacts either directly or indirectly with the tumor cell target. Various effector cells include cytotoxic T cells and NK cells
[0096] Antibody-drug conjugates have emerged as a breakthrough approach to the development of cancer therapeutics. Cancer is one of the leading causes of death worldwide. Antibody-drug conjugates (ADCs) contain monoclonal antibodies (MAbs) covalently linked to cell-killing drugs (Figure 1). This approach combines the high specificity of MAbs for their antigen targets with highly effective cytotoxic drugs, resulting in "armed" MAbs that deliver the payload (drug) to tumor cells that bear enriched levels of the antigen (Carter et al., 2008; Teicher 2014; Leal et al., 2014). Targeted delivery of the drug also minimizes its exposure in normal tissues, resulting in reduced toxicity and improved therapeutic index. The approval of two ADC drugs by the FDA, ADCETRIS® (brentuximab vedotin) in 2011 and KADCYLA® (trastuzumab emtansine or T-DM1) in 2013, has validated the efficacy of this approach. Currently, there are more than 30 ADC drug candidates in various stages of clinical trials for cancer treatment (Leal et al., 2014). Antibody engineering and linker-payload optimization are becoming increasingly mature, and new ADC drug discovery increasingly relies on the identification and validation of new targets suitable for this approach (Teicher 2009) and the production of targeted MAbs. Two criteria for ADC targets are upregulated / high level expression and robust internalization in tumor cells.
[0097] In one aspect of immunotherapy, tumor cells must have some markers that are amenable to targeting, i.e., not present on the majority of other cells. Many tumor markers exist, any of which may be suitable for targeting in the context of this embodiment. Common tumor markers include CD20, carcinoembryonic antigen, tyrosinase (p97), gp68, TAG-72, HMFG, sialyl Lewis antigen, MucA, MucB, PLAP, laminin receptor, erbB, and p155. An alternative aspect of immunotherapy is to combine anti-cancer effects with immune stimulatory effects. There are also immune stimulatory molecules, including cytokines such as IL-2, IL-4, IL-12, GM-CSF, gamma-IFN, chemokines such as MIP-1, MCP-1, IL-8, and growth factors such as FLT3 ligand.
[0098] Examples of immunotherapies currently under investigation or use include immune adjuvants such as Mycobacterium bovis, Plasmodium falciparum, dinitrochlorobenzene, and aromatic compounds (U.S. Patent Nos. 5,801,005 and 5,739,169; Hui and Hashimoto, 1998; Christodoulides et al., 1998); cytokine therapies such as interferon α, β, and γ, IL-1, GM-CSF, and TNF (Bukowski et al., 1998; Davidson et al., 1998; Hellstrand et al., 1998); gene therapies such as TNF, IL-1, IL-2, and p53 (Qin et al., 1998; Austin-Ward and Antibody therapies include, but are not limited to, monoclonal antibodies such as anti-CD20, anti-ganglioside GM2, and anti-p185 (Villaseca, 1998, U.S. Patent Nos. 5,830,880 and 5,846,945), as well as monoclonal antibodies such as anti-CD20, anti-ganglioside GM2, and anti-p185 (Hollander, 2012, Hanibuchi et al., 1998, U.S. Patent No. 5,824,311). It is contemplated that one or more anti-cancer therapies may be used in conjunction with the antibody therapies described herein.
[0099] iv.Surgery Approximately 60% of people with cancer will undergo some type of surgery, including preventive, diagnostic or staging, curative, and palliative surgery. Curative surgery includes resection, in which all or part of the cancerous tissue is physically removed, excised, and / or destroyed, and may be used in conjunction with other therapies, such as the treatment of the present invention, chemotherapy, radiation therapy, hormone therapy, gene therapy, immunotherapy, and / or alternative therapies. Tumor resection refers to the physical removal of at least a portion of the tumor. In addition to tumor resection, surgical treatments include laser surgery, cryosurgery, electrosurgery, and microsurgical control surgery (Mohs surgery).
[0100] After removal of part or all of the cancerous cells, tissues, or tumors, a cavity may be formed in the body. Treatment may be achieved by perfusion, direct injection, or local application of the area that has received additional anticancer therapy. Such treatment may be repeated, for example, every 1, 2, 3, 4, 5, 6, or 7 days, or every 1, 2, 3, 4, and 5 weeks, or every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months. These treatments may also have varying dosages.
[0101] v. Other drugs It is contemplated that other agents may be used in combination with certain aspects of the present embodiment to improve the therapeutic efficacy of the treatment. These additional agents include agents that affect the upregulation of cell surface receptors and GAP junctions, cytostatic and differentiation agents, inhibitors of cell adhesion, agents that increase the sensitivity of hyperproliferative cells to apoptosis inducers, or other biological agents. Increasing cell-cell signaling by increasing the number of GAP junctions will increase the anti-hyperproliferative effect on adjacent hyperproliferative cell populations. In other embodiments, cytostatic or differentiation agents may be used in combination with certain aspects of the present embodiment to improve the anti-hyperproliferative efficacy of the treatment. Inhibitors of cell adhesion are believed to improve the efficacy of the present embodiment. Examples of cell adhesion inhibitors include focal adhesion kinase (FAK) inhibitors and lovastatin. It is further contemplated that other agents that increase the sensitivity of hyperproliferative cells to apoptosis, such as the antibody c225, may be used in combination with certain aspects of the present embodiment to improve the therapeutic efficacy.
[0102] III. Kits and Diagnostics In various aspects of the embodiments, the kit is envisioned to contain therapeutic agents and / or other therapeutic and delivery agents. In some embodiments, the present embodiments contemplate a kit for preparing and / or administering the therapies of the embodiments. The kit may include one or more sealed vials containing any of the pharmaceutical compositions of the present embodiments. The kit may include, for example, at least one EGFL6 antibody and reagents for preparing, compounding, and / or administering the components of the embodiments or performing one or more steps of the methods of the present invention. In some embodiments, the kit may also include a suitable container, such as an Eppendorf tube, an assay plate, a syringe, a bottle, or a tube, which is a container that does not react with the components of the kit. The container may be made of a sterilizable material, such as plastic or glass.
[0103] The kit may further include instructions outlining the procedural steps of the methods described herein and following procedures substantially similar to those described herein or known to those of skill in the art. The instructional information may be in a computer-readable medium containing machine-readable instructions that, when executed using a computer, display a real or virtual procedure for delivering a pharma- ceutical effective amount of a therapeutic agent. EXAMPLES
[0104] IV. Working Examples The following examples are included to illustrate preferred embodiments of the present invention. It should be understood by those skilled in the art that the techniques disclosed in the following examples represent techniques found by the inventors to work well in practicing the invention, and thus can be considered to constitute preferred modes of practicing it. However, those skilled in the art should understand in light of this disclosure that many changes can be made in the specific embodiments disclosed and still obtain the same or similar results without departing from the spirit and scope of the invention.
[0105] Example 1 - Production and cloning of monoclonal antibodies targeting human EGFL6 EGFL6 (Genebank accession #Q8IUX8) protein was used to immunize New Zealand rabbits with RevMAb Biosciences USA, Inc. Titers of anti-EGFL6 sera were determined by serial dilutions of sera in an ELISA for binding by coating EGFL6 protein onto 96-well plates (max-sorb plates, Nunc) and detection with anti-rabbit antibodies conjugated with horseradish peroxidase (HRP) and TMB substrate. After 2-3 booster immunizations, titers were >10 6At 1 h, peripheral blood samples were collected from immunized rabbits for B cell (CD45+CD5-CD19+) isolation from freshly prepared peripheral blood mononuclear cells (PBMCs) using a fluorescence-assisted cell sorting (FACS) instrument (BD FACSAria™ III, BD Biosciences). The isolated B cells were plated as single B cells and cultured for 7–10 days. Culture supernatants were analyzed for EGFL6 binding. Cells from positive wells were lysed, total RNA was isolated, and cDNA was synthesized using Superscript Reverse Transcriptase II (Invitrogen) according to the manufacturer's instructions. DNA sequences of antibody variable regions from both heavy and light chains were amplified by polymerase chain reaction (PCR) using a set of designed primers and sequenced. Both DNA and amino acid sequences are listed below in Section V. The CDRs of anti-EGFL6 monoclonal antibodies were identified using the IMGT program and are listed in Tables 1 and 2.
[0106] Table 1 CDRs of the heavy chain variable sequence of EGFL6 antibody TIFF2024164139000003.tif201154TIFF2024164139000004.tif20185
[0107] Table 2 CDRs of the light chain variable sequence of EGFL6 antibody TIFF2024164139000005.tif189128TIFF2024164139000006.tif189163TIFF2024164139000007.tif189128
[0108] The selected EGFL6-binding hits were expressed as rabbit or rabbit / human chimeric IgG using a mammalian expression vector system in human embryonic kidney (HEK293) cells (Invitrogen). The antibodies were purified by a fast protein liquid chromatography (FPLC) separation unit using a column containing protein A resin. The purified EGFL6-binding antibodies were characterized for their biological properties.
[0109] Example 2 - Binding affinity of anti-EGFL6 monoclonal antibodies to EGFL6 protein Binding of EGFL6 by monoclonal antibodies was first screened by ELISA using supernatants harvested from B cell cultures (Figure 2). ELISA titration was used to determine the binding affinity of the panel of monoclonal antibodies to the EGFL6 antigen (Figure 3). The binding constants (K D and / or EC50) were estimated using a four-parameter curve fitting in the Prism GraphPad program. For Biacore analysis, all experiments were performed at 25°C and a flow rate of 45 μl / min. Anti-human IgGFc antibodies (ThermoFisher, 50 μg / ml each in acetate buffer, pH 5.0) were immobilized on a carboxymethyl dextran sensor chip (CM5) using an amine coupling procedure based on the manufacturer's instructions. Purified rabbit / human chimeric antibodies to be tested were diluted to a concentration of 5 μg / ml in 0.5% P20, HBS-EP buffer and injected into FC2 to reach 500-1000 RU. FC1 was used as the reference cell. The specific signal corresponds to the difference in the signal obtained with FC2 vs. FC1. The analyte (recombinant human EGFL6, apparent molecular weight 60 kDa on SDS-PAGE gel) was injected at a series of concentration dilutions (100, 50, 25, 12.5, 6.25, and 3.13, 1.56 nM) in 0.5% P20, HBS-EP buffer for 90 s. These concentrations were prepared from a stock solution in 0.5% P20, HBS-EP. The dissociation phase of the analyte was monitored over a period of 30 min. The running buffer was also injected under the same conditions as a double reference. After each running cycle, both flow cells were regenerated by injecting 20-45 μl of glycine-HCl buffer pH 1.5. The binding K for EGFL6 was D k for each EGFL6 monoclonal antibody オフ / k オン The rate was calculated (Table 3).
[0110] Table 3. EGFL6 antibody binding affinity determined by ELISA or Biacore methods TIFF2024164139000008.tif29128
[0111] Example 3 - Experimental Procedures and Methods Cell lines and culture: Human epithelial ovarian cancer cell lines, SKOV3ip1 and A2780ip2, were maintained as described (Sood, AK et al. Molecular determinants of ovarian cancer plasticity. American Journal of Pathology 158, 1279-1288, 2001). Human immortalized umbilical endothelial cells (RF24) were grown in MEM medium with supplements (sodium pyruvate, non-essential amino acids, MEM vitamins, and glutamine, Life Technologies). Derivation and characterization of mouse ovarian endothelial cells (MOEC) were previously described (Langley, RR et al. Tissue-specific microvascular endothelial cell lines from H-2K(b)-tsA58 mice for studies of angiogenesis and metastasis. Cancer Research 63, 2971-2976, 2003). Cell cultures were maintained at 37°C in a 5% CO2 incubator with 95% humidity. For in vivo injection, cells were trypsinized, centrifuged at 1,200 rpm for 5 min at 4°C, washed twice with PBS, and reconstituted in serum-free Hanks' balanced salt solution (Life Technologies, Grand Island, NY, USA). Only single-cell suspensions with >95% viability (determined by trypan blue dye exclusion) were used for in vivo intraperitoneal injection.
[0112] Endothelial cell isolation: Fresh tissue samples (5 normal ovaries, 5 wound tissues, and 10 epithelial high-grade, stage III or IV invasive serous ovarian carcinomas) were obtained from patients undergoing initial surgical exploration at MD Anderson Cancer Center after approval from the Institutional Review Board. Total RNA from purified endothelial cells was subjected to microarray analysis using the Affymetrix Human U133 plus 2.0 GeneChip platform (Lu, C. et al. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Research 67, 1757-1768, 2007).
[0113] Quantitative real-time PCR validation: Quantitative real-time RT-PCR was performed using 50 ng of purified total RNA from endothelial cells isolated using the RNeasy mini kit (Qiagen) according to the manufacturer's instructions. Complementary DNA (cDNA) was synthesized from 0.5–1 μg of total RNA using the Verso cDNA kit (Thermo Scientific). Quantitative PCR (qPCR) analysis was performed in triplicate using SYBR Green ER qPCR SuperMix Universal (Invitrogen) and Bio-Rad (Bio-Rad Laboratories, Hercules, CA, USA). Relative quantification was normalized and controlled for percent fold change. -ΔΔCT The calculations were performed using the method (Donninger, H. et al. Whole genome expression profiling of advanced stage papillary serous ovarian cancer reveals activated pathways. Oncogene 23, 8065-8077, 2004).
[0114] SiRNA constructs and delivery: SiRNAs were purchased from Sigma-Aldrich (The Woodlands, TX, USA). Non-silencing siRNAs that do not share sequence homology with any known human mRNAs based on BLAST searches were used as controls for the target siRNAs. In vitro transient transfection was performed as described (Landen, CN, Jr. et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Research 65, 6910-6918, 2005). Briefly, siRNAs (4 μg) were incubated with 10 μL of Lipofectamine 2000 transfection reagent (Lipofectamine) for 20 minutes at room temperature according to the manufacturer's instructions and added to cells in 80% confluent cultures in 10 cm culture plates.
[0115] Reverse Phase Protein Array (RPPA) and Western Blot Analysis: RPPA analysis was performed on RF24 and OVCAR3 cells in the presence or absence of human recombinant EGFL6 protein. Western blot analysis was performed as previously described (Landen, CN, Jr. et al. 2005, supra; Halder, J. et al. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clinical Cancer Research: an official journal of the American Association for Cancer Research 12, 4916-4924, 2006). Cell lysates of RF24 cells were treated with human recombinant EGFL6 protein or anti-EGFL6 antibody, and activation of PI3 kinase and AKT signaling was confirmed using anti-human EGFL6, PI3 kinase, and AKT antibodies, followed by secondary antibodies conjugated with horseradish peroxidase (HRP).
[0116] Cell migration assay: RF24 cell migration was assessed in the presence or absence of hEGFL6 siRNA using a modified Boyden chamber coated with 0.1% gelatin. After transfection with hEGFL6 or integrin siRNA for 48 h or with EGFL6 antibody or PI3 kinase inhibitor for 6 h, RF24 cells (1.0 × 10 5 ) were seeded into the upper chamber of a Transwell porous polycarbonate membrane insert (Corning, Lowell, MA, USA). The chambers were placed in a 24-well plate containing MEM medium with 15% serum in the lower chamber as a chemoattractant. Cells were allowed to migrate for 6 h in a humidified incubator. Migrated cells were stained using hematoxylin stain and counted in five random fields per sample (200x original magnification) by light microscopy. Experiments were performed in duplicate and triplicate.
[0117] Tube formation assay: Matrigel (12.5 mg / mL) was thawed at 4°C and 50 μL was quickly added to each well of a 96-well plate and allowed to solidify at 37°C for 10 min. The wells were then incubated for 6 h at 37°C with RF24 cells (20,000 per well) pretreated with EGFL6 or integrin siRNA (48 h) or EGFL6 antibody or PI3 kinase inhibitor (6 h). Experiments were performed in triplicate and repeated twice. Five images per well were acquired at 100x using an Olympus IX81 inverted microscope. The amount of nodes (defined as when at least three cells formed in a single point) per image was quantified. The highest and lowest values were removed from each group to account for cell aggregation.
[0118] Promoter analysis and chromatin immunoprecipitation (ChIP) assay: RF24 cells were cultured in low serum medium (0.5% serum) for 18 hours and then treated with either EGFL6 or HIF1α (50 ng / mL) for 6 hours. After treatment, ChIP assays were performed using the EZ ChIP™ kit (Millipore, Temecula, CA, USA) as described by the manufacturer. Briefly, crosslinked cells were harvested, lysed, and sonicated, followed by immunoprecipitation with EGFL6 (Abchem) antibody or IgG control. Immune complexes were harvested and eluted with protein G agarose beads. Crosslinks were reversed by incubation at 65°C. DNA was then extracted and purified for PCR using a primer pair upstream of the EGFL6 transcription start site.
[0119] Flow cytometry analysis: RF24 cells were washed with PBS and harvested with PBS-EDTA 5mM. Cells were then immunolabeled with different integrin primary antibodies (Sigma-Aldrich) and subsequently stained with secondary antibodies (Invitrogen). Samples were acquired on a FACSCalibur with Cell Quest software and data were analyzed with FlowJo software.
[0120] Orthotopic in vivo model of ovarian cancer and tissue processing: Female athymic nude mice (NCr-nu) were purchased from NCI-Frederick Cancer Research and Development Center (Frederick, MD, USA) and maintained as previously described (Landen, CN, Jr. et al. 2005, supra). All mouse studies were approved by the Institutional Animal Care and Use Committee. Mice were maintained in accordance with the guidelines set forth by the American Association for Accreditation of Laboratory Animal Care and the US Public Health Service Policy on Human Care and Use of Laboratory Animals. For tumor cell injection, A2780ip2 or SKOV3ip1 or OVCAR3 cells (1 × 10 6 ) was injected intraperitoneally (i.p.). For therapy experiments, each siRNA was administered twice weekly at a dose of 150 μg / kg body weight. At the time of sacrifice, mouse and tumor weights, tumor number and distribution were recorded. The individual performing the autopsy was blinded to the treatment group assignment. Tissue specimens were fixed in either formalin, OCT (Miles, Inc., Elkhart, IN, USA), or snap frozen in liquid nitrogen. For off-target effects, SKOV3ip1 tumor-bearing mice were treated with the same two different EGFL6 siRNA sequences as above.
[0121] Immunohistochemistry and immunofluorescence staining of xenografts: IHC analysis for cell proliferation (Ki67, 1:200, Zymed), microvessel density (MVD, CD31, 1:500, Pharmingen), and hypoxia (carbonic anhydrase anti-CA9, 1:500, Novus) were all performed as described (Thaker, PH et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nature Medicine 12, 939-944, 2006; Lu, C. et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell 18, 185-197, 2010). For statistical analysis, cross sections from 5 randomly selected tumors per group were stained and 5 random fields per tumor were scored. Photographs were taken at 200x or 100x magnification. To quantify MVD in mouse tumor samples, the number of vascular staining positive for CD31 was scored at 200x in 10 random 0.159-mm2 fields. To quantify PCNA expression, the number of positive cells (3,3'-diaminobenzidine staining) was scored at 200x in 10 random 0.159-mm2 fields. 2 Fields were counted at 100x magnification (Thaker, PH et al. 2006, supra; Lu, C. et al. 2010, supra). All staining was quantified blindly by two researchers. Staining for EGFL6 (Santa Cruz) and CD31 was performed using frozen tissue as described (Lu, C. et al. 2010, supra).
[0122] Matrigel plug assay: In vivo Matrigel assay was performed by subcutaneously injecting Matrigel plugs into mice. The Matrigel plugs contained either serum-free MEM complete medium (as a negative control), VEGF (as a positive control), or EGFL6 (as a test group). Six hours after injection, animals were sacrificed, Matrigel was harvested, and hemoglobin assay was performed.
[0123] Wound healing assay: On day 1, A2780ip2 cells were injected into nude mice, and on day 2, wounds were formed on the backs of tumor-bearing mice. Animals were examined by a veterinarian and kept in individual cages. Mice were divided into two groups (n=10).
[0124] CH / Control siRNA and CH / mEGFL6 siRNA nanoparticles: siRNA treatment was started on day 3 and was performed twice weekly (150 μg / kg). Wounds were measured (until wound healing was complete) on days 0, 1, 3, 5, 7, 9, 11, 13, and 15. Tumors were harvested when animals in either group became moribund.
[0125] Hindlimb ischemia: Severe hindlimb ischemia as previously described (Baluk, P., Hashizume, H. & McDonald, D.M. Cellular abnormalities of blood vessels as targets in cancer. Current Opinion in Genetics & Development 15, 102-111, 2005) was induced in female nude mice after anesthesia with ketamine (100 mg / kg) by intraperitoneal injection, and the femoral artery was isolated from its proximal point as a branch of the external iliac artery to the distal point where it branches into the saphenous and popliteal arteries. After arterial ligation, mice were immediately assigned to the following experimental groups (n=5): control group, ischemia-24 hours, and ischemia-96 hours. Continuous laser Doppler imaging analysis (Moor Instruments, Devon, UK) was performed to monitor blood flow in the hindlimb before and after femoral artery ligation (24 hours and 96 hours later). Digital color-coded images were analyzed to quantify blood flow in the knee-to-toe region and mean perfusion values were calculated. At each time point, tissue from the ischemic limb was harvested and frozen in OCT medium. MVD was determined using mouse monoclonal anti-CD31 and EGFL6 expression on frozen embedded tissues with mouse polyclonal anti-EGFL6 antibody using standard immunostaining procedures.
[0126] Human ovarian cancer specimens: After approval by the Institutional Review Board, 180 paraffin-embedded epithelial ovarian cancer specimens (collected between 1985 and 2004) with available clinical outcome data and diagnoses confirmed by a board-certified gynecologic pathologist were obtained from the Karmanos Cancer Institute tumor bank.
[0127] Immunohistochemistry of EGFL6, CD34, and VEGF on human ovarian cancer samples was performed as previously described (Ali-Fehmi, R. et al. Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival. American Journal of Obstetrics and Gynecology 192, 819-825, 2005). EGFL6 staining was performed using anti-human EGFL6 antibody (Sigma-Aldrich). Briefly, formalin-fixed paraffin-embedded tissue sections were deparaffinized and rehydrated. After antigen retrieval with Diva solution, endogenous peroxidase was blocked with 3% hydrogen peroxide in methanol for 15 min. After washing with PBS, sections were blocked with protein block (5% normal horse serum and 1% goat serum) for 20 min at room temperature (RT), followed by incubation with anti-EGFL6 antibody (Sigma-Aldrich) overnight at 4 °C. After washing with PBS, sections were incubated with horseradish peroxidase (HRP)-conjugated goat anti-rabbit (1:250, Jackson ImmunoResearch) for 1 h at room temperature. Finally, visualization was achieved by counterstaining with 3,3'-diaminobenzidine (Research Genetics) and Gill's hematoxylin (BioGenex Laboratories). Negative staining was reported as score 0, and scores 1 to 4 were used for increasing intensity of EGFL6. Stained slides were scored by two investigators based on a histochemical score (H-score, >100 defined as high expression and ≦100 as low expression) according to a previously described method (Ali-Fehmi, et al., 2005, supra), which takes into account both the intensity of staining and the percentage of stained cells.
[0128] Statistical analysis: For animal studies, 10 mice were assigned per treatment group. This sample size provided 80% power to detect a 50% reduction in tumor weight with 95% confidence. Tumor weights and tumor nodule numbers in each group were compared using Student's t-test (for comparison of two groups). A P value of less than 0.05 was considered statistically significant. All statistical tests were two-sided and performed using SPSS version 12 for Windows statistical software (SPSS, Inc., Chicago, IL, USA).
[0129] Example 4 - EGFL6 expression upregulated in tumor-associated endothelial cells Five normal ovaries, five wound tissue samples, and ten invasive epithelial ovarian tumors were obtained and negative and positive immunoselection was performed. Prior to performing microarray analysis, the purity of all samples for endothelial cells was established using endothelial cell markers P1H12 and von Willebrand factor (Figure 4A). Immunostaining revealed that the immunopurification technique resulted in >95% endothelial cell purity in all samples. Analysis of the data revealed that 375 genes were upregulated in ovarian tumor endothelial cells compared to normal and wound endothelial cells (Figure 4B). Notably, EGFL6 showed the highest differential expression in tumor endothelial cells compared to normal and wound endothelial cells (Figure 4B). The expression of EGFL6, VEGF, and CD31 in ovarian patient samples was determined (Figure 4C). To further validate this result, endothelial cells were isolated from normal ovaries, ovarian tumors, and wound healing tissues, and the expression of EGFL6 was determined using PCR. EGFL6 was mainly overexpressed only in tumor endothelial cells compared to normal or wound endothelial cells (Figure 4D). EGFL6 upregulation in tumor endothelial cells was also shown. EGFL6 was expressed in endothelial cells and most of the ovarian cancer cells tested. To demonstrate the role of EGFL6 in tumor angiogenesis, RF24 cells were treated with siEGFL6, which resulted in more than 80% knockdown in protein levels at 72 hours compared to control cells. EGFL6 siRNA-treated cells showed significantly less migration and tube formation compared to control siRNA-treated cells, indicating the importance of EGFL6 in angiogenesis.
[0130] Example 5 - EGFL6 silencing did not affect wound healing in mice The role of EGFL6 in wound healing was described using wounds created using human dermal microvascular endothelial cells (HDMEC). The effect on wound healing was performed using the following procedure: On day 1, SKOV3ip1 cells were injected into nude mice, and on day 2, wounds were created (2 cm x 2 cm) on the backs of tumor-bearing mice. Animals were randomly divided into two groups (n = 10), one of which received a control antibody, while the other group of mice was treated with EGFL6 antibody. Antibody treatment began on day 3 and was performed once a week (5 mg / kg). The wounds (area = length x width) were monitored for 2 weeks until the completion of wound healing. EGFL6 antibody did not interfere with wound healing when tested using wound healing in vivo studies (Figure 9C).
[0131] Wound healing assays revealed that after 24 hours, sicontrol and siEGFL6 treated cells had no effect on wound healing capacity (Figures 5A-5C). Similar wounds formed in tumor-bearing mice were also used to determine the effect of EGFL6 silencing in the endothelial cell compartment using murine siRNA sequences on wound healing. As shown in Figures 5D and 5E, no significant differences were observed in wound healing in animals treated with control siRNA or murine EGFL6 siRNA, and both groups also showed similar patterns of wound healing.
[0132] However, animals treated with mouse EGFL6 siRNA showed a significant reduction in tumor burden (Figures 5F-5H), indicating that silencing EGFL6 in the endothelial cell compartment significantly affected tumor growth but did not impair wound healing. EGFL6 gene silencing also led to a significant reduction in proliferation in tumor vasculature (Figures 11A-11B).
[0133] Example 6 - EGFL6 enhances angiogenesis in endothelial cells To establish that EGFL6 results in increased survival of endothelial cells under hypoxic conditions, EGFL6 was silenced in hypoxic RF24 cells using EGFL6 siRNA and cell death was investigated. As shown in Figure 6A, nearly 50% of the cells survived after 5 days in hypoxia compared to normoxia. In contrast, EGFL6 gene silencing in hypoxia resulted in 75% cell death compared to untreated cells under hypoxic and normoxia conditions (Figure 6H). Hindlimb ischemia was formed in mice by harvesting the femoral artery of the mouse's hindlimb, which resulted in the interruption of blood and oxygen supply to the hindlimb (Figure 6I). As shown in Figures 6J-6K, ischemic mice showed a significant reduction in MVD (blood vessels) and increased EGFL6 expression in endothelial cells. RF24 cell migration (Figure 12C) and tube formation (Figure 12D) were increased after treatment with EGFL6.
[0134] Example 7 - EGFL6 silencing inhibits tumor growth and angiogenesis The therapeutic efficacy of EGFL6 in gene silencing was studied using two orthotopic ovarian cancer tumor models, SKOV3ip1 and OVCAR5. Female athymic nude mice (NCr-nu) were purchased from NCI-Frederick Cancer Research and Development Center (Frederick, MD), and all mouse studies were approved by the Institutional Animal Care and Use Committee. Mice were maintained in accordance with the guidelines set forth by the American Association for Accreditation of Laboratory Animal Care and the US Public Health Service Policy on Human Care and Use of Laboratory Animals. For tumor cell injection, SKOV3ip1 cells (1 × 10 6) via the intraperitoneal (ip) route. For antibody treatment groups, purified monoclonal antibodies were administered at 5 mg / kg body weight once a week for 5 weeks. At the time of sacrifice, mouse and tumor weights, tumor number and distribution were recorded. The individual performing the autopsy was blinded to treatment group assignment. Tissue specimens were fixed in either formalin, OCT (Miles, Inc., Elkhart, IN), or snap frozen in liquid nitrogen.
[0135] As shown in Figure 8F, treatment of SKOV3ip1 tumor-bearing animals with mouse EGFL6 siRNA alone and in combination with human EGFL6 siRNA resulted in a significant reduction in tumor growth compared to tumor-bearing mice treated with control siRNA. Human EGFL6 siRNA alone had little effect on tumor reduction. The effect of EGFL6 on the number of tumor nodules and observed tumor burden is shown in Figure 8F. OVCAR5 tumor-bearing mice treated with mouse EGFL6 siRNA alone and in combination with human EGFL6 siRNA also showed a significant reduction in tumor weight and nodules.
[0136] SKOV3ip1 tumor-bearing animals treated with mEGFL6 siRNA and a combination of mouse and human EGFL6 siRNA showed a significant reduction in proliferating cells and microvessel density compared to animals treated with control siRNA (Figures 8C-8D). OVCAR5 tumor-bearing animals showed similar results. To determine the off-target effects of the mouse EGFL6 siRNA sequence, the effect of EGFL6 gene silencing on SKOV3ip1 tumor growth was confirmed using two other mouse siRNA sequences, and both sequences showed a substantial reduction in tumor growth and tumor nodules.
[0137] Treatment with anti-EGFL6 antibodies Mab #135 and #93 (E2-135 & E2-93) significantly suppressed tumor growth (Figure 8F), and only residual cancer cells were detected in EGFL6 antibody-treated mice, whereas untreated control mice had a large tumor burden and tumor spread, as shown by the number of tumor nodules. Treatment with anti-EGFL6 antibodies (Mabs E2-93 and E2-135) also inhibited cancer cell proliferation (Ki67 staining) and reduced microvessel density (tumor angiogenesis, CD31 IHC staining) when compared to the control antibody-treated group (Figure 8G).
[0138] Example 8 - Anti-EGFL6 blocking antibodies reduce angiogenesis in endothelial cells To show that EGFL6 blocking would affect its angiogenesis-mediated function, an EGFL6 functional blocking antibody was developed and tested for its activity on angiogenesis. Several EGFL6 antibody clones that bound to human and mouse EGFL6 were screened for comparable affinity. Two antibodies (93 and 135) met all binding affinity and in vitro activity criteria and were selected for further study. As shown in Figure 8B, treatment of endothelial cells with EGFL6 recombinant protein increased the expression of both phosphorylated Tie2 and AKT proteins. In contrast, EGFL6 blocking antibodies 93 and 135 led to a reduction in the expression of both phosphorylated proteins. As shown in Figure 8D-E, treatment of endothelial cells with EGFL6 recombinant protein enhanced migration and tube formation in these cells. However, the EGFL6-mediated functional effects of both tube formation and migration were significantly reduced by EGFL6 blocking antibodies.
[0139] One of the antibodies was humanized and placed into a human IgG1 backbone to enable its use in human cancer patients, showing that the binding affinity and in vitro activity of the antibody was preserved after humanization.
[0140] Example 9 - Anti-EGFL6 blocking antibodies had anti-angiogenic and anti-tumor effects in an ovarian cancer model The in vitro activity of EGFL6 reported above indicated that blocking EGFL6 function would enhance its ability to damage tumor vasculature, thereby increasing antitumor efficacy. To test this, we blocked the activity of EGFL6 and investigated its ability to inhibit angiogenesis and tumor growth and angiogenesis.
[0141] SKOV3-ip1 tumor-bearing mice were treated with control and anti-EGFL6 antibodies. After 5 weeks of treatment, tumors were harvested and analyzed for anti-tumor and anti-angiogenic activity. Treatment with anti-EGFL6 antibodies resulted in effective anti-tumor activity compared to treatment with control antibodies. Treatment with both anti-EGFL6 antibodies 93 and 135 resulted in a significant reduction in tumor weight and tumor nodules (Figures 9E and 9F). Animals treated with EGFL6 blocking antibodies also showed reduced MVD compared to the control antibody-treated group (Figure 9F), indicating that blocking EGFL6 activity inhibited tumor growth and angiogenesis. EGFL6 antibodies did not prevent wound healing in vitro or in vivo (Figure 9G), indicating that they can modulate tumor angiogenesis without affecting normal tissue repair.
[0142] V. Antibody Variable Sequences The variable DNA sequences of the anti-EGFL6 antibody are shown below.
[0143] TIFF2024164139000009.tif56149
[0144] TIFF2024164139000010.tif56150
[0145] TIFF2024164139000011.tif56150
[0146] TIFF2024164139000012.tif56150
[0147] TIFF2024164139000013.tif57150
[0148] TIFF2024164139000014.tif57150
[0149] TIFF2024164139000015.tif57150
[0150] TIFF2024164139000016.tif57150
[0151] TIFF2024164139000017.tif56150
[0152] TIFF2024164139000018.tif56150
[0153] TIFF2024164139000019.tif56150
[0154] TIFF2024164139000020.tif56150
[0155] TIFF2024164139000021.tif56150
[0156] TIFF2024164139000022.tif56150
[0157] TIFF2024164139000023.tif56149
[0158] TIFF2024164139000024.tif56150
[0159] TIFF2024164139000025.tif64150
[0160] TIFF2024164139000026.tif56150
[0161] TIFF2024164139000027.tif56150
[0162] TIFF2024164139000028.tif56150
[0163] TIFF2024164139000029.tif56150
[0164] TIFF2024164139000030.tif56150
[0165] TIFF2024164139000031.tif56149
[0166] TIFF2024164139000032.tif56150
[0167] The variable amino acid sequences of the anti-EGFL6 antibody are shown below.
[0168] TIFF2024164139000033.tif29137
[0169] TIFF2024164139000034.tif29138
[0170] TIFF2024164139000035.tif28138
[0171] TIFF2024164139000036.tif29138
[0172] TIFF2024164139000037.tif29137
[0173] TIFF2024164139000038.tif29138
[0174] TIFF2024164139000039.tif29137
[0175] TIFF2024164139000040.tif29138
[0176] TIFF2024164139000041.tif29138
[0177] TIFF2024164139000042.tif28137
[0178] TIFF2024164139000043.tif29138
[0179] TIFF2024164139000044.tif29136
[0180] TIFF2024164139000045.tif29137
[0181] TIFF2024164139000046.tif29138
[0182] TIFF2024164139000047.tif28138
[0183] TIFF2024164139000048.tif29137
[0184] TIFF2024164139000049.tif29137
[0185] TIFF2024164139000050.tif29138
[0186] TIFF2024164139000051.tif29136
[0187] TIFF2024164139000052.tif29137
[0188] TIFF2024164139000053.tif29137
[0189] TIFF2024164139000054.tif29138
[0190] TIFF2024164139000055.tif28138
[0191] TIFF2024164139000056.tif29137
[0192] All of the disclosed and claimed methods can be made without undue experimentation in light of the present disclosure. Although the compositions and methods of the present invention have been described with respect to preferred embodiments, it will be apparent to those skilled in the art that changes may be applied to the methods and steps or the sequence of steps of the methods described herein without departing from the concept, spirit, and scope of the invention. More specifically, it will be apparent that certain agents that are chemically and physiologically related may be substituted for the agents described herein while achieving the same or similar results. All such similar substitutes and modifications apparent to those skilled in the art are intended to be within the spirit, scope, and concept of the invention as defined by the appended claims.
[0193] References The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference. TIFF2024164139000057.tif189128TIFF2024164139000058.tif23143TIFF2024164139000059.tif212151TIFF2024164139000060.tif27151
[0194] Sequence information SEQUENCE LISTING <110> THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM <120> EGFL6 SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF THEIR USE <150> US 62 / 291,987 <151> 2016-02-05 <160> 180 <170> PatentIn version 3.5 <210> 1 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 1 ggactcgacc tcagtagcta ctactac 27 <210> 2 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 2 atttatgctg gtagtagtgg tagcact 27 <210> 3 <211> 42 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 3 gcgagaggtg gtggtagtac ttatgctcaa tattttaact tg 42 <210> 4 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 4 Gly Leu Asp Leu Ser Ser Tyr Tyr Tyr 1 5 <210> 5 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 5 Ile Tyr Ala Gly Ser Ser Gly Ser Thr 1 5 <210> 6 <211> 14 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 6 Ala Arg Gly Gly Gly Ser Thr Tyr Ala Gln Tyr Phe Asn Leu 1 5 10 <210> 7 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 7 ggattctcct tcagtagtat ttattgg 27 <210> 8 <211> 24 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 8 attcagatta ctagtggtat cact 24 <210> 9 <211> 45 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 9 agaaggggat atggtgccta tgctggtact ggtgcctctg acttg 45 <210> 10 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 10 Gly Phe Ser Phe Ser Ser Ile Tyr Trp 1 5 <210> 11 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 11 Ile Gln Ile Thr Ser Gly Ile Thr 1 5 <210> 12 <211> 15 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 12 Arg Arg Gly Tyr Gly Ala Tyr Ala Gly Thr Gly Ala Ser Asp Leu 1 5 10 15 <210> 13 <211> 24 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 13 ggattcaccc tcaatagtta ttat 24 <210> 14 <211> 24 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 14 attgatagtg atagtcctac tacg 24 <210> 15 <211> 33 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 15 gcgagaggct atggtcctgt tcgattggat ctc 33 <210> 16 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 16 Gly Phe Thr Leu Asn Ser Tyr Tyr 1 5 <210> 17 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 17 Ile Asp Ser Asp Ser Pro Thr Thr 1 5 <210> 18 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 18 Ala Arg Gly Tyr Gly Pro Val Arg Leu Asp Leu 1 5 10 <210> 19 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 19 ggattctcct tcagtagcgg ctactgg 27 <210> 20 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 20 atttatgctg gtagtagtgg tgggcac 27 <210> 21 <211> 45 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 21 tgtacaagag ataattatgg tggtggtggt tctgcttcca aattg 45 <210> 22 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 22 Gly Phe Ser Phe Ser Ser Gly Tyr Trp 1 5 <210> 23 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 23 Ile Tyr Ala Gly Ser Ser Gly Gly His 1 5 <210> 24 <211> 15 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 24 Cys Thr Arg Asp Asn Tyr Gly Gly Gly Gly Ser Ala Ser Lys Leu 1 5 10 15 <210> 25 <211> 24 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 25 ggattctcct tcagtagtta tgga 24 <210> 26 <211> 21 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 26 attggtctta gtagtgagat c 21 <210> 27 <211> 30 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 27 gtgagagatc tttatcatag taatggtttg 30 <210> 28 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 28 Gly Phe Ser Phe Ser Ser Tyr Gly 1 5 <210> 29 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 29 Ile Gly Leu Ser Ser Glu Ile 1 5 <210> 30 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 30 Val Arg Asp Leu Tyr His Ser Asn Gly Leu 1 5 10 <210> 31 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 31 ggattctcct tcaatagcgg ctactgg 27 <210> 32 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 32 atctatacta gtagtcctac tggtgcc 27 <210> 33 <211> 45 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 33 tgtacaagag ataattttgg tggtggtggt tctgcttcca aattg 45 <210> 34 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 34 Gly Phe Ser Phe Asn Ser Gly Tyr Trp 1 5 <210> 35 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 35 Ile Tyr Thr Ser Ser Pro Thr Gly Ala 1 5 <210> 36 <211> 15 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 36 Cys Thr Arg Asp Asn Phe Gly Gly Gly Gly Ser Ala Ser Lys Leu 1 5 10 15 <210> 37 <211> 24 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 37 ggattcaccc tcagtagcta ctac 24 <210> 38 <211> 24 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 38 attgatactg ataatgatat tagg 24 <210> 39 <211> 33 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 39 gggagaggct atggtgcgct tcggttggat ctc 33 <210> 40 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 40 Gly Phe Thr Leu Ser Ser Tyr Tyr 1 5 <210> 41 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 41 Ile Asp Thr Asp Asn Asp Ile Arg 1 5 <210> 42 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 42 Gly Arg Gly Tyr Gly Ala Leu Arg Leu Asp Leu 1 5 10 <210> 43 <211> 24 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 43 ggattctccc tcagtagcta ccac 24 <210> 44 <211> 21 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 44 attaataatt atggtgccac a 21 <210> 45 <211> 33 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 45 gccagaagtc ctgggattcc tggttataat tcg 33 <210> 46 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 46 Gly Phe Ser Leu Ser Ser Tyr His 1 5 <210> 47 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 47 Ile Asn Asn Tyr Gly Ala Thr 1 5 <210> 48 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 48 Ala Arg Ser Pro Gly Ile Pro Gly Tyr Asn Ser 1 5 10 <210> 49 <211> 24 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 49 ggattctcct tcagtagcaa ttca 24 <210> 50 <211> 24 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 50 attgctagta gtagtagtca tagt 24 <210> 51 <211> 51 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 51 gcgagagatt ctggtaatcg tggttacctt tatgcgggcg actttaactt g 51 <210> 52 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 52 Gly Phe Ser Phe Ser Ser Asn Ser 1 5 <210> 53 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 53 Ile Ala Ser Ser Ser Ser His Ser 1 5 <210> 54 <211> 17 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 54 Ala Arg Asp Ser Gly Asn Arg Gly Tyr Leu Tyr Ala Gly Asp Phe Asn 1 5 10 15 Leu <210> 55 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 55 ggattcgacc tcagtagctc ctactac 27 <210> 56 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 56 attgacggtg gtgggggtga gcccact 27 <210> 57 <211> 39 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 57 gcgagacgag atgctggtgc tgggaacgcc tttagcttg 39 <210> 58 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 58 Gly Phe Asp Leu Ser Ser Ser Tyr Tyr 1 5 <210> 59 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 59 Ile Asp Gly Gly Gly Gly Glu Pro Thr 1 5 <210> 60 <211> 13 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 60 Ala Arg Arg Asp Ala Gly Ala Gly Asn Ala Phe Ser Leu 1 5 10 <210> 61 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 61 ggattcgact tcagtagcag ctacttt 27 <210> 62 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 62 atttatactg ttattagtcg taagact 27 <210> 63 <211> 33 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 63 gcgagatcgg caacaattga aagattggat ctc 33 <210> 64 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 64 Gly Phe Asp Phe Ser Ser Ser Tyr Phe 1 5 <210> 65 <211> 9 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 65 Ile Tyr Thr Val Ile Ser Arg Lys Thr 1 5 <210> 66 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 66 Ala Arg Ser Ala Thr Ile Glu Arg Leu Asp Leu 1 5 10 <210> 67 <211> 24 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 67 ggattcacca tcaataacta caac 24 <210> 68 <211> 21 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 68 atttggaatg gtgatggcag c 21 <210> 69 <211> 18 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 69 gcgagaaatt ttaacttg 18 <210> 70 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 70 Gly Phe Thr Ile Asn Asn Tyr Asn 1 5 <210> 71 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 71 Ile Trp Asn Gly Asp Gly Ser 1 5 <210> 72 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 72 Ala Arg Asn Phe Asn Leu 1 5 <210> 73 <211> 21 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 73 ccgagtgttt ataggcacta c 21 <210> 74 <211> 9 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 74 tgggcttcc 9 <210> 75 <211> 33 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 75 gcaggcgaat atgctagtga tagtgataat cat 33 <210> 76 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 76 Pro Ser Val Tyr Arg His Tyr 1 5 <210> 77 <211> 3 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 77 Trp Ala Ser 1 <210> 78 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 78 Ala Gly Glu Tyr Ala Ser Asp Ser Asp Asn His 1 5 10 <210> 79 <211> 24 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 79 cagagtgttt ataataacaa caac 24 <210> 80 <211> 9 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 80 gaagcatcc 9 <210> 81 <211> 30 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 81 gcaggcggtt atgctggcta catttgggct 30 <210> 82 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 82 Gln Ser Val Tyr Asn Asn Asn Asn 1 5 <210> 83 <211> 3 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 83 Glu Ala Ser 1 <210> 84 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 84 Ala Gly Gly Tyr Ala Gly Tyr Ile Trp Ala 1 5 10 <210> 85 <211> 24 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 85 aagaacgcct atttatccta ctac 24 <210> 86 <211> 9 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 86 tgggcttcc 9 <210> 87 <211> 33 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 87 gcagccgaat atagtaatga tagtgataat ggt 33 <210> 88 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 88 Lys Asn Ala Tyr Leu Ser Tyr Tyr 1 5 <210> 89 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 89 Ala Ala Glu Tyr Ser Asn Asp Ser Asp Asn Gly 1 5 10 <210> 90 <211> 24 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 90 cagagtgttt atagtaacaa ccgc 24 <210> 91 <211> 9 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 91 tatgcagcc 9 <210> 92 <211> 36 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 92 gcaggatata aaactgctga ttctgatggt attgct 36 <210> 93 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 93 Gln Ser Val Tyr Ser Asn Asn Arg 1 5 <210> 94 <211> 3 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 94 Tyr Ala Ala 1 <210> 95 <211> 12 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 95 Ala Gly Tyr Lys Thr Ala Asp Ser Asp Gly Ile Ala 1 5 10 <210> 96 <211> 24 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 96 gagagcgttt ataataataa ccgc 24 <210> 97 <211> 9 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 97 tatgcatcc 9 <210> 98 <211> 36 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 98 gtagccttta aaggttatgg tactgacggc aatgct 36 <210> 99 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 99 Glu Ser Val Tyr Asn Asn Asn Arg 1 5 <210> 100 <211> 3 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 100 Tyr Ala Ser 1 <210> 101 <211> 12 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 101 Val Ala Phe Lys Gly Tyr Gly Thr Asp Gly Asn Ala 1 5 10 <210> 102 <211> 24 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 102 gagagtgttt atagtaacaa ccgc 24 <210> 103 <211> 36 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 103 gcaggatata agactgccga ttctgatggt cttggt 36 <210> 104 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 104 Glu Ser Val Tyr Ser Asn Asn Arg 1 5 <210> 105 <211> 12 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 105 Ala Gly Tyr Lys Thr Ala Asp Ser Asp Gly Leu Gly 1 5 10 <210> 106 <211> 21 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 106 ccgagtgttt ataggcacta c 21 <210> 107 <211> 33 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 107 gcaggcgaat atgctagtga tagtgataat cat 33 <210> 108 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 108 Pro Ser Val Tyr Arg His Tyr 1 5 <210> 109 <211> 11 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 109 Ala Gly Glu Tyr Ala Ser Asp Ser Asp Asn His 1 5 10 <210> 110 <211> 24 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 110 cagaatgttt atagttacaa ccgc 24 <210> 111 <211> 9 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 111 gaagcatcc 9 <210> 112 <211> 39 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 112 gcaggcggtt atgattgtag gagttctgat tgtgatgct 39 <210> 113 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 113 Gln Asn Val Tyr Ser Tyr Asn Arg 1 5 <210> 114 <211> 13 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 114 Ala Gly Gly Tyr Asp Cys Arg Ser Ser Asp Cys Asp Ala 1 5 10 <210> 115 <211> 18 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 115 cagagcatta atagttgg 18 <210> 116 <211> 39 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 116 caacagggtt atagttatag taatgttgat aataatatt 39 <210> 117 <211> 6 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 117 Gln Ser Ile Asn Ser Trp 1 5 <210> 118 <211> 13 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 118 Gln Gln Gly Tyr Ser Tyr Ser Asn Val Asp Asn Asn Ile 1 5 10 <210> 119 <211> 24 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 119 caaagtgttt atcttcagaa caac 24 <210> 120 <211> 30 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 120 cagggcggtt acagtggata tatcaattct 30 <210> 121 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 121 Gln Ser Val Tyr Leu Gln Asn Asn 1 5 <210> 122 <211> 10 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 122 Gln Gly Gly Tyr Ser Gly Tyr Ile Asn Ser 1 5 10 <210> 123 <211> 24 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 123 gagagtgttt ataataacta ccgc 24 <210> 124 <211> 9 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 124 gctgcatcc 9 <210> 125 <211> 36 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 125 gtaggatata aaagtggtta tattgatagt attcct 36 <210> 126 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 126 Glu Ser Val Tyr Asn Asn Tyr Arg 1 5 <210> 127 <211> 3 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 127 Ala Ala Ser 1 <210> 128 <211> 12 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 128 Val Gly Tyr Lys Ser Gly Tyr Ile Asp Ser Ile Pro 1 5 10 <210> 129 <211> 24 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 129 gcgagtgttt atagtaacaa ctac 24 <210> 130 <211> 36 <212> DNA <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 130 gcaggcgatt atagtagtag tagtgatatg tgtatt 36 <210> 131 <211> 8 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 131 Here Dear Val Taurus Dear Donkey Donkey Taurus 1 5 <210> 132 <211> 12 <212> PRT <213> Artificial sequence <220> <223> Synthetic CDR sequence <400> 132 Ala Gly Asp Tyr Ser Ser Ser Ser Asp Met Cys Ile 1 5 10 <210> 133 <211> 364 <212> DNA <213> Artificial sequence <220> <223> Synthetic oligonucleotide <400> 133 cagtcgctgg aggagtccga gggaggcctg gtccagcctg agggatccct gacactcacc 60 tgcaaagcct ctggactcga cctcagtagc tactactaca tgtgctgggt ccgccaggct 120 ccagggaagg ggctggagtg gatcgcatgc attatgctg gtagtagtgg tagcacttac 180 tacgcgagct gggcgaaagg ccgattcacc atctccaaaa cctcgtcgac cacggtgact 240 ctgcaaatga ccagtctgac agccgcggac acggccacct atttctgtgc gagaggtggt 300 ggtagtactt atgctcaata ttttaacttg tggggcccag gcaccctggt caccatctcc 360 tcag 364 <210> 134 <211> 331 <212> DNA <213> Artificial sequence <220> <223> Synthetic oligonucleotide <220> <221> misc_feature <222> (18)..(18) <223> n is a, c, g, or t <400> 134 gagctcgata tgacccanac accagcctcc gtgtctgcag ctgtgggagg cacagtcagc 60 atcaattgcc agtccagtcc gagtgtttat aggcactact tatcctggta tcagcagaaa 120 ccagggcagc ctcccaagct cctgatctac tgggcttcca ctctggcatc tggggtccca 180 tcgcggttca gcggcagtgg atctgggaca gagttcactc tcaccatcag cggcgtgcag 240 tgtgacgatg ctgccactta ctactgtgca ggcgaatatg ctagtgatag tgataatcat 300 ttcggcggag ggaccgagct ggagatccta g 331 <210> 135 <211> 370 <212> DNA <213> Artificial sequence <220> <223> Synthetic oligonucleotide <400> 135 gagcagtcgg tgaaggagtc cgggggaggc ctggtccagc ctgagggatc cctgacactc 60 acctgcacag cttctggatt ctccttcagt agtatttatt ggatatgctg ggtccgccag 120 gctccaggga aggggctgga gttgatcgca tgcattcaga ttactagtgg tatcacttac 180 tacgcgagct gggcgaaagg ccgattcacc atctccaaaa tgtcgtcgac cacggtgact 240 ctgcaaatga ccagtctgac agtcgcggac acggccacct atttctgtgg gagaagggga 300 tatggtgcct atgctggtac tggtgcctct gacttgtggg gcccaggcac cctggtcacc 360 gtctcttcag 370 <210> 136 <211> 331 <212> DNA <213> Artificial sequence <220> <223> Synthetic oligonucleotide <400> 136 gagctcgatc tgacccagac tgcatcgtcc gtgtctgcag ctgtgggagg caccgtcacc 60 atcaattgcc agtccagtca gagtgtttat aataacaaca acttagcctg gtatcagcag 120 aaaccagggc agcctcccaa gctcctgatc tacgaagcat ccaaactggc atctggggtc 180 ccatcgcggt tcaaaggcag tggatctggg acacagttca ctctcaccat cagcggcgtg 240 cagtgtgacg atgctgccac ttactattgt gcaggcggtt atgctggcta catttgggct 300 ttcggcggag ggaccgaggt ggtggtcaaa g 331 <210> 137 <211> 355 <212> DNA <213> Artificial sequence <220> <223> Synthetic oligonucleotide <400> 137 gagcagtcgg tggaggagtc cgggggaggc ctgttccagc ctgggggatc cctggcactc 60 acctgcaaag cctctggatt caccctcaat agttattata tgtcctgggt ccgccaggct 120 ccagggaagg ggctggagtg gatcggatgc attgatagtg atagtcctac tacgactgcc 180 tacgcgaact gggcgagagg ccgattcacc atctccaaga cctcgtcgac cacggtgact 240 ctgcaaatga ccagtctgac agccgcggac acggccacct atttctgtgc gagaggctat 300 ggtcctgttc gattggatct ctggggccag ggcaccctgg tcaccgtctc ttcag 355 <210> 138 <211> 334 <212> DNA <213> Artificial sequence <220> <223> Synthetic oligonucleotide <400> 138 acccagacac cagcctccgt gtctgcagct gtgggaggca cagtcagcat caattgccag 60 tccagtcaga gtgtttataa gaacgcctat ttatcctact acttagcctg gtatcagcag 120 aaaccagggc agcctcccaa gctcctgatc tactgggctt ccactctggc atctggggtc 180 ccatcgcggt tcaaaggcag tggatctggg acacagttca ctctcaccat cagcgacgtg 240 cagtgtgacg atgctgccac ttactactgt gcagccgaat atagtaatga tagtgataat 300 ggtttcggcg gagggaccga ggtggaaatc aaag 334 <210> 139 <211> 370 <212> DNA <213> Artificial sequence <220> <223> Synthetic oligonucleotide <400> 139 gagcagtcgt tggaggagtc cgggggagac ctggtcaagc ctgagggatc cctgacactc 60 acctgcgcag cctctggatt ctccttcagt agcggctact ggatatgctg ggtccgccag 120 gctccaggga aggggctgga gtggatcgga tgcatttatg ctggtagtag tggtgggcac 180 atttattacg cgacctgggc gaaaggccga ttcaccatct cccaaacctc gtcgaccacg 240 gtgactctgc aaatgaccag tctgacagcc gcggacacgg ccacatattt ctgtacaaga 300 gataattatg gtggtggtgg ttctgcttcc aaattgtggg gcccaggcac cctggtcacc 360 atctcttcag 370 <210> 140 <211> 337 <212> DNA <213> Artificial sequence <220> <223> Synthetic oligonucleotide <400> 140 gagctcgtga tgacccagac tccatccccc gtgtctgcag ctgtgggagg cacagtcacc 60 atcaactgcc agtccagtca gagtgtttat agtaacaacc gcttagcctg gtatcagcag 120 aaaccagggc agcctcccaa gctcctggtc tattatgcag ccactctggc atctggggtc 180 ccgtcgcggt tcaaaggcag tggatatggg acacagtcca ctctcaccat cgccgatgtg 240 gtgtgtgacg atgctgccac ttactactgt gcaggatata aaactgctga ttctgatggt 300 attgctttcg gcggagggac cgaggtggaa atcaaag 337 <210> 141 <211> 346 <212> DNA <213> Artificial sequence <220> <223> Synthetic oligonucleotide <400> 141 cagtcggtga aggagtccga gggaggcctg gtccagcctg agggatccct gacactcacc 60 tgcaaagcct ctggattctc cttcagtagt tatggagtga actgggtccg ccaggctcca 120 gggaaggggc tggagtggat cgcgtatatt ggtcttagta gtgagatcac ttactacgcg 180 ggctgggcga aaggccgatt caccatctcc aagccctcgt cgaccacggt gactctgcaa 240 atgaccagtc tgacagccgc ggacacggcc acctatttct gtgtgagaga tctttatcat 300 agtaatggtt tgtggggccc aggcaccctg gtcaccatct cttcag 346 <210> 142 <211> 337 <212> DNA <213> Artificial sequence <220> <223> Synthetic oligonucleotide <400> 142 gagctcgatc tgacccagac tccatccccc gtgtctgcag ctgtgggagg cacagtcacc 60 gtcagttgcc aggccagtga gagcgtttat aataataacc gcttatcctg gtatcagcag 120 aaaccagggc agcctcccaa gctcctgatc tattatgcat ccactctggc atctggggtc 180 ccatcgcggt tcagcggcag tggatctggg acacagttca ctctcaccat cagcagcgtg 240 caatgtgctg atgctgccac gtattattgt gtagccttta aaggttatgg tactgacggc 300 aatgctttcg gcggagggac cgaggtggaa atcaaag 337 <210> 143 <211> 370 <212> DNA <213> Artificial sequence <220> <223> Synthetic oligonucleotide <400> 143 gagcagtcgg tgaaggagtc cgggggagac ctggtcaagc ctgagggatc cctgacactc 60 acctgcacag cctctggatt ctccttcaat agcggctact gggtatgctg ggtccgccag 120 gctccaggga aggggctgga gtggatcgct tgcatctata ctagtagtcc tactggtgcc 180 atatactacg cgacctgggc gaaaggccga ttcaccatct cccaaacctc gtcgaccacg 240 gtgactctgc aaatgaccag tctgacagcc gcggacacgg ccacctattt ctgtacaaga 300 gataattttg gtggtggtgg ttctgcttcc aaattgtggg gcccaggcac cctggtcacc 360 atctcttcag 370 <210> 144 <211> 336 <212> DNA <213> Artificial sequence <220> <223> Synthetic oligonucleotide <400> 144 gagctcgtga tgacccagac tccatcttcc aagtctgtcc ctgtgggagg cacagtcacc 60 atcgattgcc aggccagtga gagtgtttat agtaacaacc gctgtgcctg gtatcagcag 120 aaaccagggc agcctcccaa gctcctgatc tattatgcat ccactctggc atctggggtc 180 ccgtcgcggt tcaaatgcag tggatctggg acacggttca ctctcaccat cagcggcgtg 240 cagtgtgaag atgctgccac ttactactgt gcaggatata agactgccga ttctgatggt 300 cttggtttcg gcggagggac cgaggtggaa atcaaa 336 <210> 145 <211> 354 <212> DNA <213> Artificial sequence <220> <223> Synthetic oligonucleotide <400> 145 gagcagtcgg tgaaggagtc cgagggagac ctggtcaagc ctgagggatc cctgacactc 60 gcctgcacag cttctggatt caccctcagt agctactaca tgtgctgggt ccgccaggct 120 ccagggaagg ggctggaatg gatcgcatgc attgatactg ataatgatat taggactgcc 180 tacgcgagct gggcgagggg ccgattcacc atctccagga cctcgtcgac cacggtgact 240 ctgcaaatga ccagtctgac agccgcggac acggccacct atttctgtgg gagaggctat 300 ggtgcgcttc ggttggatct ctggggccag ggcccctggt caccgtctct tcag 354 <210> 146 <211> 331 <212> DNA <213> Artificial sequence <220> <223> Synthetic oligonucleotide <400> 146 gagctcgatc tgacccagac accagcctcc gtgtctgcag ctgtgggagg cacagtcagc 60 atcaattgcc agtccagtcc gagtgtttat aggcactact tatcctggta tcagcagaaa 120 ccagggcagc ctcccaagct cctgatctac tgggcttcca ctctggcatc tggggtccca 180 tcgcggttca gcggcagtgg atctgggaca gagttcactc tcaccatcag cggcgtgcag 240 tgtgacgatg ctgccactta ctactgtgca ggcgaatatg ctagtgatag tgataatcat 300 ttcggcggag ggaccgaggt ggaaatcaaa g 331 <210> 147 <211> 343 <212> DNA <213> Artificial sequence <220> <223> Synthetic oligonucleotide <400> 147 cagtcggtga aggagtccga gggtcgcctg gtcacgcctg ggacacccct gacactcacc 60 tgcacagtct ctggattctc cctcagtagc taccacatgg gctgggtccg ccaggctcca 120 gggaaggggc tggaatacat cggaatcatt aataattatg gtgccacata ctacgcgagc 180 tgggcaaaag gccgattcac catctccaga acctcgacca cggtggatct gaaaatgacc 240 agtctgacaa ccgaggacac ggccacctat ttctgtgcca gaagtcctgg gattcctggt 300 tataattcgt ggggcccagg caccctggtc accatctcct cag 343 <210> 148 <211> 340 <212> DNA <213> Artificial sequence <220> <223> Synthetic oligonucleotide <400> 148 gagctcgatc tgacccagac tccatcttcc acgtctgcgg ctgtgggagg cacagtcacc 60 atcaactgcc agtccagtca gaatgtttat agttacaacc gcttatcctg gtttcagcag 120 aaaccagggc agcctcccaa gctcctgatc tacgaagcat ccaaactggc atctggggtc 180 ccatcgcggt tcaaaggcag tggatctggg acacagttca ctctcaccat cagcggcgtg 240 cagtgtgacg atgctgccac ttactactgt gcaggcggtt atgattgtag gagttctgat 300 tgtgatgctt tcggcggagg gaccgaggtg gaaatcaaac 340 <210> 149 <211> 373 <212> DNA <213> Artificial sequence <220> <223> Synthetic oligonucleotide <400> 149 agcagttcgg tggaggagtc cgggggagac ctggtcaagc ccggggcatc cctgacactc 60 acctgcacag cctctggatt ctccttcagt agcaattcaa tgtgctgggt ccgccaggct 120 ccagggaagg ggctggagtg gatcggatgc attgctagta gtagtagtca tagtacttac 180 tacgcgagct gggcgaaagg ccgattcacc atctccaaaa cctcgtcgac cacggtgact 240 ctgcaaatga ccagtctgac agccgcggac atggccacct atttctgtgc gagagattct 300 ggtaatcgtg gttaccttta tgcgggcgac tttaacttgt ggggcccagg caccctggtc 360 accgtctctt cag 373 <210> 150 <211> 334 <212> DNA <213> Artificial sequence <220> <223> Synthetic oligonucleotide <400> 150 gagctcgtgc tgacccagac tccagcctct gtggaggtag ctgtgggagg cacagtcacc 60 atcaattgcc aggccagtca gagcattaat agttggttat cctggtatca gcagaaacca 120 gggcagcgtc ccaaactcct gatctacgaa gcatccactc tggcatctgg ggtctcatcg 180 cggttcagtg gcagtggatc tgggacacag ttcactctca ccatcagcgg cgtgcagtgt 240 gacgatgctg ccacttacta ctgtcaacag ggttatagtt atagtaatgt tgataataat 300 attttcggcg gagggaccga ggtggtggtc aaag 334 <210> 151 <211> 361 <212> DNA <213> Artificial sequence <220> <223> Synthetic oligonucleotide <400> 151 cagtcgttgg aggagtccgg gggaggcctg gtcaagcctg agggatccct gacactcacc 60 tgcacagcct ctggattcga cctcagtagc tcctactaca tgtgctgggt ccgccaggct 120 ccagggaagg ggctggagtg gatcgtctgt attgacggtg gtgggggtga gcccactgcc 180 tacccgagct gggcgaaagg ccgattcacc gtctccaaaa cctcgtcgac cacggtgact 240 cttcaaatga ccagtctgac agtcgcggac acggccacgt atttctgtgc gagacgagat 300 gctggtgctg ggaacgcctt tagcttgtgg ggcccaggca ccctggtcac catctcctca 360 g 361 <210> 152 <211> 331 <212> DNA <213> Artificial sequence <220> <223> Synthetic oligonucleotide <400> 152 gagctcgata tgacccagac tccatccccc gtgtctgcag ctgtgggagg cacagtcacc 60 atcagttgcc agtccagtca aagtgtttat cttcagaaca acttagcctg gtatcagcag 120 aaaccagggc agcctcccaa gctcctgatc tattatgcat ccactctggc atctggggtc 180 tcatcgcggt tcaaaggcag tggatctggg acacagttca ctctcaccat cagcgacctg 240 gagtgtgacg atgctgccac ttactactgt cagggcggtt acagtggata tatcaattct 300 ttcggcggag ggaccgaggt ggaaatcaaa g 331 <210> 153 <211> 355 <212> DNA <213> Artificial sequence <220> <223> Synthetic oligonucleotide <400> 153 cagtcggtga aggagtccga gggagacctg gtcaagcctg gggcatccct gacactcacc 60 tgcaaagcct ctggattcga cttcagtagc agctacttta tgtgctgggt ccgccaggct 120 ccagggaggg ggctggagtg gatcgcatgc atttatactg ttattagtcg taagacttat 180 tacgcgagct gggcgaaagg ccgattcacc atctccaaaa cctcggcgac cacggtggat 240 ctgcaaatga ccagtctgac agccgcggac acggccacct atttctgtgc gagatcggca 300 acaattgaaa gattggatct ctggggccag ggcaccctgg tcaccgtctc ctcag 355 <210> 154 <211> 337 <212> DNA <213> Artificial sequence <220> <223> Synthetic oligonucleotide <400> 154 gagctcgatc tgacccagac tccatcgccc gtgtctgcac ctgtgggagg cacagtcacc 60 atcaattgcc aggccagtga gagtgtttat aataactacc gcttatcctg gtatcagcag 120 aaaccagggc agcctcccaa gctcctaatc tatgctgcat ccactctggc atctggggtc 180 ccatcgcggt tcaaaggcag tggatctggg acacagttca ctctcgccat cagcgatgtg 240 gtgtgtgacg atgctgccac ttactactgt gtaggatata aaagtggtta tattgatagt 300 attcctttcg gcggagggac cgaggtggtg gtcaaag 337 <210> 155 <211> 334 <212> DNA <213> Artificial sequence <220> <223> Synthetic oligonucleotide <400> 155 cagtcgttgg aggagtccgg gggagacctg gtcaagcctg gggcatccct gacactcacc 60 tgcacagctt ctggattcac catcaataac tacaacatta actgggtccg ccaggctcca 120 gggaaggggc tggagtggat cgcacgtatt tggaatggtg atggcagcac atactacgcg 180 agctgggcga aaggccgatt caccatctcc aaaacctcgt cgaccacggt gactctacaa 240 atgaccagtc tgacagccgc ggacacggcc acctatttct gtgcgagaaa ttttaacttg 300 tggggcccag gcaccctggt caccatctct tcag 334 <210> 156 <211> 337 <212> DNA <213> Artificial sequence <220> <223> Synthetic oligonucleotide <400> 156 gagctcgtgc tgacccagac tccatctccc gtgtctgcag ctgtgggagg cacagtcacc 60 atcaattgcc agtccagtgc gagtgtttat agtaacaact acttatcctg gtttcagcag 120 aaaccagggc agcctcccaa gcccctgatc tattatgcat ccactctggc atctggggtc 180 ccatcgcggt ttaaaggcag tggatctggg acacagttca ctctcaccat cagcgacgtg 240 cagtgtgacg atgctgccac ttactactgt gcaggcgatt atagtagtag tagtgatatg 300 tgtattttcg gcggagggac cgagctggaa atcaaag 337 <210> 157 <211> 121 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 157 Gln Ser Leu Glu Glu Ser Glu Gly Gly Leu Val Gln Pro Glu Gly Ser 1 5 10 15 Leu Thr Leu Thr Cys Lys Ala Ser Gly Leu Asp Leu Ser Ser Tyr Tyr 20 25 30 Tyr Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Ala Cys Ile Tyr Ala Gly Ser Ser Gly Ser Thr Tyr Tyr Ala Ser Trp 50 55 60 Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Thr 65 70 75 80 Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Ala Arg Gly Gly Gly Ser Thr Tyr Ala Gln Tyr Phe Asn Leu Trp Gly 100 105 110 Pro Gly Thr Leu Val Thr Ile Ser Ser 115 120 <210> 158 <211> 109 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 158 Glu Leu Asp Met Thr Thr Pro Ala Ser Val Ser Ala Ala Val Gly Gly 1 5 10 15 Thr Val Ser Ile Asn Cys Gln Ser Ser Pro Ser Val Tyr Arg His Tyr 20 25 30 Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile 35 40 45 Tyr Trp Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Gly Val Gln Cys 65 70 75 80 Asp Asp Ala Ala Thr Tyr Tyr Cys Ala Gly Glu Tyr Ala Ser Asp Ser 85 90 95 Asp Asn His Phe Gly Gly Gly Thr Glu Leu Glu Ile Leu 100 105 <210> 159 <211> 123 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 159 Glu Gln Ser Val Lys Glu Ser Gly Gly Gly Leu Val Gln Pro Glu Gly 1 5 10 15 Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser Ile 20 25 30 Tyr Trp Ile Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Leu 35 40 45 Ile Ala Cys Ile Gln Ile Thr Ser Gly Ile Thr Tyr Tyr Ala Ser Trp 50 55 60 Ala Lys Gly Arg Phe Thr Ile Ser Lys Met Ser Ser Thr Thr Val Thr 65 70 75 80 Leu Gln Met Thr Ser Leu Thr Val Ala Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Gly Arg Arg Gly Tyr Gly Ala Tyr Ala Gly Thr Gly Ala Ser Asp Leu 100 105 110 Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 160 <211> 110 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 160 Glu Leu Asp Leu Thr Gln Thr Ala Ser Ser Val Ser Ala Ala Val Gly 1 5 10 15 Gly Thr Val Thr Ile Asn Cys Gln Ser Ser Gln Ser Val Tyr Asn Asn 20 25 30 Asn Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu 35 40 45 Leu Ile Tyr Glu Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe 50 55 60 Lys Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Gly Val 65 70 75 80 Gln Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Ala Gly Gly Tyr Ala Gly 85 90 95 Tyr Ile Trp Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys 100 105 110 <210> 161 <211> 118 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 161 Glu Gln Ser Val Glu Glu Ser Gly Gly Gly Leu Phe Gln Pro Gly Gly 1 5 10 15 Ser Leu Ala Leu Thr Cys Lys Ala Ser Gly Phe Thr Leu Asn Ser Tyr 20 25 30 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Cys Ile Asp Ser Asp Ser Pro Thr Thr Thr Ala Tyr Ala Asn Trp 50 55 60 Ala Arg Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Thr 65 70 75 80 Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Ala Arg Gly Tyr Gly Pro Val Arg Leu Asp Leu Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <210> 162 <211> 111 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 162 Thr Gln Thr Pro Ala Ser Val Ser Ala Ala Val Gly Gly Thr Val Ser 1 5 10 15 Ile Asn Cys Gln Ser Ser Gln Ser Val Tyr Lys Asn Ala Tyr Leu Ser 20 25 30 Tyr Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu 35 40 45 Leu Ile Tyr Trp Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe 50 55 60 Lys Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Val 65 70 75 80 Gln Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Ala Ala Glu Tyr Ser Asn 85 90 95 Asp Ser Asp Asn Gly Phe Gly Gly Gly Thr Glu Val Glu Ile Lys 100 105 110 <210> 163 <211> 123 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 163 Glu Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Glu Gly 1 5 10 15 Ser Leu Thr Leu Thr Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Gly 20 25 30 Tyr Trp Ile Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp 35 40 45 Ile Gly Cys Ile Tyr Ala Gly Ser Ser Gly Gly His Ile Tyr Tyr Ala 50 55 60 Thr Trp Ala Lys Gly Arg Phe Thr Ile Ser Gln Thr Ser Ser Thr Thr 65 70 75 80 Val Thr Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr 85 90 95 Phe Cys Thr Arg Asp Asn Tyr Gly Gly Gly Gly Ser Ala Ser Lys Leu 100 105 110 Trp Gly Pro Gly Thr Leu Val Thr Ile Ser Ser 115 120 <210> 164 <211> 112 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 164 Glu Leu Val Met Thr Gln Thr Pro Ser Pro Val Ser Ala Ala Val Gly 1 5 10 15 Gly Thr Val Thr Ile Asn Cys Gln Ser Ser Gln Ser Val Tyr Ser Asn 20 25 30 Asn Arg Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu 35 40 45 Leu Val Tyr Tyr Ala Ala Thr Leu Ala Ser Gly Val Pro Ser Arg Phe 50 55 60 Lys Gly Ser Gly Tyr Gly Thr Gln Ser Thr Leu Thr Ile Ala Asp Val 65 70 75 80 Val Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Ala Gly Tyr Lys Thr Ala 85 90 95 Asp Ser Asp Gly Ile Ala Phe Gly Gly Gly Thr Glu Val Glu Ile Lys 100 105 110 <210> 165 <211> 115 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 165 Gln Ser Val Lys Glu Ser Glu Gly Gly Leu Val Gln Pro Glu Gly Ser 1 5 10 15 Leu Thr Leu Thr Cys Lys Ala Ser Gly Phe Ser Phe Ser Ser Tyr Gly 20 25 30 Val Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Ala 35 40 45 Tyr Ile Gly Leu Ser Ser Glu Ile Thr Tyr Tyr Ala Gly Trp Ala Lys 50 55 60 Gly Arg Phe Thr Ile Ser Lys Pro Ser Ser Thr Thr Val Thr Leu Gln 65 70 75 80 Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys Val Arg 85 90 95 Asp Leu Tyr His Ser Asn Gly Leu Trp Gly Pro Gly Thr Leu Val Thr 100 105 110 Ile Ser Ser 115 <210> 166 <211> 112 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 166 Glu Leu Asp Leu Thr Gln Thr Pro Ser Pro Val Ser Ala Ala Val Gly 1 5 10 15 Gly Thr Val Thr Val Ser Cys Gln Ala Ser Glu Ser Val Tyr Asn Asn 20 25 30 Asn Arg Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu 35 40 45 Leu Ile Tyr Tyr Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe 50 55 60 Ser Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Ser Val 65 70 75 80 Gln Cys Ala Asp Ala Ala Thr Tyr Tyr Cys Val Ala Phe Lys Gly Tyr 85 90 95 Gly Thr Asp Gly Asn Ala Phe Gly Gly Gly Thr Glu Val Glu Ile Lys 100 105 110 <210> 167 <211> 123 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 167 Glu Gln Ser Val Lys Glu Ser Gly Gly Asp Leu Val Lys Pro Glu Gly 1 5 10 15 Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Asn Ser Gly 20 25 30 Tyr Trp Val Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp 35 40 45 Ile Ala Cys Ile Tyr Thr Ser Ser Pro Thr Gly Ala Ile Tyr Tyr Ala 50 55 60 Thr Trp Ala Lys Gly Arg Phe Thr Ile Ser Gln Thr Ser Ser Thr Thr 65 70 75 80 Val Thr Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr 85 90 95 Phe Cys Thr Arg Asp Asn Phe Gly Gly Gly Gly Ser Ala Ser Lys Leu 100 105 110 Trp Gly Pro Gly Thr Leu Val Thr Ile Ser Ser 115 120 <210> 168 <211> 112 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 168 Glu Leu Val Met Thr Gln Thr Pro Ser Ser Lys Ser Val Pro Val Gly 1 5 10 15 Gly Thr Val Thr Ile Asp Cys Gln Ala Ser Glu Ser Val Tyr Ser Asn 20 25 30 Asn Arg Cys Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu 35 40 45 Leu Ile Tyr Tyr Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe 50 55 60 Lys Cys Ser Gly Ser Gly Thr Arg Phe Thr Leu Thr Ile Ser Gly Val 65 70 75 80 Gln Cys Glu Asp Ala Ala Thr Tyr Tyr Cys Ala Gly Tyr Lys Thr Ala 85 90 95 Asp Ser Asp Gly Leu Gly Phe Gly Gly Gly Thr Glu Val Glu Ile Lys 100 105 110 <210> 169 <211> 118 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 169 Glu Gln Ser Val Lys Glu Ser Glu Gly Asp Leu Val Lys Pro Glu Gly 1 5 10 15 Ser Leu Thr Leu Ala Cys Thr Ala Ser Gly Phe Thr Leu Ser Ser Tyr 20 25 30 Tyr Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Ala Cys Ile Asp Thr Asp Asn Asp Ile Arg Thr Ala Tyr Ala Ser Trp 50 55 60 Ala Arg Gly Arg Phe Thr Ile Ser Arg Thr Ser Ser Thr Thr Val Thr 65 70 75 80 Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Gly Arg Gly Tyr Gly Ala Leu Arg Leu Asp Leu Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Ile Ser Ser 115 <210> 170 <211> 110 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 170 Glu Leu Asp Leu Thr Gln Thr Pro Ala Ser Val Ser Ala Ala Val Gly 1 5 10 15 Gly Thr Val Ser Ile Asn Cys Gln Ser Ser Pro Ser Val Tyr Arg His 20 25 30 Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu 35 40 45 Ile Tyr Trp Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Gly Val Gln 65 70 75 80 Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Ala Gly Glu Tyr Ala Ser Asp 85 90 95 Ser Asp Asn His Phe Gly Gly Gly Thr Glu Val Glu Ile Lys 100 105 110 <210> 171 <211> 114 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 171 Gln Ser Val Lys Glu Ser Glu Gly Arg Leu Val Thr Pro Gly Thr Pro 1 5 10 15 Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Ser Tyr His 20 25 30 Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Ile Gly 35 40 45 Ile Ile Asn Asn Tyr Gly Ala Thr Tyr Tyr Ala Ser Trp Ala Lys Gly 50 55 60 Arg Phe Thr Ile Ser Arg Thr Ser Thr Thr Val Asp Leu Lys Met Thr 65 70 75 80 Ser Leu Thr Thr Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Ser Pro 85 90 95 Gly Ile Pro Gly Tyr Asn Ser Trp Gly Pro Gly Thr Leu Val Thr Ile 100 105 110 Ser Ser <210> 172 <211> 113 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 172 Glu Leu Asp Leu Thr Gln Thr Pro Ser Ser Thr Ser Ala Ala Val Gly 1 5 10 15 Gly Thr Val Thr Ile Asn Cys Gln Ser Ser Gln Asn Val Tyr Ser Tyr 20 25 30 Asn Arg Leu Ser Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu 35 40 45 Leu Ile Tyr Glu Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe 50 55 60 Lys Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Gly Val 65 70 75 80 Gln Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Ala Gly Gly Tyr Asp Cys 85 90 95 Arg Ser Ser Asp Cys Asp Ala Phe Gly Gly Gly Thr Glu Val Glu Ile 100 105 110 Lys <210> 173 <211> 124 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 173 Ser Ser Ser Val Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser Asn 20 25 30 Ser Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Cys Ile Ala Ser Ser Ser Ser His Ser Thr Tyr Tyr Ala Ser Trp 50 55 60 Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Thr 65 70 75 80 Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Met Ala Thr Tyr Phe Cys 85 90 95 Ala Arg Asp Ser Gly Asn Arg Gly Tyr Leu Tyr Ala Gly Asp Phe Asn 100 105 110 Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 174 <211> 111 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 174 Glu Leu Val Leu Thr Gln Thr Pro Ala Ser Val Glu Val Ala Val Gly 1 5 10 15 Gly Thr Val Thr Ile Asn Cys Gln Ala Ser Gln Ser Ile Asn Ser Trp 20 25 30 Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Arg Pro Lys Leu Leu Ile 35 40 45 Tyr Glu Ala Ser Thr Leu Ala Ser Gly Val Ser Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Gly Val Gln Cys 65 70 75 80 Asp Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Gly Tyr Ser Tyr Ser Asn 85 90 95 Val Asp Asn Asn Ile Phe Gly Gly Gly Thr Glu Val Val Val Lys 100 105 110 <210> 175 <211> 120 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 175 Gln Ser Leu Glu Glu Ser Gly Gly Gly Leu Val Lys Pro Glu Gly Ser 1 5 10 15 Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Asp Leu Ser Ser Ser Tyr 20 25 30 Tyr Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Val Cys Ile Asp Gly Gly Gly Gly Glu Pro Thr Ala Tyr Pro Ser Trp 50 55 60 Ala Lys Gly Arg Phe Thr Val Ser Lys Thr Ser Ser Thr Thr Val Thr 65 70 75 80 Leu Gln Met Thr Ser Leu Thr Val Ala Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Ala Arg Arg Asp Ala Gly Ala Gly Asn Ala Phe Ser Leu Trp Gly Pro 100 105 110 Gly Thr Leu Val Thr Ile Ser Ser 115 120 <210> 176 <211> 110 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 176 Glu Leu Asp Met Thr Gln Thr Pro Ser Pro Val Ser Ala Ala Val Gly 1 5 10 15 Gly Thr Val Thr Ile Ser Cys Gln Ser Ser Gln Ser Val Tyr Leu Gln 20 25 30 Asn Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu 35 40 45 Leu Ile Tyr Tyr Ala Ser Thr Leu Ala Ser Gly Val Ser Ser Arg Phe 50 55 60 Lys Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Leu 65 70 75 80 Glu Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Gln Gly Gly Tyr Ser Gly 85 90 95 Tyr Ile Asn Ser Phe Gly Gly Gly Thr Glu Val Glu Ile Lys 100 105 110 <210> 177 <211> 118 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 177 Gln Ser Val Lys Glu Ser Glu Gly Asp Leu Val Lys Pro Gly Ala Ser 1 5 10 15 Leu Thr Leu Thr Cys Lys Ala Ser Gly Phe Asp Phe Ser Ser Ser Tyr 20 25 30 Phe Met Cys Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp Ile 35 40 45 Ala Cys Ile Tyr Thr Val Ile Ser Arg Lys Thr Tyr Tyr Ala Ser Trp 50 55 60 Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ala Thr Thr Val Asp 65 70 75 80 Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Ala Arg Ser Ala Thr Ile Glu Arg Leu Asp Leu Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser 115 <210> 178 <211> 112 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 178 Glu Leu Asp Leu Thr Gln Thr Pro Ser Pro Val Ser Ala Pro Val Gly 1 5 10 15 Gly Thr Val Thr Ile Asn Cys Gln Ala Ser Glu Ser Val Tyr Asn Asn 20 25 30 Tyr Arg Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu 35 40 45 Leu Ile Tyr Ala Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe 50 55 60 Lys Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Ala Ile Ser Asp Val 65 70 75 80 Val Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Val Gly Tyr Lys Ser Gly 85 90 95 Tyr Ile Asp Ser Ile Pro Phe Gly Gly Gly Thr Glu Val Val Val Lys 100 105 110 <210> 179 <211> 111 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 179 Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser 1 5 10 15 Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Thr Ile Asn Asn Tyr Asn 20 25 30 Ile Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Ala 35 40 45 Arg Ile Trp Asn Gly Asp Gly Ser Thr Tyr Tyr Ala Ser Trp Ala Lys 50 55 60 Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Thr Leu Gln 65 70 75 80 Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys Ala Arg 85 90 95 Asn Phe Asn Leu Trp Gly Pro Gly Thr Leu Val Thr Ile Ser Ser 100 105 110 <210> 180 <211> 112 <212> PRT <213> Artificial sequence <220> <223> Synthetic polypeptide <400> 180 Glu Leu Val Leu Thr Gln Thr Pro Ser Pro Val Ser Ala Ala Val Gly 1 5 10 15 Gly Thr Val Thr Ile Asn Cys Gln Ser Ser Ala Ser Val Tyr Ser Asn 20 25 30 Asn Tyr Leu Ser Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro Lys Pro 35 40 45 Leu Ile Tyr Tyr Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe 50 55 60 Lys Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Val 65 70 75 80 Gln Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Ala Gly Asp Tyr Ser Ser 85 90 95 Ser Ser Asp Met Cys Ile Phe Gly Gly Gly Thr Glu Leu Glu Ile Lys 100 105 110
Claims
1. An isolated monoclonal antibody, said antibody specifically binding to EGFL6, (I) (a) the first V H the CDRs are identical to SEQ ID NO:4; (b) the second V H the CDRs are identical to SEQ ID NO:5; (c) The third V H the CDRs are identical to SEQ ID NO:6; (d) the first V L the CDRs are identical to SEQ ID NO: 76; (e) the second V L the CDRs are identical to SEQ ID NO: 77; (f) the third V L the CDRs are identical to SEQ ID NO: 78; (II) (a) the first V H the CDRs are identical to SEQ ID NO: 10; (b) the second V H the CDRs are identical to SEQ ID NO: 11; (c) The third V H the CDRs are identical to SEQ ID NO: 12; (d) the first V L the CDRs are identical to SEQ ID NO:82; (e) the second V L the CDRs are identical to SEQ ID NO: 83; (f) the third V L the CDRs are identical to SEQ ID NO:84; (III) (a) the first V H the CDRs are identical to SEQ ID NO: 16; (b) the second V H the CDRs are identical to SEQ ID NO: 17; (c) The third V H the CDRs are identical to SEQ ID NO: 18; (d) the first V L the CDRs are identical to SEQ ID NO:88; (e) the second V L the CDRs are identical to SEQ ID NO: 77; (f) the third V L the CDRs are identical to SEQ ID NO:89; (IV) (a) the first V H the CDRs are identical to SEQ ID NO:22; (b) the second V H the CDRs are identical to SEQ ID NO:23; (c) The third V H the CDRs are identical to SEQ ID NO:24; (d) the first V L the CDRs are identical to SEQ ID NO:93; (e) the second V L the CDRs are identical to SEQ ID NO:94; (f) the third V L the CDRs are identical to SEQ ID NO:95; (V) (a) the first V H the CDRs are identical to SEQ ID NO:28; (b) the second V H the CDRs are identical to SEQ ID NO:29; (c) The third V H the CDRs are identical to SEQ ID NO: 30; (d) the first V L the CDRs are identical to SEQ ID NO:99; (e) the second V L the CDRs are identical to SEQ ID NO: 100; (f) the third V L the CDRs are identical to SEQ ID NO: 101; (VI) (a) the first V H the CDRs are identical to SEQ ID NO: 34; (b) the second V H the CDRs are identical to SEQ ID NO: 35; (c) The third V H the CDRs are identical to SEQ ID NO: 36; (d) the first V Lthe CDRs are identical to SEQ ID NO: 104; (e) the second V L the CDRs are identical to SEQ ID NO: 100; (f) the third V L the CDRs are identical to SEQ ID NO: 105; (VII) (a) the first V H the CDRs are identical to SEQ ID NO: 40; (b) the second V H the CDRs are identical to SEQ ID NO: 41; (c) The third V H the CDRs are identical to SEQ ID NO: 42; (d) the first V L the CDRs are identical to SEQ ID NO: 108; (e) the second V L the CDRs are identical to SEQ ID NO: 77; (f) the third V L the CDRs are identical to SEQ ID NO: 109; (VIII) (a) the first V H the CDRs are identical to SEQ ID NO: 46; (b) the second V H the CDRs are identical to SEQ ID NO: 47; (c) The third V H the CDRs are identical to SEQ ID NO:48; (d) the first V L the CDRs are identical to SEQ ID NO: 113; (e) the second V L the CDRs are identical to SEQ ID NO: 83; (f) the third V L the CDRs are identical to SEQ ID NO: 114; (IX) (a) the first V H the CDRs are identical to SEQ ID NO:52; (b) the second V H the CDRs are identical to SEQ ID NO:53; (c) The third V H the CDRs are identical to SEQ ID NO:54; (d) the first V L the CDRs are identical to SEQ ID NO: 117; (e) the second V L the CDRs are identical to SEQ ID NO: 83; (f) the third V L the CDRs are identical to SEQ ID NO: 119; (X) (a) the first V H the CDRs are identical to SEQ ID NO:58; (b) the second V H the CDRs are identical to SEQ ID NO:59; (c) The third V H the CDRs are identical to SEQ ID NO: 60; (d) the first V L the CDRs are identical to SEQ ID NO: 121; (e) the second V L the CDRs are identical to SEQ ID NO: 100; (f) the third V L the CDRs are identical to SEQ ID NO: 122; (XI) (a) the first V H the CDRs are identical to SEQ ID NO:64; (b) the second V H the CDRs are identical to SEQ ID NO:65; (c) The third V H the CDRs are identical to SEQ ID NO:66; (d) the first V L the CDRs are identical to SEQ ID NO: 126; (e) the second V L the CDRs are identical to SEQ ID NO: 127; (f) the third V L the CDRs are identical to SEQ ID NO: 128, or (XII) (a) the first V H the CDRs are identical to SEQ ID NO: 70; (b) the second V H the CDRs are identical to SEQ ID NO: 71; (c) The third V H the CDRs are identical to SEQ ID NO: 72; (d) the first V L the CDRs are identical to SEQ ID NO: 131; (e) the second V L the CDRs are identical to SEQ ID NO: 100; (f) the third V L CDRs are identical to SEQ ID NO: 132 1. An isolated antibody comprising:
2. (a) the first V H the CDRs are identical to SEQ ID NO:4; (b) the second V H the CDRs are identical to SEQ ID NO:5; (c) The third V H the CDRs are identical to SEQ ID NO:6; (d) the first V L the CDRs are identical to SEQ ID NO: 76; (e) the second V L the CDRs are identical to SEQ ID NO: 77; (f) the third V L CDRs are identical to SEQ ID NO:78 The isolated antibody of claim 1 , comprising:
3. (a) the first V H the CDRs are identical to SEQ ID NO: 10; (b) the second V H the CDRs are identical to SEQ ID NO: 11; (c) The third V H the CDRs are identical to SEQ ID NO: 12; (d) the first V L the CDRs are identical to SEQ ID NO:82; (e) the second V L the CDRs are identical to SEQ ID NO: 83; (f) the third V L CDRs are identical to SEQ ID NO:84 The isolated antibody of claim 1 , comprising:
4. (a) the first V H the CDRs are identical to SEQ ID NO: 16; (b) the second V H the CDRs are identical to SEQ ID NO: 17; (c) The third V H the CDRs are identical to SEQ ID NO: 18; (d) the first V L the CDRs are identical to SEQ ID NO:88; (e) the second V L the CDRs are identical to SEQ ID NO: 77; (f) the third V L CDRs are identical to SEQ ID NO:89 The isolated antibody of claim 1 , comprising:
5. (a) the first V H the CDRs are identical to SEQ ID NO:22; (b) the second V H the CDRs are identical to SEQ ID NO:23; (c) The third V H the CDRs are identical to SEQ ID NO:24; (d) the first V L the CDRs are identical to SEQ ID NO:93; (e) the second V L the CDRs are identical to SEQ ID NO:94; (f) the third V L CDRs are identical to SEQ ID NO:95 The isolated antibody of claim 1 , comprising:
6. (a) the first V H the CDRs are identical to SEQ ID NO:28; (b) the second V H the CDRs are identical to SEQ ID NO:29; (c) The third V H the CDRs are identical to SEQ ID NO: 30; (d) the first V L the CDRs are identical to SEQ ID NO:99; (e) the second V L the CDRs are identical to SEQ ID NO: 100; (f) the third V L CDRs are identical to SEQ ID NO: 101 The isolated antibody of claim 1 , comprising:
7. (a) the first V H the CDRs are identical to SEQ ID NO: 34; (b) the second V H the CDRs are identical to SEQ ID NO: 35; (c) The third V H the CDRs are identical to SEQ ID NO: 36; (d) the first V L the CDRs are identical to SEQ ID NO: 104; (e) the second V L the CDRs are identical to SEQ ID NO: 100; (f) the third V L CDRs are identical to SEQ ID NO: 105 The isolated antibody of claim 1 , comprising:
8. (a) the first V H the CDRs are identical to SEQ ID NO: 40; (b) the second V H the CDRs are identical to SEQ ID NO: 41; (c) The third V H the CDRs are identical to SEQ ID NO: 42; (d) the first V L the CDRs are identical to SEQ ID NO: 108; (e) the second V L the CDRs are identical to SEQ ID NO: 77; (f) the third V L CDRs are identical to SEQ ID NO: 109 The isolated antibody of claim 1 , comprising:
9. (a) the first V H the CDRs are identical to SEQ ID NO: 46; (b) the second V H the CDRs are identical to SEQ ID NO: 47; (c) The third V Hthe CDRs are identical to SEQ ID NO:48; (d) the first V L the CDRs are identical to SEQ ID NO: 113; (e) the second V L the CDRs are identical to SEQ ID NO: 83; (f) the third V L CDRs are identical to SEQ ID NO: 114 The isolated antibody of claim 1 , comprising:
10. (a) the first V H the CDRs are identical to SEQ ID NO:52; (b) the second V H the CDRs are identical to SEQ ID NO:53; (c) The third V H the CDRs are identical to SEQ ID NO:54; (d) the first V L the CDRs are identical to SEQ ID NO: 117; (e) the second V L the CDRs are identical to SEQ ID NO: 83; (f) the third V L CDRs are identical to SEQ ID NO: 119 The isolated antibody of claim 1 , comprising:
11. (a) the first V H the CDRs are identical to SEQ ID NO:58; (b) the second V H the CDRs are identical to SEQ ID NO:59; (c) The third V H the CDRs are identical to SEQ ID NO: 60; (d) the first V L the CDRs are identical to SEQ ID NO: 121; (e) the second V L the CDRs are identical to SEQ ID NO: 100; (f) the third V L CDRs are identical to SEQ ID NO: 122 The isolated antibody of claim 1 , comprising:
12. (a) the first V H the CDRs are identical to SEQ ID NO:64; (b) the second V H the CDRs are identical to SEQ ID NO:65; (c) The third V H the CDRs are identical to SEQ ID NO:66; (d) the first V L the CDRs are identical to SEQ ID NO: 126; (e) the second V L the CDRs are identical to SEQ ID NO: 127; (f) the third V L CDRs are identical to SEQ ID NO: 128 The isolated antibody of claim 1 , comprising:
13. (a) the first V H the CDRs are identical to SEQ ID NO: 70; (b) the second V H the CDRs are identical to SEQ ID NO: 71; (c) The third V H the CDRs are identical to SEQ ID NO: 72; (d) the first V L the CDRs are identical to SEQ ID NO: 131; (e) the second V L the CDRs are identical to SEQ ID NO: 100; (f) the third V L CDRs are identical to SEQ ID NO: 132 The isolated antibody of claim 1 , comprising:
14. (i) V of E1-33 (SEQ ID NO: 157) H Domain or humanized V of E1-33 mAB H V domain that is at least about 80% identical H Domain, and V of E1-33 (SEQ ID NO: 158) L Domain or humanized V of E1-33 mAB L V domain that is at least about 80% identical L domain, (ii) V of E1-34 (SEQ ID NO: 159) H Domain or humanized V of E1-34 mAB H V domain that is at least about 80% identical H domain, and V of E1-34 (SEQ ID NO: 160) L Domain or humanized V of E1-34mA L V domain that is at least about 80% identical L domain, (iii) V of E1-80 (SEQ ID NO: 161) H Domain or humanized V of E1-80 mAB H V domain that is at least about 80% identical H domain, and V of E1-80 (SEQ ID NO: 162) L Domain or humanized V of E1-80 mAB L V domain that is at least about 80% identical L domain, (iv) V of E1-89 (SEQ ID NO: 163) H Domain or humanized V of E1-89 mAB H V domain that is at least about 80% identical H domain, and V of E1-89 (SEQ ID NO: 164) L Domain or humanized V of E1-80 mAB L V domain that is at least about 80% identical L domain, (v) V of E2-93 (SEQ ID NO: 165) H Domain or humanized V of E2-93 mAB H V domain that is at least about 80% identical H domain, and V of E2-93 (SEQ ID NO: 166) L Domain or humanized V of E2-93 mAB L V domain that is at least about 80% identical L domain, (vi) V of E1-38 (SEQ ID NO: 167) H Domain or humanized V of E1-38 mAB H V domain that is at least about 80% identical H Domain, and V of E1-38 (SEQ ID NO: 168) LDomain or humanized V of E1-38 mAB L V domain that is at least about 80% identical L domain, (vii) E1-52 (SEQ ID NO: 169) V H Domain or humanized V of E1-52 mAB H V domain that is at least about 80% identical H domain, and V of E1-52 (SEQ ID NO: 170) L Domain or humanized V of E1-52 mAB L V domain that is at least about 80% identical L domain, (viii) V of E2-36 (SEQ ID NO: 171) H Domain or humanized V of E2-36 mAB H V domain that is at least about 80% identical H domain, and V of E2-36 (SEQ ID NO: 172) L Domain or humanized V of E2-36 mAB L V domain that is at least about 80% identical L domain, (ix) E1-95 (SEQ ID NO: 173) V H Domain or humanized V of E1-95 mAB H V domain that is at least about 80% identical H domain, and V of E1-95 (SEQ ID NO: 174) L Domain or humanized V of E1-95 mAB L V domain that is at least about 80% identical L domain, (x) V of E2-116 (SEQ ID NO: 175) H Domain or humanized V of E2-116 mAB H V domain that is at least about 80% identical H domain, and V of E2-116 (SEQ ID NO: 176) L Domain or humanized V of E2-116 mAB L V domain that is at least about 80% identical L domain, (xi) V of E2-135 (SEQ ID NO: 177) HDomain or humanized V of E2-135 mAB H V domain that is at least about 80% identical H domain, and V of E2-135 (SEQ ID NO: 178) L Domain or humanized V of E2-135 mAB L V domain that is at least about 80% identical L Domain, or (xii) E1-142 (SEQ ID NO: 179) V H Domain or humanized V of E1-142 mAB H V domain that is at least about 80% identical H domain, and V of E1-142 (SEQ ID NO: 180) L Domain or humanized V of E1-142 mAB L V domain that is at least about 80% identical L domain The antibody of claim 1 , comprising:
15. V of E1-33 (SEQ ID NO: 157) H Same V as domain H domain and V of E1-33 (SEQ ID NO: 158) L Same V as domain L The antibody of claim 14, comprising:
16. V of E1-34 (SEQ ID NO: 159) H Same V as domain H domain and V of E1-34 (SEQ ID NO: 160) L Same V as domain L The antibody of claim 14, comprising:
17. V of E1-80 (SEQ ID NO: 161) H Same V as domain H domain and V of E1-80 (SEQ ID NO: 162) L Same V as domain L The antibody of claim 14, comprising:
18. V of E1-89 (SEQ ID NO: 163) H Same V as domain H domain and V of E1-89 (SEQ ID NO: 164) L Same V as domain L The antibody of claim 14, comprising:
19. V of E2-93 (SEQ ID NO: 165) H Same V as domain H domain and V of E2-93 (SEQ ID NO: 166) L Same V as domain L The antibody of claim 14, comprising:
20. V of E1-38 (SEQ ID NO: 167) H Same V as domain H domain and V of E1-38 (SEQ ID NO: 168) L Same V as domain L The antibody of claim 14, comprising:
21. V of E1-52 (SEQ ID NO: 169) H Same V as domain H domain and V of E1-52 (SEQ ID NO: 170) L Same V as domain L The antibody of claim 14, comprising:
22. V of E2-36 (SEQ ID NO: 171) H Same V as domain H domain and V of E2-36 (SEQ ID NO: 172) L Same V as domain L The antibody of claim 14, comprising:
23. V of E1-95 (SEQ ID NO: 173) H Same V as domain H domain and V of E1-95 (SEQ ID NO: 174) L Same V as domain L The antibody of claim 14, comprising:
24. V of E2-116 (SEQ ID NO: 175) H Same V as domain Hdomain and V of E2-116 (SEQ ID NO: 176) L Same V as domain L The antibody of claim 14, comprising:
25. V of E2-135 (SEQ ID NO: 177) H Same V as domain H domain and V of E2-135 (SEQ ID NO: 178) L Same V as domain L The antibody of claim 14, comprising:
26. E1-142 (SEQ ID NO: 179) V H Same V as domain H domain and V of E1-142 (SEQ ID NO: 180) L Same V as domain L The antibody of claim 14, comprising:
27. The antibody of claim 14, which is an E1-33, E1-34, E1-80, E1-89, E2-93, E1-38, E1-52, E2-36, E1-95, E2-116, E2-135, or E1-142 antibody.
28. The antibody of any one of claims 1 to 27, which is recombinant.
29. The antibody of claim 1 which is an IgG, IgM, IgA, or an antigen-binding fragment thereof.
30. 28. The antibody of any one of claims 1 to 27, which is a Fab', F(ab')2, F(ab')3, monovalent scFv, bivalent scFv, or single domain antibody.
31. The antibody of any one of claims 1 to 13, which is a human antibody, a humanized antibody, or a deimmunized antibody.
32. 28. The antibody of any one of claims 1 to 27, conjugated to an imaging agent, a chemotherapeutic agent, a toxin, or a radionuclide.
33. 33. The antibody of claim 32 conjugated to a toxin.
34. 34. The antibody of claim 33, wherein the toxin is an auristatin.
35. 34. The antibody of claim 33, wherein the toxin is monomethylauristatin E (MMAE).
36. A composition comprising an antibody according to any one of claims 1 to 27 in a pharma- ceutically acceptable carrier.
37. An isolated polynucleotide molecule comprising a nucleic acid sequence encoding the antibody of any one of claims 1 to 27.
38. V of E1-33 (SEQ ID NOs: 4, 5, and 6) H CDRs 1 to 3 of the domain, V of E1-34 (SEQ ID NOs: 10, 11, and 12) H CDRs 1 to 3 of the domain, V of E1-80 (SEQ ID NOs: 16, 17, and 18) H CDRs 1 to 3 of the domain, V of E1-89 (SEQ ID NOs: 22, 23, and 24) H CDRs 1 to 3 of the domain, V of E2-93 (SEQ ID NOs: 28, 29, and 30) H CDRs 1 to 3 of the domain, V of E1-38 (SEQ ID NOs: 34, 35, and 36) H CDRs 1 to 3 of the domain, V of E1-52 (SEQ ID NOs: 40, 41, and 42) H CDRs 1 to 3 of the domain, V of E2-36 (SEQ ID NOs: 46, 47, and 48) H CDRs 1 to 3 of the domain, V of E1-95 (SEQ ID NOs: 52, 53, and 54) H CDRs 1 to 3 of the domain, V of E2-116 (SEQ ID NOs: 58, 59, and 60) H CDRs 1 to 3 of the domain, V of E2-135 (SEQ ID NOs: 64, 65, and 66) H CDR1-3 of the domain, or V of E1-142 (SEQ ID NOs: 70, 71, and 72) H CDR1-3 of the domain Antibody V comprising H A recombinant polypeptide comprising a domain.
39. V of E1-33 (SEQ ID NOs: 76, 77, and 78) L CDRs 1 to 3 of the domain, V of E1-34 (SEQ ID NOs: 82, 83, and 84) L CDRs 1 to 3 of the domain, V of E1-80 (SEQ ID NOs: 88, 77, and 89) L CDRs 1 to 3 of the domain, V of E1-89 (SEQ ID NOs: 93, 94, and 95) L CDRs 1 to 3 of the domain, V of E2-93 (SEQ ID NOs: 99, 100, and 101) L CDRs 1 to 3 of the domain, V of E1-38 (SEQ ID NOs: 104, 100, and 105) L CDRs 1 to 3 of the domain, V of E1-52 (SEQ ID NOs: 108, 77, and 109) L CDRs 1 to 3 of the domain, V of E2-36 (SEQ ID NOs: 113, 83, and 114) L CDRs 1 to 3 of the domain, V of E1-95 (SEQ ID NOs: 117, 83, and 118) L CDRs 1 to 3 of the domain, V of E2-116 (SEQ ID NOs: 121, 100, and 122) L CDRs 1 to 3 of the domain, V of E2-135 (SEQ ID NOs: 126, 127, and 128) L CDR1-3 of the domain, or V of E1-142 (SEQ ID NOs: 131, 100, and 132) L CDR1-3 of the domain Antibody V comprising L A recombinant polypeptide comprising a domain.
40. 40. An isolated polynucleotide molecule comprising a nucleic acid sequence encoding the polypeptide of claim 38 or 39.
41. A host cell comprising one or more polynucleotide molecules encoding the antibody of any one of claims 1 to 27 or the recombinant polypeptide of claim 38 or 39.
42. 42. The host cell of claim 41, which is a mammalian cell, a yeast cell, a bacterial cell, a ciliate cell, or an insect cell.
43. (a) detecting in a cell the V of an antibody according to any one of claims 1 to 27; L and V H expressing one or more polynucleotide molecules encoding the chains; (b) purifying the antibody from the cells; A method for producing an antibody, comprising:
44. A method for treating a subject having cancer, comprising administering to the subject an effective amount of an antibody according to any one of claims 1 to 27.
45. 45. The method of claim 44, wherein the cancer is breast cancer, lung cancer, head and neck cancer, prostate cancer, esophageal cancer, tracheal cancer, skin cancer, brain cancer, liver cancer, bladder cancer, stomach cancer, pancreatic cancer, ovarian cancer, uterine cancer, cervical cancer, testicular cancer, colon cancer, rectal cancer, or skin cancer.
46. 45. The method of claim 44, wherein the cancer is an epithelial cancer.
47. 45. The method of claim 44, wherein the cancer is colorectal adenocarcinoma, lung adenocarcinoma, lung squamous cell carcinoma, breast cancer, hepatocellular carcinoma, ovarian cancer, clear cell renal cell carcinoma, lung cancer, or renal cancer.
48. 45. The method of claim 44, wherein the antibody is in a pharma- ceutically acceptable composition.
49. 45. The method of claim 44, wherein the antibody is administered systemically.
50. 45. The method of claim 44, wherein the antibody is administered intravenously, intradermally, intratumorally, intramuscularly, intraperitoneally, subcutaneously, or topically.
51. 45. The method of claim 44, further comprising administering to the subject at least a second anti-cancer therapy.
52. 52. The method of claim 51, wherein the second anti-cancer therapy is surgery, chemotherapy, radiation therapy, cryotherapy, hormone therapy, immunotherapy, or cytokine therapy.
53. 1. A method for detecting cancer in a subject, comprising testing for the presence of elevated EGFL6 in a sample from the subject as compared to a control, A method, wherein the testing step comprises contacting the sample with an antibody according to any one of claims 14 to 27 or 32.
54. 54. The method of claim 53, further defined as an in vitro method.
55. (a) V of E1-33 (SEQ ID NO: 4), E1-34 (SEQ ID NO: 10), E1-80 (SEQ ID NO: 16), E1-89 (SEQ ID NO: 22), E2-93 (SEQ ID NO: 28), E1-38 (SEQ ID NO: 34), E1-52 (SEQ ID NO: 40), E2-36 (SEQ ID NO: 46), E1-95 (SEQ ID NO: 52), E2-116 (SEQ ID NO: 58), E2-135 (SEQ ID NO: 64), or E1-142 (SEQ ID NO: 70) H A first V that is at least 80% identical to CDR1 H CDRs, (b) V of E1-33 (SEQ ID NO:5), E1-34 (SEQ ID NO:11), E1-80 (SEQ ID NO:17), E1-89 (SEQ ID NO:23), E2-93 (SEQ ID NO:29), E1-38 (SEQ ID NO:35), E1-52 (SEQ ID NO:41), E2-36 (SEQ ID NO:47), E1-95 (SEQ ID NO:53), E2-116 (SEQ ID NO:59), E2-135 (SEQ ID NO:65), or E1-142 (SEQ ID NO:71) H A second V that is at least 80% identical to CDR2 H CDRs, (c) E1-33 (SEQ ID NO: 6), E1-34 (SEQ ID NO: 12), E1-80 (SEQ ID NO: 18), E1-89 (SEQ ID NO: 24), E2-93 (SEQ ID NO: 30), E1-38 (SEQ ID NO: 36), E1-52 (SEQ ID NO: 42), E2-36 (SEQ ID NO: 48), E1-95 (SEQ ID NO: 54), E2-116 (SEQ ID NO: 60), E2-135 (SEQ ID NO: 66), or E1-142 (SEQ ID NO: 72) V H A third V that is at least 80% identical to CDR3 H CDRs, (d) E1-33 (SEQ ID NO: 76), E1-34 (SEQ ID NO: 82), E1-80 (SEQ ID NO: 88), E1-89 (SEQ ID NO: 93), E2-93 (SEQ ID NO: 99), E1-38 (SEQ ID NO: 104), E1-52 (SEQ ID NO: 108), E2-36 (SEQ ID NO: 113), E1-95 (SEQ ID NO: 117), E2-116 (SEQ ID NO: 121), E2-135 (SEQ ID NO: 126), or E1-142 (SEQ ID NO: 131) V L A first V that is at least 80% identical to CDR1 L CDRs, (e) E1-33 (SEQ ID NO: 77), E1-34 (SEQ ID NO: 83), E1-80 (SEQ ID NO: 77), E1-89 (SEQ ID NO: 94), E2-93 (SEQ ID NO: 100), E1-38 (SEQ ID NO: 100), E1-52 (SEQ ID NO: 77), E2-36 (SEQ ID NO: 83), E1-95 (SEQ ID NO: 83), E2-116 (SEQ ID NO: 100), E2-135 (SEQ ID NO: 127), or E1-142 (SEQ ID NO: 100) V L A second V that is at least 80% identical to CDR2 L CDRs, (f) E1-33 (SEQ ID NO: 78), E1-34 (SEQ ID NO: 84), E1-80 (SEQ ID NO: 89), E1-89 (SEQ ID NO: 95), E2-93 (SEQ ID NO: 101), E1-38 (SEQ ID NO: 105), E1-52 (SEQ ID NO: 109), E2-36 (SEQ ID NO: 114), E1-95 (SEQ ID NO: 118), E2-116 (SEQ ID NO: 122), E2-135 (SEQ ID NO: 128), or E1-142 (SEQ ID NO: 132) V L A third V that is at least 80% identical to CDR3 L CDR and 1. An isolated antibody comprising:
Citation Information
Patent Citations
EGF motif protein, EGFL6 materials and methods
WO2002030977A2
Compositions and methods relating to inhibiting cancer cell growth and / or proliferation
WO2014150720A1
